

Approved



Uganda
Country Operational Plan
FY 2017



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		717,272		717,272	55,000	772,272
USAID		89,888,430		89,888,430	62,939,736	152,828,166
DOD		12,888,606		12,888,606	1,102,229	13,990,835
PC		1,158,937		1,158,937	1,125,764	2,284,701
HHS/CDC	3,212,500	136,046,173		139,258,673	63,995,640	203,254,313
HHS/HRSA		338,175		338,175	0	338,175
State/AF		50,000		50,000	250,000	300,000
State/PRM		687,665		687,665	0	687,665
State/OGAC		4,649,648		4,649,648	0	4,649,648
Total	3,212,500	246,424,906	0	249,637,406	129,468,369	379,105,775

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency									Total
	State	DOD	HHS/CDC	PC	State/OGAC	State/PRM	USAID	HHS/HRSA	State/AF	
CIRC		502,168	5,299,661		71,137	32,796	3,838,543			9,744,305
HBHC	17,560	1,852,641	18,119,123	0	343,428	129,784	7,436,111			27,898,647
HKID	31,607	1,459,809	8,191,978	421,047		132,581	17,737,702			27,974,724
HLAB		258,316	2,378,821		225,323		278,906	338,175		3,479,541
HMBL			3,715							3,715
HMIN		0	1,857							1,857
HTXD		545	24,591,115				7,768,738			32,360,398
HTXS	14,048	3,377,919	35,471,677		587,073	267,940	20,629,797		11,928	60,360,382



Budget Code	Agency									Total
	State	DOD	HHS/CDC	PC	State/OGAC	State/PRM	USAID	HHS/HRSA	State/AF	
HVAB		3,867	711,849			0	1,016,722			1,732,438
HVCT		856,983	8,490,143		49,709	45,759	5,221,923			14,664,517
HVMS	654,057	412,627	10,827,181	273,918			6,276,501			18,444,284
HVOP		1,828,634	8,688,796	463,972	119,063	0	6,493,290		20,179	17,613,934
HVSI		935,350	2,632,852		903,277		1,828,852			6,300,331
HVTB		837,114	3,596,015		7,210	31,575	3,178,467		5,964	7,656,345
IDUP			0							0
MTCT		381,442	3,915,969		18,024	31,136	2,061,811		11,929	6,420,311
OHSS			2,557,581		2,223,098		3,706,155			8,486,834
PDCS		107,199	2,760,778		36,783	8,736	1,747,427			4,660,923
PDTX		73,992	1,019,562		65,523	7,358	667,485			1,833,920
	717,272	12,888,606	139,258,673	1,158,937	4,649,648	687,665	89,888,430	338,175	50,000	249,637,406



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	27,707,696	0
HKID	27,320,115	0
HVTB	7,538,707	0
PDCS	4,528,352	0
Total Technical Area Planned Funding:	67,094,870	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	3,139,454	0
HVSI	5,136,763	0
OHSS	7,724,761	0
Total Technical Area Planned Funding:	16,000,978	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	9,595,173	0
HMIN	0	
HVAB	1,731,215	0
HVCT	14,547,452	0
HVOP	17,125,383	0
IDUP	0	
MTCT	6,219,835	0
Total Technical Area Planned	49,219,058	0

Approved



Funding:		
-----------------	--	--

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	32,291,353	0
HTXS	60,145,535	0
PDTX	1,732,879	0
Total Technical Area Planned Funding:	94,169,767	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2018
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	790,392
	Number of new ANC and L&D clients	
	By Age (Denominator): Unknown Age	0
	By Age (Denominator): <10	0
	By Age (Denominator): 10-14	7,907
	By Age (Denominator): <15-19	150,187
	By Age (Denominator): 20-24	150,187
	By Age (Denominator): 25-49	482,111
	By Age (Denominator): 50+	0
	By Number of known positives: Unknown Age	0
	By Number of known positives: <10	0
	By Number of known positives: 10-14	183
	By Number of known positives: 15-19	5,239
	By Number of known positives: 20-24	9,364
By Number of known positives:	12,739	



	25-49	
	By Number of known positives: 50+	0
	By Number of new positives: Unknown Age	0
	By Number of new positives: <10	0
	By Number of new positives: 10-14	117
	By Number of new positives: 15-19	3,847
	By Number of new positives: 20-24	6,876
	By Number of new positives: 25-49	9,407
	By Number of new positives: 50+	0
	By Number of new negative: Unknown Age	0
	By Number of new negative: <10	0
	By Number of new negative: 10-14	7,597
	By Number of new negative: 15-19	140,927
	By Number of new negative: 20-24	133,953
	By Number of new negative: 25-49	459,549
	By Number of new negative: 50+	594
	By Age (Numerator): Unknown Age	0
	By Age (Numerator): <10	0
	By Age (Numerator): 10-14	7,907
	By Age (Numerator): 15-19	150,187
	By Age (Numerator): 20-24	150,187
	By Age (Numerator): 25-49	482,111
	By Age (Numerator): 50+	0
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and	712,414



	received their results)	
	Number of new ANC and L&D clients	
	By Age (Denominator): Unknown Age	
	By Age (Denominator): <10	
	By Age (Denominator): 10-14	7,117
	By Age (Denominator): 15-19	135,357
	By Age (Denominator): 20-24	135,357
	By Age (Denominator): 25-49	434,583
	By Age (Denominator): 50+	
	By known positives: <Unknown Age	
	By known positives: <10	
	By known positives: 10-14	98
	By known positives: 15-19	4,021
	By known positives: 20-24	7,163
	By known positives: 25-49	9,833
	By known positives: 50+	
	By new positives: Unknown Age	
	By new positives: <10	
	By new positives: 10-14	66
	By new positives: 15-19	3,247
	By new positives: 20-24	5,781
	By new positives: 25-49	7,966
	By new positives: 50+	
	By new negatives: Unknown Age	
	By new negatives: <10	
	By new negatives: 10-14	6,953
	By new negatives: 15-19	128,089
	By new negatives: 20-24	122,413
	By new negatives: 25-49	416,784
	By new negatives: 50+	



	By Age (Numerator): Unknown Age	
	By Age (Numerator): <10	
	By Age (Numerator): 10-14	7,117
	By Age (Numerator): : 15-19	135,357
	By Age (Numerator): 20-24	135,357
	By Age (Numerator): 25-49	434,583
	By Age (Numerator): 50+	
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	6 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	45,415
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	790,392
	New on ART	20,551
	Already on ART at beginning of current pregnancy	24,864
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	5 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	36,248



	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	712,414
	New on ART	16,421
	Already on ART at beginning of current pregnancy	19,827
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	696,924
	By Age: 0-60 days	
	By Age: 2 months - 9 years	
	By Age: 10-14	67,936
	By Age: 15-19	125,451
	By Age: 20-24	167,266
	By Age: 25-29	266,573
	By Age: 30-49	41,816
	By Age: 50+	27,882
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	7,028
	By circumcision technique: Device-based VMMC	784



	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement	
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	11,757
	Male 10-14	
	Male 15-19	1,472
	Male 20-24	1,472
	Male 25-49	1,472
	Male 50+	1,472
	Female 10-14	
	Female 15-19	1,472
	Female 20-24	1,472
	Female 25-49	1,472
	Female 50+	1,453
	(15-19)	
	(20-24)	
	FSW	1,063
MSM	46	



	TG	16
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	804,598
	Total number of people in the target population	
	Age/sex: 10-14 Male	30,914
	Age/sex: 15-19 Male	87,176
	Age/sex: 20-24 Male	159,282
	Age/sex: 25-49 Male	315,725
	Age/sex: 50+ Male	4,932
	Age/sex: 10-14 Female	56,109
	Age/sex: 15-19 Female	46,546
	Age/sex: 20-24 Female	50,317
	Age/sex: 25-49 Female	49,374
	Age/sex: 50+ Female	4,223
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	
	Aggregated Age/sex: <15 Female	
Aggregated Age/sex: 15+ Female		
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a



	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	192,429
	Total estimated number of key population in the catchment area	
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,622
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,441
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	651
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual	695



	and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	88,870
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	98,150



	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID)	



	(Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: Returning beneficiary within the current report period	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,771,561
	By Test Result: Positive	118,421
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 10-14, Male,	



	Negative	
	Service Delivery Point (Community) Homebased testing: 10-14, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	
	Service Delivery Point (Community)	



	Homebased testing: 25-49, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 50+, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 50+, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Homebased testing: <1, Negative	
	Service Delivery Point (Community) Homebased testing: <1, Positive	
	Service Delivery Point (Community) Homebased testing: 1-9, Negative	



	Service Delivery Point (Community) Homebased testing: 1-9, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: <15, Female, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: <15, Female, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: <15, Male, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: <15, Male, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: 15+, Female, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: 15+, Female, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: 15+, Male, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: 15+, Male, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: Unknown Age, Male, Negative	



	Service Delivery Point Agg Age (Community) Homebased testing: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	5,923
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	59
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	7,967
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	64
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	20,205
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	662
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	2,625
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	79
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	72,132
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	2,441
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	17,592
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	653
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	299,301
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	10,626
	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	268,688
	Service Delivery Point (Facility)	10,593



	Inpatient: 25-49, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	29,171
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	1,044
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	31,655
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	1,237
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Inpatient: <1, Negative	7,037
	Service Delivery Point (Facility) Inpatient: <1, Positive	67
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	44,267
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	451
	Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Negative	
	Service Delivery Point Agg Age (Facility) Inpatient: <15, Female,	



	Positive	
	Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Negative	
	Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Positive	
	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Negative	
	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Positive	
	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Negative	
	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Positive	
	Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Malnutrition: Negative	1,754
	Service Delivery Point (Facility) Malnutrition: Positive	26



	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	



	Positive	
	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Positive	



	Service Delivery Point (Community) Mobile Testing: <1, Negative	
	Service Delivery Point (Community) Mobile Testing: <1, Positive	
	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	
	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: <15, Female, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: <15, Female, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: <15, Male, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: <15, Male, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Female, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Female, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Male, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Male, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Female, Negative	



	Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	5,886
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	63
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	7,927
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	81
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	24,936
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	915
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	3,575
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	143
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	85,235
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	3,146



	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	20,342
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	892
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	332,629
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	13,426
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	333,728
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	14,561
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	32,062
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1,277
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	37,292
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	1,612
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	



	Service Delivery Point (Facility) Other PITC: <1, Negative	6,887
	Service Delivery Point (Facility) Other PITC: <1, Positive	75
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	44,385
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	488
	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Negative	
	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Positive	
	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Negative	
	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Positive	
	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	
	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive	
	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	
	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive	
	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Female, Negative	



	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Other: 10-14, Female, Negative	
	Service Delivery Point (Community) Other: 10-14, Female, Positive	
	Service Delivery Point (Community) Other: 10-14, Male, Negative	
	Service Delivery Point (Community) Other: 10-14, Male, Positive	
	Service Delivery Point (Community) Other: 15-19, Female, Negative	
	Service Delivery Point (Community) Other: 15-19, Female, Positive	
	Service Delivery Point (Community) Other: 15-19, Male, Negative	
	Service Delivery Point (Community) Other: 15-19, Male, Positive	
	Service Delivery Point (Community) Other: 20-24, Female, Negative	
	Service Delivery Point (Community) Other: 20-24, Female, Positive	
	Service Delivery Point (Community) Other: 20-24, Male, Negative	
	Service Delivery Point (Community) Other: 20-24, Male, Positive	
	Service Delivery Point (Community)	



	Other: 25-49, Female, Negative	
	Service Delivery Point (Community) Other: 25-49, Female, Positive	
	Service Delivery Point (Community) Other: 25-49, Male, Negative	
	Service Delivery Point (Community) Other: 25-49, Male, Positive	
	Service Delivery Point (Community) Other: 50+, Female, Negative	
	Service Delivery Point (Community) Other: 50+, Female, Positive	
	Service Delivery Point (Community) Other: 50+, Male, Negative	
	Service Delivery Point (Community) Other: 50+, Male, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Other: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Other: <1, Negative	
	Service Delivery Point (Community) Other: <1, Positive	
	Service Delivery Point (Community) Other: 1-9, Negative	
	Service Delivery Point (Community)	



	Other: 1-9, Positive	
	Service Delivery Point Agg Age (Community) Other: <15, Female, Negative	
	Service Delivery Point Agg Age (Community) Other: <15, Female, Positive	
	Service Delivery Point Agg Age (Community) Other: <15, Male, Negative	
	Service Delivery Point Agg Age (Community) Other: <15, Male, Positive	
	Service Delivery Point Agg Age (Community) Other: 15+, Female, Negative	
	Service Delivery Point Agg Age (Community) Other: 15+, Female, Positive	
	Service Delivery Point Agg Age (Community) Other: 15+, Male, Negative	
	Service Delivery Point Agg Age (Community) Other: 15+, Male, Positive	
	Service Delivery Point Agg Age (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Community) Other: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age	



	(Community) Other: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Pediatric : <5 Negative	34,394
	Service Delivery Point (Facility) Pediatric : <5 Positive	377
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	151
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	241
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	41
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	10
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	13
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	4
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	262
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	54
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	64
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	19
	Service Delivery Point (Facility) TB: 25-49, Female, Negative	1,676
	Service Delivery Point (Facility) TB: 25-49, Female, Positive	815



	Service Delivery Point (Facility) TB: 25-49, Male, Negative	1,684
	Service Delivery Point (Facility) TB: 25-49, Male, Positive	634
	Service Delivery Point (Facility) TB: 50+, Female, Negative	62
	Service Delivery Point (Facility) TB: 50+, Female, Positive	9
	Service Delivery Point (Facility) TB: 50+, Male, Negative	105
	Service Delivery Point (Facility) TB: 50+, Male, Positive	25
	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) TB: <1, Negative	282
	Service Delivery Point (Facility) TB: <1, Positive	3
	Service Delivery Point (Facility) TB: 1-9, Negative	1,079
	Service Delivery Point (Facility) TB: 1-9, Positive	22
	Service Delivery Point Agg Age (Facility) TB: <15, Female, Negative	
	Service Delivery Point Agg Age (Facility) TB: <15, Female, Positive	
	Service Delivery Point Agg Age (Facility) TB: <15, Male, Negative	



	Service Delivery Point Agg Age (Facility) TB: <15, Male, Positive	
	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Negative	
	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Positive	
	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Negative	
	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Positive	
	Service Delivery Point Agg Age (Facility) TB: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) TB: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) TB: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) TB: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) VMMC: <1, Negative	
	Service Delivery Point (Facility) VMMC: <1, Positive	
	Service Delivery Point (Facility) VMMC: 10-14, Negative	
	Service Delivery Point (Facility) VMMC: 10-14, Positive	
	Service Delivery Point (Facility) VMMC: 15-19, Negative	46,575
	Service Delivery Point (Facility) VMMC: 15-19, Positive	361



	Service Delivery Point (Facility) VMMC: 1-9, Negative	
	Service Delivery Point (Facility) VMMC:	
	Service Delivery Point (Facility) VMMC: 20-24, Negative	54,308
	Service Delivery Point (Facility) VMMC: 20-24, Positive	1,007
	Service Delivery Point (Facility) VMMC: 25-49, Negative	46,575
	Service Delivery Point (Facility) VMMC: 25-49, Positive	1,133
	Service Delivery Point (Facility) VMMC: 50+, Negative	7,766
	Service Delivery Point (Facility) VMMC: 50+, Positive	96
	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	
	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	
	Service Delivery Point Agg Age (Facility) VMMC: <15, Negative	
	Service Delivery Point Agg Age (Facility) VMMC: <15, Positive	
	Service Delivery Point Agg Age (Facility) VMMC: 15+, Negative	
	Service Delivery Point Agg Age (Facility) VMMC: 15+, Positive	
	Service Delivery Point Agg Age (Facility) VMMC: Unknown Age, Negative	
	Service Delivery Point Agg Age (Facility) VMMC: Unknown Age, Positive	



	Service Delivery Point (Facility) Index: 10-14, Female, Negative	3,221
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	20
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	4,121
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	38
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,228
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	694
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	221
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	107
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	4,477
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	2,520
	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,378
	Service Delivery Point (Facility) Index: 20-24, Male, Positive	761
	Service Delivery Point (Facility) Index: 25-49, Female, Negative	21,358
	Service Delivery Point (Facility) Index: 25-49, Female, Positive	12,051
	Service Delivery Point (Facility) Index: 25-49, Male, Negative	26,440
	Service Delivery Point (Facility) Index: 25-49, Male, Positive	14,867
	Service Delivery Point (Facility) Index: 50+, Female, Negative	2,037



	Service Delivery Point (Facility) Index: 50+, Female, Positive	1,142
	Service Delivery Point (Facility) Index: 50+, Male, Negative	3,041
	Service Delivery Point (Facility) Index: 50+, Male, Positive	1,707
	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Index: <1, Negative	3,663
	Service Delivery Point (Facility) Index: <1, Positive	27
	Service Delivery Point (Facility) Index: 1-9, Negative	23,359
	Service Delivery Point (Facility) Index: 1-9, Positive	292
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	
	Service Delivery Point Agg Age	



	(Facility) Index: <15, Male, Positive	
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	
	By Key Population: FSW, Negative	
	By Key Population: FSW, Positive	
	By Key Population: MSM, Negative	
	By Key Population: MSM, Positive	
	By Key Population: People in prisons and other enclosed settings, Negative	
	By Key Population: People in prisons and other enclosed settings, Positive	
	By Key Population: PWID, Negative	



	By Key Population: PWID, Positive	
	By Key Population: TG, Negative	
	By Key Population: TG, Positive	
	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	
	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	
	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	
	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	
	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	
	Service Delivery Point (Community)	



	Index Mod: 25-49, Female, Positive	
	Service Delivery Point (Community)	
	Index Mod: 25-49, Male, Negative	
	Service Delivery Point (Community)	
	Index Mod: 25-49, Male, Positive	
	Service Delivery Point (Community)	
	Index Mod: 50+, Female, Negative	
	Service Delivery Point (Community)	
	Index Mod: 50+, Female, Positive	
	Service Delivery Point (Community)	
	Index Mod: 50+, Male, Negative	
	Service Delivery Point (Community)	
	Index Mod: 50+, Male, Positive	
	Service Delivery Point (Community)	
	Index Mod: Unknown Age, Female, Negative	
	Service Delivery Point (Community)	
	Index Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community)	
	Index Mod: Unknown Age, Male, Negative	
	Service Delivery Point (Community)	
	Index Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community)	
	Index Mod: <1, Negative	
	Service Delivery Point (Community)	
	Index Mod: <1, Positive	
	Service Delivery Point (Community)	
	Index Mod: 1-9, Negative	
	Service Delivery Point (Community)	
	Index Mod: 1-9, Positive	
	Service Delivery Point Agg Age	



	(Community) Index Mod: <15, Female, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: <15, Female, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: <15, Male, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: <15, Male, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: 15+, Female, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: 15+, Female, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: 15+, Male, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: 15+, Male, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: Unknown Age, Male, Positive	



	Service Delivery Point (Facility) ANC: <1, Negative	
	Service Delivery Point (Facility) ANC: <1, Positive	
	Service Delivery Point (Facility) ANC: 10-14, Negative	
	Service Delivery Point (Facility) ANC: 10-14, Positive	
	Service Delivery Point (Facility) ANC: 15-19, Negative	185,452
	Service Delivery Point (Facility) ANC: 15-19, Positive	4,529
	Service Delivery Point (Facility) ANC: 1-9, Negative	
	Service Delivery Point (Facility) ANC: 1-9, Positive	
	Service Delivery Point (Facility) ANC: 20-24, Negative	216,201
	Service Delivery Point (Facility) ANC: 20-24, Positive	5,149
	Service Delivery Point (Facility) ANC: 25-49, Negative	185,452
	Service Delivery Point (Facility) ANC: 25-49, Positive	4,529
	Service Delivery Point (Facility) ANC: 50+, Negative	30,949
	Service Delivery Point (Facility) ANC: 50+, Positive	737
	Service Delivery Point (Facility) ANC: Unknown Age, Negative	
	Service Delivery Point (Facility) ANC: Unknown Age, Positive	
	Service Delivery Point Agg Age (Facility) ANC: <15, Negative	



	Service Delivery Point Agg Age (Facility) ANC: <15, Positive	
	Service Delivery Point Agg Age (Facility) ANC: 15+, Negative	
	Service Delivery Point Agg Age (Facility) ANC: 15+, Positive	
	Service Delivery Point Agg Age (Facility) ANC: Unknown Age, Negative	
	Service Delivery Point Agg Age (Facility) ANC: Unknown Age, Positive	
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	



	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	
	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	
	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	
	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	
	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) VCT: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) VCT: <1, Negative	
	Service Delivery Point (Facility) VCT: <1, Positive	
	Service Delivery Point (Facility) VCT: 1-9, Negative	



	Service Delivery Point (Facility) VCT: 1-9, Positive	
	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Negative	
	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Positive	
	Service Delivery Point Agg Age (Facility) VCT: <15, Male, Negative	
	Service Delivery Point Agg Age (Facility) VCT: <15, Male, Positive	
	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	
	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive	
	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	
	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive	
	Service Delivery Point Agg Age (Facility) VCT: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) VCT: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) VCT: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) VCT: Unknown Age, Male, Positive	
	Service Delivery Point (Community)	



	VCT Mod: 10-14, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	
	Service Delivery Point (Community)	



	VCT Mod: 50+, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community) VCT Mod: <1, Negative	
	Service Delivery Point (Community) VCT Mod: <1, Positive	
	Service Delivery Point (Community) VCT Mod: 1-9, Negative	
	Service Delivery Point (Community) VCT Mod: 1-9, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: <15, Female, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: <15, Female, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: <15, Male, Negative	



	Service Delivery Point Agg Age (Community) VCT Mod: <15, Male, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: 15+, Female, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: 15+, Female, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: 15+, Male, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: 15+, Male, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown Age, Male, Positive	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	100 %
	Number of registered new and relapsed TB cases with documented HIV status, during the	37,098



	reporting period.	
	Total number of registered new and relapsed TB cases, during the reporting period.	37,098
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with	



	documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,461
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	22,270



	reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,094
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12,273
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	



	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,463
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB	22,270



	cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,096
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	12,273
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	100 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	16,492
	Total number of registered new and relapsed TB cases, during the reporting period.	16,492
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	425
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	610
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	5,464
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of	9,993



	registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	610
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9,993
	Aggregated Age/Sex: Female <15	425



	(Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,464
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and	



	relapsed TB cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,578,510
	By Test Result: Positive	223,794
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 10-14, Male,	



	Negative	
	Service Delivery Point (Community) Homebased testing: 10-14, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	
	Service Delivery Point (Community)	



	Homebased testing: 25-49, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 50+, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 50+, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Homebased testing: <1, Negative	
	Service Delivery Point (Community) Homebased testing: <1, Positive	
	Service Delivery Point (Community) Homebased testing: 1-9, Negative	



	Service Delivery Point (Community) Homebased testing: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative	
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative	
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Negative	
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Male, Negative	



	Service Delivery Point by Agg Age (Community) by Aggregated Age: Homebased testing: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	6,494
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	82
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	6,080
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	64
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	28,248
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	1,183
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	4,292
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	140
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	91,832
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	3,865
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	20,943
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	860
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	375,659
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	16,226
	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	390,500



	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	18,430
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	36,976
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	1,601
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	47,903
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	2,252
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Inpatient: <1, Negative	6,987
	Service Delivery Point (Facility) Inpatient: <1, Positive	84
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	37,080
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	488
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	1,921
	Service Delivery Point by Agg Age	77



	(Facility) Inpatient: <15, Female, Positive	
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	1,982
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	69
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	35,765
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	235
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	29,506
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	284
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	0
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	0
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	0
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	0
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	



	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	6,488
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	559
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	19,434
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	1,746
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	12,971
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	1,182
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	32,452
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	3,049
	Service Delivery Point (Community) Mobile Testing: 25-49, Female,	12,734



	Negative	
	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	1,242
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	32,432
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	2,979
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	6,463
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	528
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	6,463
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	528
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: <1, Negative	
	Service Delivery Point (Community)	



	Mobile Testing: <1, Positive	
	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	
	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Positive	



	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	6,433
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	73
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	6,073
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	61
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	29,322
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	1,235
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	5,122
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	197
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	96,587
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	4,067
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	26,475
	Service Delivery Point (Facility)	1,146



	Other PITC: 20-24, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	419,891
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	18,617
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	404,691
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	21,383
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	41,410
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1,833
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	49,157
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	2,596
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	
	Service Delivery Point (Facility)Other PITC: <1, Negative	6,877
	Service Delivery Point (Facility)	76



	Other PITC: <1, Positive	
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	37,100
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	443
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	8,120
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	169
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	8,360
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	165
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	151,455
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	987
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	124,931
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	1,049
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	0



	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	0
	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	
	Service Delivery Point (Community) Other: 10-14, Female, Positive	
	Service Delivery Point (Community) Other: 10-14, Male, Negative	
	Service Delivery Point (Community) Other: 10-14, Male, Positive	
	Service Delivery Point (Community) Other: 15-19, Female, Negative	
	Service Delivery Point (Community) Other: 15-19, Female, Positive	
	Service Delivery Point (Community) Other: 15-19, Male, Negative	
	Service Delivery Point (Community) Other: 15-19, Male, Positive	
	Service Delivery Point (Community) Other: 20-24, Female, Negative	
	Service Delivery Point (Community) Other: 20-24, Female, Positive	
	Service Delivery Point (Community) Other: 20-24, Male, Negative	
	Service Delivery Point (Community) Other: 20-24, Male, Positive	
	Service Delivery Point (Community) Other: 25-49, Female, Negative	
	Service Delivery Point (Community)	



	Other: 25-49, Female, Positive	
	Service Delivery Point (Community) Other: 25-49, Male, Negative	
	Service Delivery Point (Community) Other: 25-49, Male, Positive	
	Service Delivery Point (Community) Other: 50+, Female, Negative	
	Service Delivery Point (Community) Other: 50+, Female, Positive	
	Service Delivery Point (Community) Other: 50+, Male, Negative	
	Service Delivery Point (Community) Other: 50+, Male, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Other: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Other: <1, Negative	
	Service Delivery Point (Community) Other: <1, Positive	
	Service Delivery Point (Community) Other: 1-9, Negative	
	Service Delivery Point (Community) Other: 1-9, Positive	
	Service Delivery Point by Agg Age	



	(Community) Other: <15, Female, Negative	
	Service Delivery Point by Agg Age (Community) Other: <15, Female, Positive	
	Service Delivery Point by Agg Age (Community) Other: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) Other: <15, Male, Positive	
	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	
	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	
	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Positive	



	Service Delivery Point (Facility) Pediatric : <5 Negative	32,123
	Service Delivery Point (Facility) Pediatric : <5 Positive	598
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	283
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	214
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	121
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	33
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	16
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	5
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	545
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	176
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	121
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	29
	Service Delivery Point (Facility) TB: 25-49, Female, Negative	2,978
	Service Delivery Point (Facility) TB: 25-49, Female, Positive	1,339
	Service Delivery Point (Facility) TB: 25-49, Male, Negative	3,146



	Service Delivery Point (Facility) TB: 25-49, Male, Positive	1,242
	Service Delivery Point (Facility) TB: 50+, Female, Negative	199
	Service Delivery Point (Facility) TB: 50+, Female, Positive	53
	Service Delivery Point (Facility) TB: 50+, Male, Negative	326
	Service Delivery Point (Facility) TB: 50+, Male, Positive	103
	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) TB: <1, Negative	274
	Service Delivery Point (Facility) TB: <1, Positive	
	Service Delivery Point (Facility) TB: 1-9, Negative	1,505
	Service Delivery Point (Facility) TB: 1-9, Positive	29
	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	40
	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	12
	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	41
	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	3



	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	677
	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	17
	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	547
	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	11
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	0
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	0
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	0
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) VMMC: <1, Negative	
	Service Delivery Point (Facility) VMMC: <1, Positive	
	Service Delivery Point (Facility) VMMC: 10-14, Negative	
	Service Delivery Point (Facility) VMMC: 10-14, Positive	
	Service Delivery Point (Facility) VMMC: 15-19, Negative	139,128
	Service Delivery Point (Facility) VMMC: 15-19, Positive	1,050
	Service Delivery Point (Facility) VMMC: 1-9, Negative	



	Service Delivery Point (Facility) VMMC: 1-9, Positive	
	Service Delivery Point (Facility) VMMC: 20-24, Negative	162,272
	Service Delivery Point (Facility) VMMC: 20-24, Positive	2,835
	Service Delivery Point (Facility) VMMC: 25-49, Negative	139,128
	Service Delivery Point (Facility) VMMC: 25-49, Positive	3,289
	Service Delivery Point (Facility) VMMC: 50+, Negative	23,195
	Service Delivery Point (Facility) VMMC: 50+, Positive	287
	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	
	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	
	Service Delivery Point (Facility) VMMC: <15, Negative	
	Service Delivery Point by Agg Age (Facility) VMMC: <15, Positive	
	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	
	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	
	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Negative	
	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Positive	
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	3,529



	Service Delivery Point (Facility) Index: 10-14, Female, Positive	23
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	3,300
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	22
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	2,322
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	1,302
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	412
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	202
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	7,559
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	4,252
	Service Delivery Point (Facility) Index: 20-24, Male, Negative	2,004
	Service Delivery Point (Facility) Index: 20-24, Male, Positive	1,118
	Service Delivery Point (Facility) Index: 25-49, Female, Negative	33,966
	Service Delivery Point (Facility) Index: 25-49, Female, Positive	19,176
	Service Delivery Point (Facility) Index: 25-49, Male, Negative	43,385
	Service Delivery Point (Facility) Index: 25-49, Male, Positive	24,414
	Service Delivery Point (Facility) Index: 50+, Female, Negative	3,351
	Service Delivery Point (Facility) Index: 50+, Female, Positive	1,873



	Service Delivery Point (Facility) Index: 50+, Male, Negative	5,292
	Service Delivery Point (Facility) Index: 50+, Male, Positive	2,954
	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Index: <1, Negative	3,812
	Service Delivery Point (Facility) Index: <1, Positive	29
	Service Delivery Point (Facility) Index: 1-9, Negative	19,959
	Service Delivery Point (Facility) Index: 1-9, Positive	277
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	2,228
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	91
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	2,091
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	89
	Service Delivery Point Agg Age	38,033



	(Facility) Index: 15+, Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	542
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	31,386
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	546
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	0
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	0
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Negative	0
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	0
	By Key Population: FSW, Negative	
	By Key Population: FSW, Positive	
	By Key Population: MSM, Negative	
	By Key Population: MSM, Positive	
	By Key Population: People in prisons and other enclosed settings, Negative	
	By Key Population: People in prisons and other enclosed settings, Positive	
	By Key Population: PWID, Negative	
	By Key Population: PWID, Positive	
	By Key Population: TG, Negative	



	By Key Population: TG, Positive	
	Service Delivery Point (Facility) Malnutrition: Negative	62,025
	Service Delivery Point (Facility) Malnutrition: Positive	867
	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	2,735
	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	2
	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	2,662
	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	9
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	731
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	343
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	117
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	54
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	2,558
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	1,356
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	643
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	298
	Service Delivery Point (Community) Index Mod: 25-49, Female,	12,240



	Negative	
	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	7,268
	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	16,688
	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	9,373
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	1,051
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	511
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	1,758
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	926
	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Index Mod: <1, Negative	3,063
	Service Delivery Point (Community) Index Mod: <1, Positive	11
	Service Delivery Point (Community) Index Mod: 1-9, Negative	15,776
	Service Delivery Point (Community)	249



	Index Mod: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age	



	(Community) Index Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) ANC: <1, Negative	
	Service Delivery Point (Facility) ANC: <1, Positive	
	Service Delivery Point (Facility) ANC: 10-14, Negative	
	Service Delivery Point (Facility) ANC: 10-14, Positive	
	Service Delivery Point (Facility) ANC: 15-19, Negative	223,522
	Service Delivery Point (Facility) ANC: 15-19, Positive	6,461
	Service Delivery Point (Facility) ANC: 1-9, Negative	
	Service Delivery Point (Facility) ANC: 1-9, Positive	
	Service Delivery Point (Facility) ANC: 20-24, Negative	260,611
	Service Delivery Point (Facility) ANC: 20-24, Positive	7,469
	Service Delivery Point (Facility) ANC: 25-49, Negative	223,522
	Service Delivery Point (Facility) ANC: 25-49, Positive	6,461
	Service Delivery Point (Facility) ANC: 50+, Negative	37,279
	Service Delivery Point (Facility) ANC: 50+, Positive	1,069
	Service Delivery Point (Facility) ANC: Unknown Age, Negative	
	Service Delivery Point (Facility) ANC: Unknown Age, Positive	



	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	0
	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	0
	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	79,671
	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	1,840
	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	0
	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	0
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	



	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	
	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	
	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	
	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	
	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) VCT:	
	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) VCT: <1, Negative	
	Service Delivery Point (Facility) VCT: <1, Positive	



	Service Delivery Point (Facility) VCT: 1-9, Negative	
	Service Delivery Point (Facility) VCT: 1-9, Positive	
	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	457
	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	35
	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	469
	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	33
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	8,188
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	100
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	6,755
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	123
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	0
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Positive	0
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	0
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male,	0



	Positive	
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Positive	
	Service Delivery Point (Community)	



	VCT Mod: 50+, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community) VCT Mod: <1, Negative	
	Service Delivery Point (Community) VCT Mod: <1, Positive	
	Service Delivery Point (Community) VCT Mod: 1-9, Negative	
	Service Delivery Point (Community) VCT Mod: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Female, Positive	
	Service Delivery Point by Agg Age	



	(Community) VCT Mod: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Male, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Positive	
GEND_GBV_DSD	Number of people receiving post-GBV care	13,476
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	2,321
	By type of service: Sexual Violence	8,126



	(Post-Rape Care)	
	By PEP service provision (related to sexual violence services provided)	1,180
	<10, Female, Physical and/or Emotional Violence	19
	<10, Female, Sexual Violence (Post-Rape Care)	62
	<10, Male, Physical and/or Emotional Violence	2
	<10, Male, Sexual Violence (Post-Rape Care)	14
	10-14, Female, Physical and/or Emotional Violence	46
	10-14, Female, Sexual Violence (Post-Rape Care)	94
	10-14, Male, Physical and/or Emotional Violence	1
	10-14, Male, Sexual Violence (Post-Rape Care)	11
	15-19, Female, Physical and/or Emotional Violence	61
	15-19, Female, Sexual Violence (Post-Rape Care)	154
	15-19, Male, Physical and/or Emotional Violence	13
	15-19, Male, Sexual Violence (Post-Rape Care)	40
	20-24, Female, Physical and/or Emotional Violence	77
	20-24, Female, Sexual Violence (Post-Rape Care)	186
	20-24, Male, Physical and/or Emotional Violence	24
	20-24, Male, Sexual Violence	70



	(Post-Rape Care)	
	25-49, Female, Physical and/or Emotional Violence	61
	25-49, Female, Sexual Violence (Post-Rape Care)	385
	25-49, Male, Physical and/or Emotional Violence	40
	25-49, Male, Sexual Violence (Post-Rape Care)	111
	50+, Female, Physical and/or Emotional Violence	61
	50+, Female, Sexual Violence (Post-Rape Care)	166
	50+, Male, Physical and/or Emotional Violence	40
	50+, Male, Sexual Violence (Post-Rape Care)	111
	Unknown Age, Female, Physical and/or Emotional Violence	
	Unknown Age, Female, Sexual Violence (Post-Rape Care)	
	Unknown Age, Male, Physical and/or Emotional Violence	
	Unknown Age, Male, Sexual Violence (Post-Rape Care)	
GEND_GBV_TA	Number of people receiving post-GBV care	13,700
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	2,423
	By type of service: Sexual Violence (Post-Rape Care)	8,498
	By PEP service provision (related to sexual violence services provided)	1,256



	<10, Female, Physical and/or Emotional Violence	14
	<10, Female, Sexual Violence (Post-Rape Care)	47
	<10, Male, Physical and/or Emotional Violence	2
	<10, Male, Sexual Violence (Post-Rape Care)	14
	10-14, Female, Physical and/or Emotional Violence	17
	10-14, Female, Sexual Violence (Post-Rape Care)	52
	10-14, Male, Physical and/or Emotional Violence	
	10-14, Male, Sexual Violence (Post-Rape Care)	10
	15-19, Female, Physical and/or Emotional Violence	48
	15-19, Female, Sexual Violence (Post-Rape Care)	120
	15-19, Male, Physical and/or Emotional Violence	13
	15-19, Male, Sexual Violence (Post-Rape Care)	37
	20-24, Female, Physical and/or Emotional Violence	58
	20-24, Female, Sexual Violence (Post-Rape Care)	155
	20-24, Male, Physical and/or Emotional Violence	26
	20-24, Male, Sexual Violence (Post-Rape Care)	65
	25-49, Female, Physical and/or Emotional Violence	58



	25-49, Female, Sexual Violence (Post-Rape Care)	293
	25-49, Male, Physical and/or Emotional Violence	38
	25-49, Male, Sexual Violence (Post-Rape Care)	103
	50+, Female, Physical and/or Emotional Violence	58
	50+, Female, Sexual Violence (Post-Rape Care)	154
	50+, Male, Physical and/or Emotional Violence	38
	50+, Male, Sexual Violence (Post-Rape Care)	103
	Unknown Age, Female, Physical and/or Emotional Violence	
	Unknown Age, Female, Sexual Violence (Post-Rape Care)	
	Unknown Age, Male, Physical and/or Emotional Violence	
	Unknown Age, Male, Sexual Violence (Post-Rape Care)	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	436,933
	Age/Sex: 10-14 Male	39,639
	Age/Sex: 15-17 Male	37,015
	By: Age/sex: Male 18-24	39,937
	By: Age/sex: Male 25+	9,135
	Age/Sex: 18+ Male	
	Age/Sex: 10-14 Female	57,234
	Age/Sex: 15-17 Female	30,642
	By: Age/sex: 18-24 Female	45,670



	By: Age/sex: 25+ Female	13,134
	Age/Sex: 18+ Female	
	Sum of Age/Sex disaggregates	164,530
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	
	Required only for DREAMS countries - By service, age and sex:	



	Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS	



	countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex:	



	Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	



	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	17,353
	Age/Sex: 1-9	145,606
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	



	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	329,913
	Program Completion: Graduation	63,283
	Program Completion: Transferred	21,997
	Program Completion: Exited without graduation	21,740
	By Aggregated Age/Sex: <18 Male	
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex:	



	Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	95 %
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	15,335
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	16,145
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	



	<p>Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	



	reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	566
	Aggregated Age/Sex: Male 15+	9,284



	(Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	409
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5,076
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and	



	relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19	



	(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	597
	Aggregated Age/Sex: Male 15+ (Denominator: The number of	9,759



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	440
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	5,349
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	95 %
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	6,721
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	7,070
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	



	reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	205
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,168
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	148
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,200
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	



	period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	



	period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	215
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	4,388
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	157
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	2,310
TB_PREV_DSD	TB_PREV_DSD TB_PREV_DSD	50 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	103,795
	The number of ART patients who	207,580



	were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
	By Age/Sex (Denominator): <15, Female	3,133
	By Age/Sex (Denominator): <15, Male	2,604
	By Age/Sex (Denominator): 15+, Female	101,849
	By Age/Sex (Denominator): 15+, Male	100,035
	By Therapy type (Denominator): 6-12 Month IPT	207,580
	By Therapy type (Denominator): Alternative Regimen	0
	By Therapy type (Denominator): Continuous IPT	0
	By Age/Sex (Numerator): <15, Female	1,427
	By Age/Sex (Numerator): <15, Male	1,236
	By Age/Sex (Numerator): 15+, Female	50,918
	By Age/Sex (Numerator): 15+, Male	50,214
	By Therapy type (Numerator): 6-12 Month IPT	103,795
	By Therapy type (Numerator): Alternative Regimen	0
	By Therapy type (Numerator):	0



	Continuous IPT	
	TB_PREV_TA TB_PREV_TA	50 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	40,192
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	80,387
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	1,337
	By Age/Sex (Denominator): <15, Male	993
	By Age/Sex (Denominator): 15+, Female	38,645
	By Age/Sex (Denominator): 15+, Male	39,412
	By Therapy type (Denominator): 6-12 Month IPT	80,387
	By Therapy type (Denominator):Alternative Regimen	
	By Therapy type (Denominator):Continuous IPT	
	By Age/Sex (Numerator): <15, Female	492
	By Age/Sex (Numerator): <15, Male	419



	By Age/Sex (Numerator): 15+, Female	19,338
	By Age/Sex (Numerator): 15+, Male	19,943
	By Therapy type (Numerator): 6-12 Month IPT	40,192
	By Therapy type (Numerator): Alternative Regimen	
	By Therapy type (Numerator): Continuous IPT	
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	2 %
	Number of ART patients who were started on TB treatment during the reporting period.	17,332
	Number of ART patients who were screened for TB at least once during the reporting period	866,355
	Numerator: By Aggregated Age/Sex: <15, Female	553
	Numerator: By Aggregated Age/Sex: <15, Male	457
	Numerator: By Aggregated Age/Sex: 15+, Female	10,272
	Numerator: By Aggregated Age/Sex: 15+, Male	6,050
	Denominator: By Aggregated Age/Sex: <15, Female	30,906
	Denominator: By Aggregated Age/Sex: <15, Male	25,622
	Denominator: By Aggregated Age/Sex: 15+, Female	512,217
	Denominator: By Aggregated Age/Sex: 15+, Male	297,600



	Denominator: By Screen Result: Negative	797,046
	Denominator: By Screen Result: Positive	69,309
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	69,515
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	6,902
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	13,859
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	48,548
TX_TB_TA	TX_TB_TA The proportion of ART patients who were screened who are receiving TB treatment	2 %
	Number of ART patients who were started on TB treatment during the reporting period.	6,842
	Number of ART patients who were screened for TB at least once during the reporting period	341,737
	Numerator: By Aggregated Age/Sex: <15, Female	143
	Numerator: By Aggregated Age/Sex: <15, Male	105
	Numerator: By Aggregated Age/Sex: 15+, Female	3,977
	Numerator: By Aggregated Age/Sex: 15+, Male	2,617
	Denominator: By Aggregated	11,309



	Age/Sex: <15, Female	
	Denominator: By Aggregated Age/Sex: <15, Male	9,292
	Denominator: By Aggregated Age/Sex: 15+, Female	196,221
	Denominator: By Aggregated Age/Sex: 15+, Male	124,915
	Denominator: By Screen Result: Negative	314,405
	Denominator: By Screen Result: Positive	27,332
	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	27,332
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	2,704
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	5,460
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	19,168
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	36,873
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into	



	PMTCT)	
	By infants who received a virologic test within 2 months of birth	
	By infants who received their first virologic HIV test between 2 and 12 months of age	
	Sum of Infant Age disaggregates	
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	1,007
	Number of infants with a positive virological test result within 12 months of birth	
	Unknown, <= 2 months	0
	Unknown, 2 - 12 months	0
	Number of infants with a negative virological test result within 2 months of birth	24,310
	Number of infants with a positive virological test result between 2 and 12 months of birth	427
	Number of infants with a negative virological test result between 2 and 12 months of birth	11,129
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	29,227
	Number of HIV- positive pregnant	



	women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	
	By infants who received their first virologic HIV test between 2 and 12 months of age	
	Sum of Infant Age disaggregates	
	By infants with a positive virologic test result within 12 months of birth	
	Unknown, <= 2 months	
	Unknown, 2 - 12 months	
	Number of infants with a positive virological test result within 2 months of birth	936
	Number of infants with a negative virological test result within 2 months of birth	19,317
	Number of infants with a positive virological test result between 2 and 12 months of birth	369
	Number of infants with a negative virological test result between 2 and 12 months of birth	8,605
	Number of infants with a positive virological test result within 12 months of birth	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	866,000
	Age/Sex: 15-19 Male	5,031
	Age/Sex: 15-19 Female	19,406



	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	671
	Aggregated Age/Sex: 15+ Male	1,061
	Aggregated Age/Sex: <15 Female	819
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	4,244
	Sum of Aggregated Age/Sex <15	1,490
	Sum of Aggregated Age/Sex 15+	5,305
	Sum of Aggregated Age/Sex disaggregates	6,795
	Age/Sex: <1	2,072
	Age/Sex: <1-9	33,583
	Age/Sex: 10-14 Male	8,149
	Age/Sex: 10-14 Female	11,229
	Aggregated Age/Sex: 1-14 Male	
	Age/Sex: 20-24 Male	18,899
	Age/Sex: 25-49 Male	241,976
	Age/Sex: 50+ Male	30,639
	Age/Sex: 20-24 Female	59,518
	Age/Sex: 25-49 Female	390,388
	Age/Sex: 50+ Female	38,670
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	341,737
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	2,410
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	



	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	9,529
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	11,939
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	
	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	
	Sum of Aggregated Age/Sex disaggregates	
	Age/Sex: <1	862
	Age/Sex: 1-9	12,435
	Age/Sex: 10-14 Male	3,082
	Age/Sex: 10-14 Female	4,222
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	9,573
	Age/Sex: 25-49 Male	101,903
	Age/Sex: 50+ Male	11,032
	Age/Sex: 20-24 Female	28,177
	Age/Sex: 25-49 Female	144,426
	Age/Sex: 50+ Female	14,086
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	230,804



	By Age/Sex: <1	1,827
	By Age/Sex: 1-9	2,169
	By Age/Sex: 10-14 Male	470
	By Age/Sex: 15-19 Male	1,056
	By Age/Sex: 20-24 Male	4,166
	By Age/Sex: 25-49 Male	92,462
	By Age/Sex: 50+ Male	11,551
	By Age/Sex: 10-14 Female	544
	By Age/Sex: 15-19 Female	5,515
	By Age/Sex: 20-24 Female	17,203
	By Age/Sex: 25-49 Female	80,204
	By Age/Sex: 50+ Female	7,941
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	648
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	1,853
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	734
	Aggregated Grouping by Age/Sex: 15+ Female	2,461
	Pregnancy status	55,279
	Breastfeeding status	643
	FSW	
	MSM	
	People in prisons and other enclosed settings	



	TG	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	By Key populations: People who inject drugs (PWID)	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	89,261
	By Age/Sex: <1	781
	By Age/Sex: 1-9	1,237
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	218
	By Age/Sex: 15-19 Male	532
	By Age/Sex: 20-24 Male	2,239
	By Age/Sex: 25-49 Male	37,079
	By Age/Sex: 50+ Male	4,054
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	223
	By Age/Sex: 15-19 Female	2,273
	By Age/Sex: 20-24 Female	7,049
	By Age/Sex: 25-49 Female	30,607
	By Age/Sex: 50+ Female	2,969
	Sum of Age/Sex disaggregates	87,243
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	
Aggregated Grouping by Age/Sex:		



	1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	
	Sum of Aggregated Age/Sex disaggregates	
	Pregnancy status	20,586
	Breastfeeding status	196
	FSW	
	MSM	
	People in prisons and other enclosed settings	
	TG	
	By Key populations: People who inject drugs (PWID)	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	90 %
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results	702,042



	within the past 12 months.	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	780,087
	Numerator: Indication: Routine	702,042
	Numerator: Indication: Targeted	0
	Numerator: Preg/BF by Indication: Pregnant Routine	70,277
	Numerator: Preg/BF by Indication: Breastfeeding Routine	3,593
	Numerator: Preg/BF by Indication: Pregnant Targeted	0
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	0
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	



	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	0
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	0



	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	0
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	0
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	20,773
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	241,136
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	25,058
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	415,075
	Denominator: Indication: Routine	780,054
	Denominator: Indication: Targeted	0
	Denominator: Preg/BF by Indication: Pregnant Routine	77,994
	Denominator: Preg/BF by Indication: Breastfeeding Routine	3,908
	Denominator: Preg/BF by Indication: Pregnant Targeted	0
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	0
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	



	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	



	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	0
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	0
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	0
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	0
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	23,153
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	267,978
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	27,901
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	461,029
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	



	<15, Routine, Unknown Sex	0
	<15, Targeted, Unknown Sex	0
	<15, Undocumented Test Indication, Female	0
	<15, Undocumented Test Indication, Male	0
	<15, Undocumented Test Indication, Unknown Sex	0
	15+, Routine, Unknown Sex	0
	15+, Targeted, Unknown Sex	0
	15+, Undocumented Test Indication, Female	0
	15+, Undocumented Test Indication, Male	0
	15+, Undocumented Test Indication, Unknown Sex	0
	Unknown Age, Routine, Female	0
	Unknown Age, Routine, Male	0
	Unknown Age, Routine, Unknown Sex	0
	Unknown Age, Targeted, Female	0
	Unknown Age, Targeted, Male	0
	Unknown Age, Targeted, Unknown Sex	0
	Unknown Age, Undocumented Test Indication, Female	0
	Unknown Age, Undocumented Test Indication, Male	0
	Unknown Age, Undocumented Test Indication, Unknown Sex	0
	Breastfeeding, Undocumented Test Indication	0
	Pregnant, Undocumented Test Indication	0



	Undocumented Test Indication	0
	<15, Routine, Unknown Sex	0
	<15, Targeted, Unknown Sex	0
	<15, Undocumented Test Indication, Female	0
	<15, Undocumented Test Indication, Male	0
	<15, Undocumented Test Indication, Unknown Sex	0
	15+, Routine, Unknown Sex	0
	15+, Targeted, Unknown Sex	0
	15+, Undocumented Test Indication, Female	0
	15+, Undocumented Test Indication, Male	0
	15+, Undocumented Test Indication, Unknown Sex	0
	Unknown Age, Routine, Female	0
	Unknown Age, Routine, Male	0
	Unknown Age, Routine, Unknown Sex	0
	Unknown Age, Targeted, Female	0
	Unknown Age, Targeted, Male	0
	Unknown Age, Targeted, Unknown Sex	0
	Unknown Age, Undocumented Test Indication, Female	0
	Unknown Age, Undocumented Test Indication, Male	0
	Unknown Age, Undocumented Test Indication, Unknown Sex	0
	Breastfeeding, Undocumented Test Indication	0



	Pregnant, Undocumented Test Indication	0
	Undocumented Test Indication	0
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	90 %
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	276,802
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	307,598
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	



	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	



	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	9,141
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	7,538
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	158,957
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	101,166
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	276,802
	Numerator: Indication: Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	1,445
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	27,742
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	307,598
	Denominator: Indication: Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	



	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	



	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	10,265
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	8,445
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	176,423
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	112,465
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	1,522
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	30,750
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	



	Numerator Aggregated Age/Sex: 15+ Male	
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	
	<15, Routine, Unknown Sex	
	<15, Targeted, Unknown Sex	
	<15, Undocumented Test Indication, Female	
	<15, Undocumented Test Indication, Male	
	<15, Undocumented Test Indication, Unknown Sex	
	15+, Routine, Unknown Sex	
	15+, Targeted, Unknown Sex	
	15+, Undocumented Test Indication, Female	
	15+, Undocumented Test Indication, Male	
	15+, Undocumented Test Indication, Unknown Sex	
	Unknown Age, Routine, Female	
	Unknown Age, Routine, Male	
	Unknown Age, Routine, Unknown Sex	



	Unknown Age, Targeted, Female	
	Unknown Age, Targeted, Male	
	Unknown Age, Targeted, Unknown Sex	
	Unknown Age, Undocumented Test Indication, Female	
	Unknown Age, Undocumented Test Indication, Male	
	Unknown Age, Undocumented Test Indication, Unknown Sex	
	Breastfeeding, Undocumented Test Indication	
	Pregnant, Undocumented Test Indication	
	Undocumented Test Indication	
	<15, Routine, Unknown Sex	
	<15, Targeted, Unknown Sex	
	<15, Undocumented Test Indication, Female	
	<15, Undocumented Test Indication, Male	
	<15, Undocumented Test Indication, Unknown Sex	
	15+, Routine, Unknown Sex	
	15+, Targeted, Unknown Sex	
	15+, Undocumented Test Indication, Female	
	15+, Undocumented Test Indication, Male	
	15+, Undocumented Test Indication, Unknown Sex	
	Unknown Age, Routine, Female	
	Unknown Age, Routine, Male	



	Unknown Age, Routine, Unknown Sex	
	Unknown Age, Targeted, Female	
	Unknown Age, Targeted, Male	
	Unknown Age, Targeted, Unknown Sex	
	Unknown Age, Undocumented Test Indication, Female	
	Unknown Age, Undocumented Test Indication, Male	
	Unknown Age, Undocumented Test Indication, Unknown Sex	
	Breastfeeding, Undocumented Test Indication	
	Pregnant, Undocumented Test Indication	
	Undocumented Test Indication	
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	91 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	84,246
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	93,087
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female	



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator:	



	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator:	



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	40
	Numerator by Status: Breastfeeding	2
	Denominator by Status: Pregnant	52
	Denominator by Status: Breastfeeding	4
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,780
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and	29,044



	children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,130
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	49,292
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,788
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	32,435
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	3,141



	those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	54,726
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	90 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	48,492
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	53,670
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children	



	<p>who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,</p>	



	those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of	



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,607
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16,623
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,823
	Aggregated Age/Sex: 15+ Female	28,439



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,609
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18,683
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,826
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	31,552



HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	461
	By Graduates: Doctors	
	By Graduates: Nurses	25
	By Graduates: Midwives	53
	By Graduates: Social service workers	
	By Graduates: Laboratory professionals	
	By Graduates: Other	383
	Sum of Graduates disaggreagtes	461



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
9043	Henry Jackson Foundation	Private Contractor	U.S. Department of Defense	GHP-State	9,490,422
9167	Kalangala District Health Office	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
9183	The AIDS Support Organization	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
9303	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	41,750
10326	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	0
11479	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	50,000
11480	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	149,410
12981	Uganda Virus	Host Country	U.S. Department	GHP-State	0



	Research Institute	Government Agency	of Health and Human Services/Centers for Disease Control and Prevention		
13002	United Nations High Commissioner for Refugees	Multi-lateral Agency	U.S. Department of State/Bureau of Population, Refugees, and Migration	GHP-State	687,665
13029	Regional Procurement Support Office/Frankfurt	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	0
13170	Makerere University School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13317	Joint Clinical Research Center, Uganda	NGO	U.S. Agency for International Development	GHP-State	0
13466	Uganda Protestant Medical Board	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13717	Registered Trustees for the Uganda Episcopal Conference	Implementing Agency	U.S. Department of Health and Human Services/Centers	GHP-State	0



			for Disease Control and Prevention		
13835	Baylor College of Medicine Children's Foundation	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13837	QED Group, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	956,639
13841	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	240,480
13864	Ministry of Health, Uganda	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13874	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	626,250
13877	Children's AIDS Fund	NGO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	0



			Control and Prevention		
13880	Makerere University School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13892	Research Triangle International	Private Contractor	U.S. Agency for International Development	GHP-State	937,601
13901	FHI 360	NGO	U.S. Agency for International Development	GHP-State	1,795,686
16594	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development	GHP-State	776,750
16626	Cardno Emerging Markets	NGO	U.S. Agency for International Development	GHP-State	0
17063	Uganda Health Marketing Group	NGO	U.S. Agency for International Development	GHP-State	1,260,000
17065	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	7,428,800
17066	World Vision	NGO	U.S. Agency for International Development	GHP-State	1,061,113
17078	University Research Council	NGO	U.S. Agency for International Development	GHP-State	1,003,500
17094	Management	NGO	U.S. Agency for	GHP-State	1,276,535



	Sciences for Health		International Development		
17649	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	10,025,345
17651	TBD	TBD	Redacted	Redacted	Redacted
17654	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Agency for International Development	GHP-State	11,521,435
17688	TBD	TBD	Redacted	Redacted	Redacted
17690	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	594,907
17696	World Education	NGO	U.S. Agency for International Development	GHP-State	8,304,049
17698	Uganda Prisons Services	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,111,208
17703	Makerere University School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,539,387
17704	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	0



			Control and Prevention		
17705	Makerere University John Hopkins University Collaboration	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	417,500
17706	Infectious Disease Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	10,932,012
17855	Research Triangle International	Private Contractor	U.S. Department of Defense	GHP-State	1,951,131
17874	National Medical Research Unit	NGO	U.S. Department of Defense	GHP-State	125,250
17976	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17977	American International Health Alliance Twinning Center	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	338,175
17978	Infectious Disease Institute	NGO	U.S. Department of Health and	GHP-State	19,666,670



			Human Services/Centers for Disease Control and Prevention		
17979	Medical Access Uganda Limited (MAUL)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	39,581,963
18003	Global Healthcare Public Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	157,112
18017	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,001
18032	TBD	TBD	Redacted	Redacted	Redacted
18033	TBD	TBD	Redacted	Redacted	Redacted
18034	The AIDS Support Organization	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,287,306
18041	TBD	TBD	Redacted	Redacted	Redacted



18042	Makerere University School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	850,000
18273	TBD	TBD	Redacted	Redacted	Redacted
18274	TBD	TBD	Redacted	Redacted	Redacted
18276	DevTech Systems Inc	Private Contractor	U.S. Agency for International Development	GHP-State	500,000
18361	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	59,035
18369	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	16,222,162
18502	Population Services International	NGO	U.S. Department of Defense	GHP-State	850,000
18553	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	182,545
18554	Right to Care	NGO	U.S. Agency for International Development	GHP-State	208,750
18557	TBD	TBD	Redacted	Redacted	Redacted
18559	TBD	TBD	Redacted	Redacted	Redacted
18560	TBD	TBD	Redacted	Redacted	Redacted
18561	TBD	TBD	Redacted	Redacted	Redacted
18562	TBD	TBD	Redacted	Redacted	Redacted
18563	TBD	TBD	Redacted	Redacted	Redacted
18565	TBD	TBD	Redacted	Redacted	Redacted



18566	TBD	TBD	Redacted	Redacted	Redacted
18567	TBD	TBD	Redacted	Redacted	Redacted
18568	Population Council	NGO	U.S. Agency for International Development	GHP-State	54,764
18569	UNICEF	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	101,818
18583	STOP TB Partnership Trust Fund	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	987,367
18668	TBD	TBD	Redacted	Redacted	Redacted
18671	Infectious Disease Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
18672	TBD	TBD	Redacted	Redacted	Redacted



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 9043	Mechanism Name: Makerere University Walter Reed Project (MUWRP)
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Henry Jackson Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 9,490,422	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 9,490,422	
Funding Source	Funding Amount
GHP-State	9,490,422

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	10,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	40,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions



	for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Gender: GBV	130,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Collection and Use of Gender-related Strategic Information
Food and Nutrition: Commodities	10,000
Condom programming	12,000
Motor Vehicles: Purchased	150,000
Human Resources for Health	110,000
Economic Strengthening	10,000
Construction	1,400,000
Food and Nutrition: Policy, Tools, and Service Delivery	2,000

Budget Code Information

Mechanism ID:	9043		
Mechanism Name:	Makerere University Walter Reed Project (MUWRP)		
Prime Partner Name:	Henry Jackson Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	1,514,522	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,156,803	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	754,488	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	81,063	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	225,450	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	750,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	375,101	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	3,867	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	615,353	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	977,817	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	348,893	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,635,628	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	51,437	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,968
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	47,209
PMTCT_ART_DSD	New on ART	1,345
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,623
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,746
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	27,295
PMTCT_ART_TA	New on ART	795
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	951
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	47,209
PMTCT_STAT_DSD	By Age (Denominator): 10-14	474
PMTCT_STAT_DSD	By Age (Denominator): <15-19	8,972
PMTCT_STAT_DSD	By Age (Denominator): 20-24	8,972
PMTCT_STAT_DSD	By Age (Denominator): 25-49	28,791
PMTCT_STAT_DSD	By Number of known positives: 10-14	14
PMTCT_STAT_DSD	By Number of known positives: 15-19	301



PMTCT_STAT_DSD	By Number of known positives: 20-24	538
PMTCT_STAT_DSD	By Number of known positives: 25-49	734
PMTCT_STAT_DSD	By Number of new positives: 10-14	13
PMTCT_STAT_DSD	By Number of new positives: 15-19	293
PMTCT_STAT_DSD	By Number of new positives: 20-24	522
PMTCT_STAT_DSD	By Number of new positives: 25-49	709
PMTCT_STAT_DSD	By Number of new negative: 10-14	447
PMTCT_STAT_DSD	By Number of new negative: 15-19	8,378
PMTCT_STAT_DSD	By Number of new negative: 20-24	7,912
PMTCT_STAT_DSD	By Number of new negative: 25-49	27,348
PMTCT_STAT_DSD	By Age (Numerator): 10-14	474
PMTCT_STAT_DSD	By Age (Numerator): 15-19	8,972
PMTCT_STAT_DSD	By Age (Numerator): 20-24	8,972
PMTCT_STAT_DSD	By Age (Numerator): 25-49	28,791
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	27,295
PMTCT_STAT_TA	By Age (Denominator): 10-14	273
PMTCT_STAT_TA	By Age (Denominator): 15-19	5,186
PMTCT_STAT_TA	By Age (Denominator): 20-24	5,186
PMTCT_STAT_TA	By Age (Denominator): 25-49	16,650
PMTCT_STAT_TA	By known positives: 10-14	2
PMTCT_STAT_TA	By known positives: 15-19	184
PMTCT_STAT_TA	By known positives: 20-24	326
PMTCT_STAT_TA	By known positives: 25-49	451
PMTCT_STAT_TA	By new positives: 10-14	2
PMTCT_STAT_TA	By new positives: 15-19	167
PMTCT_STAT_TA	By new positives: 20-24	295
PMTCT_STAT_TA	By new positives: 25-49	410
PMTCT_STAT_TA	By new negatives: 10-14	269
PMTCT_STAT_TA	By new negatives: 15-19	4,835
PMTCT_STAT_TA	By new negatives: 20-24	4,565



PMTCT_STAT_TA	By new negatives: 25-49	15,789
PMTCT_STAT_TA	By Age (Numerator): 10-14	273
PMTCT_STAT_TA	By Age (Numerator): : 15-19	5,186
PMTCT_STAT_TA	By Age (Numerator): 20-24	5,186
PMTCT_STAT_TA	By Age (Numerator): 25-49	16,650
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	33,801
VMMC_CIRC_DSD	By Age: 10-14	3,382
VMMC_CIRC_DSD	By Age: 15-19	6,083
VMMC_CIRC_DSD	By Age: 20-24	8,113
VMMC_CIRC_DSD	By Age: 25-29	12,846
VMMC_CIRC_DSD	By Age: 30-49	2,027
VMMC_CIRC_DSD	By Age: 50+	1,350
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	18,928
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	33,801
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	2,863
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	319
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,400
PrEP_NEW_DSD	Male 15-19	176
PrEP_NEW_DSD	Male 20-24	176
PrEP_NEW_DSD	Male 25-49	176
PrEP_NEW_DSD	Male 50+	176
PrEP_NEW_DSD	Female 15-19	176
PrEP_NEW_DSD	Female 20-24	176
PrEP_NEW_DSD	Female 25-49	176
PrEP_NEW_DSD	Female 50+	168
PrEP_NEW_DSD	FSW	126
PrEP_NEW_DSD	MSM	5
PrEP_NEW_DSD	TG	1



PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	59,070
PP_PREV_DSD	Age/sex: 10-14 Male	3,222
PP_PREV_DSD	Age/sex: 15-19 Male	6,272
PP_PREV_DSD	Age/sex: 20-24 Male	10,730
PP_PREV_DSD	Age/sex: 25-49 Male	22,219
PP_PREV_DSD	Age/sex: 50+ Male	476
PP_PREV_DSD	Age/sex: 10-14 Female	3,899
PP_PREV_DSD	Age/sex: 15-19 Female	3,555
PP_PREV_DSD	Age/sex: 20-24 Female	3,684
PP_PREV_DSD	Age/sex: 25-49 Female	4,628
PP_PREV_DSD	Age/sex: 50+ Female	385
PP_PREV_DSD	Sum of Age/Sex disaggregates	59,070
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	19,755
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	11,659
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,096
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	207,468
HTC_TST_DSD	By Test Result: Positive	17,039
HTC_TST_DSD	Sum of Test Result disaggregates	17,039
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14,	39



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	86
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	800
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	172
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,594
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	123
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	721
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	15,373
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	858
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	18,303
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	1,121
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	1,507
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	84
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male,	2,258



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	138
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	332
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	380
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	780
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	84
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	2,333
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	260
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	1,554
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	173
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	3,885
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	442
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	1,536
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	168
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	3,885
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	436
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	777
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+,	81



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	777
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	81
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	40
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	72
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	817
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	53
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	141
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	2,755
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	188
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	660
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	17,967
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	1,302
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	21,252
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	1,747
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+,	1,766



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	126
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	2,589
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	213
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	306
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	378
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	397
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	150
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	69
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	197
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	82
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female,	1



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	6,877
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	55
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	8,011
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	142
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	6,877
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	162
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	1,144
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	125
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	73
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	422
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	236
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	145
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	80



HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	3,219
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	1,818
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	4,724
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	2,657
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	314
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	175
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	582
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	323
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	153
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	227
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	33
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	132



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	68
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	37
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	1,021
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	586
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	1,448
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	817
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	94
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	50
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	172
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	100
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	72
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	126
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	14,003
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	487
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	16,334
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	561



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	14,003
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	487
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	2,335
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	82
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	88,090
HTC_TST_TA	By Test Result: Positive	6,625
HTC_TST_TA	Sum of Test Result disaggregates	6,625
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	328
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	17
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	42
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,356
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	62
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	347
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	16
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	7,486
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	410
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	8,217
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	492
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female,	768



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	42
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	1,063
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	63
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	89
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	147
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	416
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	24
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	35
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,818
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	107
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	395
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	26
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	10,158
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49,	711



	Female, Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	11,002
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	859
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,010
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	63
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,359
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	103
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	103
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	171
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	176
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Negative	84
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Positive	39
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Negative	90
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Positive	34
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	1



HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	2,110
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	15
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	2,452
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	50
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Negative	2,110
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Positive	48
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	353
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	54
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	32
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	10
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	234
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	132
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	71
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	39
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Negative	1,636
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Positive	921
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Negative	2,239
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Positive	1,260



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	153
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	86
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	276
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	156
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	73
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	73
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	6,883
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	243
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	8,027
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	272
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Negative	6,883
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Positive	243
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	1,149
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Positive	39
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,174
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,174
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	45
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	702
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	36



TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	391
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	45
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	702
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	36
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	391
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	294
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	294
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	7
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	10
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	96
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	181
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	10
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of	181



	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	96
GEND_GBV_DSD	Number of people receiving post-GBV care	835
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	151
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	522
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	74
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	25
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	7
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	2



GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	7
GEND_GBV_TA	Number of people receiving post-GBV care	532
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	93
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	338
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	49
GEND_GBV_TA	15-19, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_TA	20-24, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	20-24, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	25-49, Female, Sexual Violence (Post-Rape Care)	39
GEND_GBV_TA	25-49, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_TA	50+, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	50+, Male, Sexual Violence (Post-Rape Care)	2
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	21,409
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,940
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,841
OVC_SERV_DSD	By: Age/sex: Male 18-24	1,955
OVC_SERV_DSD	By: Age/sex: Male 25+	453
OVC_SERV_DSD	Age/Sex: 10-14 Female	2,820
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,500
OVC_SERV_DSD	By: Age/sex: 18-24 Female	2,276
OVC_SERV_DSD	By: Age/sex: 25+ Female	641
OVC_SERV_DSD	Sum of Age/Sex disaggregates	8,101
OVC_SERV_DSD	Age/Sex: <1	850
OVC_SERV_DSD	Age/Sex: 1-9	7,133
OVC_SERV_DSD	Program Completion: Active	16,163
OVC_SERV_DSD	Program Completion: Graduation	3,103
OVC_SERV_DSD	Program Completion: Transferred	1,078



OVC_SERV_DSD	Program Completion: Exited without graduation	1,065
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	530
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	559
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	19
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	325
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	13
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	173
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	21
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	338
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	14



TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	186
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	130
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	135
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	84
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	42
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	3
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	89
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The	1



	number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	42
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,399
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	70
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	1,586
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	31
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	712
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,411
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	43
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	935
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	15
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	418
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	48,591
TX_CURR_DSD	Age/Sex: 15-19 Male	310
TX_CURR_DSD	Age/Sex: 15-19 Female	1,268
TX_CURR_DSD	Sum of age/sex disaggregates	1,578
TX_CURR_DSD	Age/Sex: <1	85
TX_CURR_DSD	Age/Sex: <1-9	1,296



TX_CURR_DSD	Age/Sex: 10-14 Male	289
TX_CURR_DSD	Age/Sex: 10-14 Female	418
TX_CURR_DSD	Age/Sex: 20-24 Male	1,320
TX_CURR_DSD	Age/Sex: 25-49 Male	14,677
TX_CURR_DSD	Age/Sex: 50+ Male	1,812
TX_CURR_DSD	Age/Sex: 20-24 Female	4,018
TX_CURR_DSD	Age/Sex: 25-49 Female	21,019
TX_CURR_DSD	Age/Sex: 50+ Female	2,079
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	10,487
TX_CURR_TA	Age/Sex: 15-19 Male	54
TX_CURR_TA	Age/Sex: 15-19 Female	240
TX_CURR_TA	Sum of Age/Sex disaggregations	294
TX_CURR_TA	Age/Sex: <1	17
TX_CURR_TA	Age/Sex: 1-9	288
TX_CURR_TA	Age/Sex: 10-14 Male	69
TX_CURR_TA	Age/Sex: 10-14 Female	91
TX_CURR_TA	Age/Sex: 20-24 Male	238
TX_CURR_TA	Age/Sex: 25-49 Male	3,265
TX_CURR_TA	Age/Sex: 50+ Male	403
TX_CURR_TA	Age/Sex: 20-24 Female	761
TX_CURR_TA	Age/Sex: 25-49 Female	4,605
TX_CURR_TA	Age/Sex: 50+ Female	456
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	18,111
TX_NEW_DSD	By Age/Sex: <1	132
TX_NEW_DSD	By Age/Sex: 1-9	27
TX_NEW_DSD	By Age/Sex: 10-14 Male	7
TX_NEW_DSD	By Age/Sex: 15-19 Male	60
TX_NEW_DSD	By Age/Sex: 20-24 Male	265
TX_NEW_DSD	By Age/Sex: 25-49 Male	8,639
TX_NEW_DSD	By Age/Sex: 50+ Male	1,068



TX_NEW_DSD	By Age/Sex: 10-14 Female	4
TX_NEW_DSD	By Age/Sex: 15-19 Female	258
TX_NEW_DSD	By Age/Sex: 20-24 Female	832
TX_NEW_DSD	By Age/Sex: 25-49 Female	6,203
TX_NEW_DSD	By Age/Sex: 50+ Female	616
TX_NEW_DSD	Sum of Age/Sex disaggregates	17,952
TX_NEW_DSD	Pregnancy status	4,533
TX_NEW_DSD	Breastfeeding status	55
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,034
TX_NEW_TA	By Age/Sex: <1	27
TX_NEW_TA	By Age/Sex: 1-9	2
TX_NEW_TA	By Age/Sex: 15-19 Male	10
TX_NEW_TA	By Age/Sex: 20-24 Male	63
TX_NEW_TA	By Age/Sex: 25-49 Male	1,969
TX_NEW_TA	By Age/Sex: 50+ Male	243
TX_NEW_TA	By Age/Sex: 15-19 Female	51
TX_NEW_TA	By Age/Sex: 20-24 Female	188
TX_NEW_TA	By Age/Sex: 25-49 Female	1,349
TX_NEW_TA	By Age/Sex: 50+ Female	132
TX_NEW_TA	Sum of Age/Sex disaggregates	4,005
TX_NEW_TA	Pregnancy status	1,012
TX_NEW_TA	Breastfeeding status	8
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	39,362
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	43,735
TX_PVLS_DSD	Numerator: Indication: Routine	39,362
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	3,941
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding	202



	Routine	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	757
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	14,677
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	932
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	22,996
TX_PVLS_DSD	Denominator: Indication: Routine	43,735
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	4,376
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	221
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	843
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	16,313
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,041
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	25,538
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	8,494
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	9,442
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	203
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	169
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	4,919



TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,203
TX_PVLS_TA	Numerator: Indication: Routine	8,494
TX_PVLS_TA	Numerator: Preg/BF by Indication: Breastfeeding Routine	46
TX_PVLS_TA	Numerator: Preg/BF by Indication: Pregnant Routine	852
TX_PVLS_TA	Denominator: Indication: Routine	9,442
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	232
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	190
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	5,460
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,560
TX_PVLS_TA	Denominator: Preg/BF by Indication: Breastfeeding Routine	46
TX_PVLS_TA	Denominator: Preg/BF by Indication: Pregnant Routine	942
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,434
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,003
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	178
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,877
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	203
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number	3,176



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	179
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,091
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	204
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,529
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,281
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,526
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	75
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	786
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number	87



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,333
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	75
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	881
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	87
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,483
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	8,152
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	16,303



TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	88
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	69
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	7,121
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	9,025
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	16,303
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	35
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	31
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	3,563
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	4,523
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	8,152
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,817
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	3,631
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	23
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	7
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	1,546
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	2,055
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	3,631
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	1
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	1
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	776
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	1,039
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	1,817
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	970
TX_TB_DSD	Number of ART patients who were screened for TB at	48,591



	least once during the reporting period	
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	20
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	17
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	570
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	363
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,152
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	936
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	28,377
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	18,126
TX_TB_DSD	Denominator: By Screen Result: Negative	44,701
TX_TB_DSD	Denominator: By Screen Result: Positive	3,890
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	3,890
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	388
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	778
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2,724
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	210
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	10,487
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	1
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	122
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	87
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	255
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	210
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	6,069
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	3,953
TX_TB_TA	Denominator: By Screen Result: Negative	9,649
TX_TB_TA	Denominator: By Screen Result: Positive	838



TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	838
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	86
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	169
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	583

Implementing Mechanism Details

Mechanism ID: 9167	Mechanism Name: Provision of Comprehensive Public Health services for the fishing communities in Kalangala District in the Republic of Uganda under the President's Emergency Plan for AIDS Relief	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Kalangala District Health Office		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:		9167	
Mechanism Name:		Provision of Comprehensive Public Health services for the fishing communities in Kalangala District in the Republic of Uganda under the	
Prime Partner Name:		President's Emergency Plan for AIDS Relief Kalangala District Health Office	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9183	Mechanism Name: Accelerating Delivery of Comprehensive HIV/AIDS/TB services including Prevention, Care, Support and Treatment of people living with HIV/AIDS in the Republic of Uganda under the President's Emergency Plan for AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: The AIDS Support Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,204,928	
Total All Funding Sources and Applied Pipeline Amount: 1,204,928	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	9183		
Mechanism Name:	Accelerating Delivery of Comprehensive HIV/AIDS/TB services including Prevention, Care, Support and Treatment of people living with HIV/AIDS in the Republic of Uganda under the President's Emergency Plan for AIDS Relief		
Prime Partner Name:	The AIDS Support Organization		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	22
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	280
PMTCT_ART_DSD	New on ART	9
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	13
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	109
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,087
PMTCT_ART_TA	New on ART	50
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	59
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	280
PMTCT_STAT_DSD	By Age (Denominator): 10-14	5



PMTCT_STAT_DSD	By Age (Denominator): <15-19	54
PMTCT_STAT_DSD	By Age (Denominator): 20-24	54
PMTCT_STAT_DSD	By Age (Denominator): 25-49	167
PMTCT_STAT_DSD	By Number of known positives: 15-19	4
PMTCT_STAT_DSD	By Number of known positives: 20-24	6
PMTCT_STAT_DSD	By Number of known positives: 25-49	4
PMTCT_STAT_DSD	By Number of new positives: 15-19	3
PMTCT_STAT_DSD	By Number of new positives: 20-24	4
PMTCT_STAT_DSD	By Number of new positives: 25-49	4
PMTCT_STAT_DSD	By Number of new negative: 10-14	5
PMTCT_STAT_DSD	By Number of new negative: 15-19	50
PMTCT_STAT_DSD	By Number of new negative: 20-24	46
PMTCT_STAT_DSD	By Number of new negative: 25-49	154
PMTCT_STAT_DSD	By Age (Numerator): 10-14	5
PMTCT_STAT_DSD	By Age (Numerator): 15-19	54
PMTCT_STAT_DSD	By Age (Numerator): 20-24	54
PMTCT_STAT_DSD	By Age (Numerator): 25-49	167
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,087
PMTCT_STAT_TA	By Age (Denominator): 10-14	21
PMTCT_STAT_TA	By Age (Denominator): 15-19	397
PMTCT_STAT_TA	By Age (Denominator): 20-24	397
PMTCT_STAT_TA	By Age (Denominator): 25-49	1,272
PMTCT_STAT_TA	By known positives: 10-14	1
PMTCT_STAT_TA	By known positives: 15-19	11
PMTCT_STAT_TA	By known positives: 20-24	19
PMTCT_STAT_TA	By known positives: 25-49	23
PMTCT_STAT_TA	By new positives: 10-14	1
PMTCT_STAT_TA	By new positives: 15-19	12
PMTCT_STAT_TA	By new positives: 20-24	21
PMTCT_STAT_TA	By new positives: 25-49	27



PMTCT_STAT_TA	By new negatives: 10-14	20
PMTCT_STAT_TA	By new negatives: 15-19	375
PMTCT_STAT_TA	By new negatives: 20-24	358
PMTCT_STAT_TA	By new negatives: 25-49	1,219
PMTCT_STAT_TA	By Age (Numerator): 10-14	21
PMTCT_STAT_TA	By Age (Numerator): : 15-19	397
PMTCT_STAT_TA	By Age (Numerator): 20-24	397
PMTCT_STAT_TA	By Age (Numerator): 25-49	1,272
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	24,560
VMMC_CIRC_DSD	By Age: 10-14	2,458
VMMC_CIRC_DSD	By Age: 15-19	4,423
VMMC_CIRC_DSD	By Age: 20-24	5,895
VMMC_CIRC_DSD	By Age: 25-29	9,332
VMMC_CIRC_DSD	By Age: 30-49	1,475
VMMC_CIRC_DSD	By Age: 50+	977
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	13,753
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	24,560
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,976
PP_PREV_DSD	Age/sex: 10-14 Male	777
PP_PREV_DSD	Age/sex: 15-19 Male	405
PP_PREV_DSD	Age/sex: 20-24 Male	373
PP_PREV_DSD	Age/sex: 25-49 Male	1,284
PP_PREV_DSD	Age/sex: 50+ Male	114
PP_PREV_DSD	Age/sex: 10-14 Female	942
PP_PREV_DSD	Age/sex: 15-19 Female	507
PP_PREV_DSD	Age/sex: 20-24 Female	363
PP_PREV_DSD	Age/sex: 25-49 Female	1,117
PP_PREV_DSD	Age/sex: 50+ Female	94



PP_PREV_DSD	Sum of Age/Sex disaggregates	5,976
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	5,319
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	159
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	239
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	64
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	68
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,789
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	15,202
HTC_TST_DSD	By Test Result: Positive	1,124
HTC_TST_DSD	Sum of Test Result disaggregates	1,124



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	118
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	374
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	1,086
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	62
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	1,878
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	115
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	107
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	233
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	48



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	141
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	96
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	234
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	93
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	234
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	48
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	48
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	6



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	185
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	674
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	924
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	79
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	69
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	116
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female,	6



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	1,142
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	1,335
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	1,142
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	192
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	40



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	135
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	76
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	256
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	145
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	11



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	61
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	84
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	47
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	802
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	935
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	802
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	134
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	7
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,147
HTC_TST_TA	By Test Result: Positive	511
HTC_TST_TA	Sum of Test Result disaggregates	511



HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	110
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	354
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	20
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	76
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	1,092
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	61
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	762
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	42
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	107
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	93
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	17



HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	54
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	12
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	167
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	31
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	117
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	22
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1



HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	16
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	52
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	29
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	11
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female,	159



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Positive	89
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Negative	111
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Positive	62
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	16
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	667
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	21
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	778
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	24
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Negative	667
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Positive	21
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	111
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Positive	4
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	210
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	210
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	125
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number	7



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	69
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	125
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	7
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	69
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	62
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	62
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	21
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	36
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented	3



	HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	36
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	21
GEND_GBV_DSD	Number of people receiving post-GBV care	24
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	4
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	19
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1
GEND_GBV_TA	Number of people receiving post-GBV care	39
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	8
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	27
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	4
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	113
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	118
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with	65



	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	38
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	67
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	5
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	40
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	25
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	26
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	1

	TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	15
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	15
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	9
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	20
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	13
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	7



PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	86
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	4
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	57
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	2
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	23
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	43,970
TX_CURR_DSD	Age/Sex: 15-19 Male	195
TX_CURR_DSD	Age/Sex: 15-19 Female	821
TX_CURR_DSD	Sum of age/sex disaggregates	1,016
TX_CURR_DSD	Age/Sex: <1	134
TX_CURR_DSD	Age/Sex: <1-9	2,078
TX_CURR_DSD	Age/Sex: 10-14 Male	471
TX_CURR_DSD	Age/Sex: 10-14 Female	670
TX_CURR_DSD	Age/Sex: 20-24 Male	830
TX_CURR_DSD	Age/Sex: 25-49 Male	13,146
TX_CURR_DSD	Age/Sex: 50+ Male	1,624
TX_CURR_DSD	Age/Sex: 20-24 Female	2,598
TX_CURR_DSD	Age/Sex: 25-49 Female	19,479
TX_CURR_DSD	Age/Sex: 50+ Female	1,924
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,558
TX_CURR_TA	Age/Sex: 15-19 Male	12
TX_CURR_TA	Age/Sex: 15-19 Female	46
TX_CURR_TA	Sum of Age/Sex disaggregations	58
TX_CURR_TA	Age/Sex: <1	5
TX_CURR_TA	Age/Sex: 1-9	77
TX_CURR_TA	Age/Sex: 10-14 Male	17



TX_CURR_TA	Age/Sex: 10-14 Female	25
TX_CURR_TA	Age/Sex: 20-24 Male	51
TX_CURR_TA	Age/Sex: 25-49 Male	689
TX_CURR_TA	Age/Sex: 50+ Male	85
TX_CURR_TA	Age/Sex: 20-24 Female	144
TX_CURR_TA	Age/Sex: 25-49 Female	1,280
TX_CURR_TA	Age/Sex: 50+ Female	127
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,917
TX_NEW_DSD	By Age/Sex: <1	56
TX_NEW_DSD	By Age/Sex: 1-9	3
TX_NEW_DSD	By Age/Sex: 10-14 Male	1
TX_NEW_DSD	By Age/Sex: 15-19 Male	18
TX_NEW_DSD	By Age/Sex: 20-24 Male	69
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,246
TX_NEW_DSD	By Age/Sex: 50+ Male	281
TX_NEW_DSD	By Age/Sex: 10-14 Female	1
TX_NEW_DSD	By Age/Sex: 15-19 Female	127
TX_NEW_DSD	By Age/Sex: 20-24 Female	401
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,559
TX_NEW_DSD	By Age/Sex: 50+ Female	155
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,858
TX_NEW_DSD	Pregnancy status	1,231
TX_NEW_DSD	Breastfeeding status	17
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	385
TX_NEW_TA	By Age/Sex: <1	5
TX_NEW_TA	By Age/Sex: 15-19 Male	3
TX_NEW_TA	By Age/Sex: 20-24 Male	11
TX_NEW_TA	By Age/Sex: 25-49 Male	109
TX_NEW_TA	By Age/Sex: 50+ Male	14
TX_NEW_TA	By Age/Sex: 15-19 Female	16



TX_NEW_TA	By Age/Sex: 20-24 Female	52
TX_NEW_TA	By Age/Sex: 25-49 Female	159
TX_NEW_TA	By Age/Sex: 50+ Female	16
TX_NEW_TA	Sum of Age/Sex disaggregates	380
TX_NEW_TA	Pregnancy status	96
TX_NEW_TA	Breastfeeding status	1
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,214
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	4,425
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	29
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	24
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	2,010
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	2,362
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	4,425
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	15
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	13
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,006
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,180
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	2,214
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	173
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the	346



	minimum requirements for the previous reporting period).	
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	2
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	2
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	217
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	125
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	346
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	1
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	1
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	108
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	63
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	173
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	879
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	43,970
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	37
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	31
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	496
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	315
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,841
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,512
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	24,815
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	15,802
TX_TB_DSD	Denominator: By Screen Result: Negative	40,452
TX_TB_DSD	Denominator: By Screen Result: Positive	3,518
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	3,518
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	351
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	704



TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2,463
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	51
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	2,558
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	1
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Male	1
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	32
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	17
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	68
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	56
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	1,597
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	837
TX_TB_TA	Denominator: By Screen Result: Negative	2,353
TX_TB_TA	Denominator: By Screen Result: Positive	205
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	205
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	20
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	41
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	144

Implementing Mechanism Details

Mechanism ID: 9303	Mechanism Name: DOD Mechanism
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
Total All Funding Sources: 41,750	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 41,750	
Funding Source	Funding Amount
GHP-State	41,750

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 9303			
Mechanism Name: DOD Mechanism			
Prime Partner Name: U.S. Department of Defense (Defense)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	41,750	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10326	Mechanism Name: Strengthening Uganda's Systems for Treating AIDS Nationally (SUSTAIN)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 3,538,720	
Total All Funding Sources and Applied Pipeline Amount: 3,538,720	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10326		
Mechanism Name:	Strengthening Uganda's Systems for Treating AIDS Nationally		
Prime Partner Name:	(SUSTAIN) University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11479	Mechanism Name: State Department
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 50,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 250,000	
Total All Funding Sources and Applied Pipeline Amount: 300,000	
Funding Source	Funding Amount



GHP-State	50,000
-----------	--------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 11479			
Mechanism Name: State Department			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	5,964	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	20,179	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	11,929	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	11,928	0

Implementing Mechanism Indicator Information

Approved



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11480	Mechanism Name: US Peace Corps
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 149,410	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 145,134	
Total All Funding Sources and Applied Pipeline Amount: 294,544	
Funding Source	Funding Amount
GHP-State	149,410

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	11480		
Mechanism Name:	US Peace Corps		
Prime Partner Name:	U.S. Peace Corps		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	45,653	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	103,757	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,410
PP_PREV_DSD	Age/sex: 10-14 Male	313
PP_PREV_DSD	Age/sex: 15-19 Male	164
PP_PREV_DSD	Age/sex: 20-24 Male	150
PP_PREV_DSD	Age/sex: 25-49 Male	520
PP_PREV_DSD	Age/sex: 50+ Male	47
PP_PREV_DSD	Age/sex: 10-14 Female	380
PP_PREV_DSD	Age/sex: 15-19 Female	204
PP_PREV_DSD	Age/sex: 20-24 Female	146
PP_PREV_DSD	Age/sex: 25-49 Female	449
PP_PREV_DSD	Age/sex: 50+ Female	37
PP_PREV_DSD	Sum of Age/Sex disaggregates	2,410
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,600
OVC_SERV_DSD	Age/Sex: 10-14 Male	144
OVC_SERV_DSD	Age/Sex: 15-17 Male	140
OVC_SERV_DSD	By: Age/sex: Male 18-24	145
OVC_SERV_DSD	By: Age/sex: Male 25+	34
OVC_SERV_DSD	Age/Sex: 10-14 Female	210
OVC_SERV_DSD	Age/Sex: 15-17 Female	113
OVC_SERV_DSD	By: Age/sex: 18-24 Female	172
OVC_SERV_DSD	By: Age/sex: 25+ Female	47
OVC_SERV_DSD	Sum of Age/Sex disaggregates	607



OVC_SERV_DSD	Age/Sex: <1	64
OVC_SERV_DSD	Age/Sex: 1-9	531
OVC_SERV_DSD	Program Completion: Active	1,211
OVC_SERV_DSD	Program Completion: Graduation	229
OVC_SERV_DSD	Program Completion: Transferred	81
OVC_SERV_DSD	Program Completion: Exited without graduation	79

Implementing Mechanism Details

Mechanism ID: 12981	Mechanism Name: Strengthening capacity through improved management and coordination of laboratory, surveillance, and epidemiology activities, public health evaluations and training in Uganda – Lab Quality Assurance	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Uganda Virus Research Institute		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 172,415		
Total All Funding Sources and Applied Pipeline Amount: 172,415		
Funding Source	Funding Amount	
GHP-State	0	

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	12981		
Mechanism Name:	Strengthening capacity through improved management and coordination of laboratory, surveillance, and epidemiology activities,		
Prime Partner Name:	public health evaluations and training in Uganda – Lab Quality Assurance Uganda Virus Research Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13002	Mechanism Name: Supporting the Continuity of HIV/AIDS prevention and care programs for refugees in Uganda
Funding Agency: State/PRM	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations High Commissioner for Refugees	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 687,665	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 687,665	
Funding Source	Funding Amount
GHP-State	687,665

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	13002		
Mechanism Name:	Supporting the Continuity of HIV/AIDS prevention and care programs for refugees in Uganda		
Prime Partner Name:	United Nations High Commissioner for Refugees		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	129,784	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	132,581	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	31,575	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	8,736	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	32,796	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	45,759	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	MTCT	31,136	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	267,940	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	7,358	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	490
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	10,839
PMTCT_ART_DSD	New on ART	222
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	268
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	10,839
PMTCT_STAT_DSD	By Age (Denominator): 10-14	108
PMTCT_STAT_DSD	By Age (Denominator): <15-19	2,059
PMTCT_STAT_DSD	By Age (Denominator): 20-24	2,059
PMTCT_STAT_DSD	By Age (Denominator): 25-49	6,613
PMTCT_STAT_DSD	By Number of known positives: 10-14	2
PMTCT_STAT_DSD	By Number of known positives: 15-19	53
PMTCT_STAT_DSD	By Number of known positives: 20-24	95
PMTCT_STAT_DSD	By Number of known positives: 25-49	131
PMTCT_STAT_DSD	By Number of new positives: 10-14	1
PMTCT_STAT_DSD	By Number of new positives: 15-19	44



PMTCT_STAT_DSD	By Number of new positives: 20-24	78
PMTCT_STAT_DSD	By Number of new positives: 25-49	111
PMTCT_STAT_DSD	By Number of new negative: 10-14	105
PMTCT_STAT_DSD	By Number of new negative: 15-19	1,962
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,886
PMTCT_STAT_DSD	By Number of new negative: 25-49	6,371
PMTCT_STAT_DSD	By Age (Numerator): 10-14	108
PMTCT_STAT_DSD	By Age (Numerator): 15-19	2,059
PMTCT_STAT_DSD	By Age (Numerator): 20-24	2,059
PMTCT_STAT_DSD	By Age (Numerator): 25-49	6,613
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	13,022
VMMC_CIRC_DSD	By Age: 10-14	1,303
VMMC_CIRC_DSD	By Age: 15-19	2,344
VMMC_CIRC_DSD	By Age: 20-24	3,125
VMMC_CIRC_DSD	By Age: 25-29	4,949
VMMC_CIRC_DSD	By Age: 30-49	780
VMMC_CIRC_DSD	By Age: 50+	521
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	7,293
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	13,022
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	39,689
HTC_TST_DSD	By Test Result: Positive	1,693
HTC_TST_DSD	Sum of Test Result disaggregates	1,693
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	254
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19,	11



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	800
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	152
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	3,294
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	135
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	2,949
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	123
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	327
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	368
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	86
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	144
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	12



	15-19, Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	36
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	24
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	61
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	24
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	61
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	12
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	12
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14,	28



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	174
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	544
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	106
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	2,187
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	121
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	2,105
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	116
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	218
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	261
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	96
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9,	142



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	188
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	3,869
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	4,511
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	79
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	3,869
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	93
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	645
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	19



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	78
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	356
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	200
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	327
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	184
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	40
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	56



HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	16
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	69
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	42
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	63
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	35
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+,	8



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	37
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	61
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	2,634
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	3,072
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	71
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	2,634
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	439
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	11
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	215
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	215
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	130
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	71
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total	7



	number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	130
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	7
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	71
GEND_GBV_DSD	Number of people receiving post-GBV care	114
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	23
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	79
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	12
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,357
OVC_SERV_DSD	Age/Sex: 10-14 Male	213
OVC_SERV_DSD	Age/Sex: 15-17 Male	203
OVC_SERV_DSD	By: Age/sex: Male 18-24	216
OVC_SERV_DSD	By: Age/sex: Male 25+	49
OVC_SERV_DSD	Age/Sex: 10-14 Female	310
OVC_SERV_DSD	Age/Sex: 15-17 Female	166
OVC_SERV_DSD	By: Age/sex: 18-24 Female	248
OVC_SERV_DSD	By: Age/sex: 25+ Female	72
OVC_SERV_DSD	Sum of Age/Sex disaggregates	892
OVC_SERV_DSD	Age/Sex: <1	95
OVC_SERV_DSD	Age/Sex: 1-9	785
OVC_SERV_DSD	Program Completion: Active	1,780
OVC_SERV_DSD	Program Completion: Graduation	342
OVC_SERV_DSD	Program Completion: Transferred	118



OVC_SERV_DSD	Program Completion: Exited without graduation	117
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	72
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	74
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	45
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	23
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	46
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	2



TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	24
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	398
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	9
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	263
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	4
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	122
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,953
TX_CURR_DSD	Age/Sex: 15-19 Male	32
TX_CURR_DSD	Age/Sex: 15-19 Female	207
TX_CURR_DSD	Sum of age/sex disaggregates	239
TX_CURR_DSD	Age/Sex: <1	18
TX_CURR_DSD	Age/Sex: <1-9	273
TX_CURR_DSD	Age/Sex: 10-14 Male	58
TX_CURR_DSD	Age/Sex: 10-14 Female	89
TX_CURR_DSD	Age/Sex: 20-24 Male	139
TX_CURR_DSD	Age/Sex: 25-49 Male	1,902
TX_CURR_DSD	Age/Sex: 50+ Male	234
TX_CURR_DSD	Age/Sex: 20-24 Female	656
TX_CURR_DSD	Age/Sex: 25-49 Female	3,044
TX_CURR_DSD	Age/Sex: 50+ Female	301
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,898
TX_NEW_DSD	By Age/Sex: <1	10
TX_NEW_DSD	By Age/Sex: 1-9	6



TX_NEW_DSD	By Age/Sex: 10-14 Male	1
TX_NEW_DSD	By Age/Sex: 15-19 Male	8
TX_NEW_DSD	By Age/Sex: 20-24 Male	31
TX_NEW_DSD	By Age/Sex: 25-49 Male	733
TX_NEW_DSD	By Age/Sex: 50+ Male	91
TX_NEW_DSD	By Age/Sex: 10-14 Female	1
TX_NEW_DSD	By Age/Sex: 15-19 Female	53
TX_NEW_DSD	By Age/Sex: 20-24 Female	165
TX_NEW_DSD	By Age/Sex: 25-49 Female	727
TX_NEW_DSD	By Age/Sex: 50+ Female	72
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,882
TX_NEW_DSD	Pregnancy status	476
TX_NEW_DSD	Breastfeeding status	5
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	5,632
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	6,258
TX_PVLS_DSD	Numerator: Indication: Routine	5,632
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	562
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	28
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	158
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,867
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	195
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	3,412
TX_PVLS_DSD	Denominator: Indication: Routine	6,258



TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	625
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	30
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	175
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	2,077
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	218
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	3,788
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	749
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	826
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	26
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	256
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	439
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	26
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total	285



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	487
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	854
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,708
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	11
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	7
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	915
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	775
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	1,708
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	3
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	3
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	458
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	390
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	854



TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	139
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	6,953
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	4
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	3
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	86
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	46
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	243
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	195
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	4,209
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	2,306
TX_TB_DSD	Denominator: By Screen Result: Negative	6,396
TX_TB_DSD	Denominator: By Screen Result: Positive	557
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	557
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	56
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	111
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	390

Implementing Mechanism Details

Mechanism ID: 13029	Mechanism Name: National Lab Infrastructure Initiative
Funding Agency: State/AF	Procurement Type: Cooperative Agreement
Prime Partner Name: Regional Procurement Support Office/Frankfurt	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13029		
Mechanism Name:	National Lab Infrastructure Initiative		
Prime Partner Name:	Regional Procurement Support Office/Frankfurt		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13170	Mechanism Name: Surveillance - Epi
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Makerere University School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Approved



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 538,146	
Total All Funding Sources and Applied Pipeline Amount: 538,146	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13170		
Mechanism Name:	Surveillance - Epi		
Prime Partner Name:	Makerere University School of Public Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13317	Mechanism Name: Targeted HIV/AIDS and Laboratory Services (THALAS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Joint Clinical Research Center, Uganda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Approved



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13317			
Mechanism Name: Targeted HIV/AIDS and Laboratory Services (THALAS)			
Prime Partner Name: Joint Clinical Research Center, Uganda			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13466	Mechanism Name: Provision of Comprehensive HIV/AIDS Care, Treatment and Prevention services in Track 1.0 Health Facilities in Uganda		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Uganda Protestant Medical Board			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		
Total All Funding Sources: 0		Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 887,065			
Total All Funding Sources and Applied Pipeline Amount: 887,065			
Funding Source	Funding Amount		
GHP-State	0		

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	13466		
Mechanism Name:	Provision of Comprehensive HIV/AIDS Care, Treatment and Prevention services in Track 1.0 Health Facilities in Uganda		
Prime Partner Name:	Uganda Protestant Medical Board		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	300
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,041
PMTCT_ART_DSD	New on ART	136
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	164
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,041
PMTCT_STAT_DSD	By Age (Denominator): 10-14	70



PMTCT_STAT_DSD	By Age (Denominator): <15-19	1,337
PMTCT_STAT_DSD	By Age (Denominator): 20-24	1,337
PMTCT_STAT_DSD	By Age (Denominator): 25-49	4,297
PMTCT_STAT_DSD	By Number of known positives: 15-19	34
PMTCT_STAT_DSD	By Number of known positives: 20-24	63
PMTCT_STAT_DSD	By Number of known positives: 25-49	86
PMTCT_STAT_DSD	By Number of new positives: 15-19	25
PMTCT_STAT_DSD	By Number of new positives: 20-24	45
PMTCT_STAT_DSD	By Number of new positives: 25-49	61
PMTCT_STAT_DSD	By Number of new negative: 10-14	70
PMTCT_STAT_DSD	By Number of new negative: 15-19	1,278
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,229
PMTCT_STAT_DSD	By Number of new negative: 25-49	4,150
PMTCT_STAT_DSD	By Age (Numerator): 10-14	70
PMTCT_STAT_DSD	By Age (Numerator): 15-19	1,337
PMTCT_STAT_DSD	By Age (Numerator): 20-24	1,337
PMTCT_STAT_DSD	By Age (Numerator): 25-49	4,297
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,142
VMMC_CIRC_DSD	By Age: 10-14	114
VMMC_CIRC_DSD	By Age: 15-19	206
VMMC_CIRC_DSD	By Age: 20-24	273
VMMC_CIRC_DSD	By Age: 25-29	435
VMMC_CIRC_DSD	By Age: 30-49	68
VMMC_CIRC_DSD	By Age: 50+	46
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	639
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	1,142
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	40
PP_PREV_DSD	Age/sex: 10-14 Male	4



PP_PREV_DSD	Age/sex: 15-19 Male	2
PP_PREV_DSD	Age/sex: 20-24 Male	2
PP_PREV_DSD	Age/sex: 25-49 Male	3
PP_PREV_DSD	Age/sex: 50+ Male	2
PP_PREV_DSD	Age/sex: 10-14 Female	8
PP_PREV_DSD	Age/sex: 15-19 Female	6
PP_PREV_DSD	Age/sex: 20-24 Female	3
PP_PREV_DSD	Age/sex: 25-49 Female	8
PP_PREV_DSD	Age/sex: 50+ Female	2
PP_PREV_DSD	Sum of Age/Sex disaggregates	40
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	342
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	342
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	45,967
HTC_TST_DSD	By Test Result: Positive	1,826
HTC_TST_DSD	Sum of Test Result disaggregates	1,826
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	234
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	191
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	373



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	56
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,177
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	292
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	3,765
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	157
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	5,886
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	175
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	366
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	709
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	278
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,070
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	12



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	19
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	57
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	38
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	95
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	37
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	95
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	230
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	187
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	2



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	393
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,231
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	306
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	3,987
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	178
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	6,086
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	194
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	388
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	734
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	273
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	3



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,052
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	942
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	45
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	309
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	2



HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	361
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	309
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	51
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	125
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	102
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	334
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	182
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	309



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	174
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	148
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	567
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	51
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	52
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	42
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49,	63



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	38
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	56
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	61
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	236
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	2,997
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	3,492
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	80
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	2,997
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	499
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	12
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	234
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	234



TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	142
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	77
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	142
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	6
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	77
GEND_GBV_DSD	Number of people receiving post-GBV care	150
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	30
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	104
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	16
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	5,985
OVC_SERV_DSD	Age/Sex: 10-14 Male	542
OVC_SERV_DSD	Age/Sex: 15-17 Male	515



OVC_SERV_DSD	By: Age/sex: Male 18-24	545
OVC_SERV_DSD	By: Age/sex: Male 25+	125
OVC_SERV_DSD	Age/Sex: 10-14 Female	788
OVC_SERV_DSD	Age/Sex: 15-17 Female	420
OVC_SERV_DSD	By: Age/sex: 18-24 Female	638
OVC_SERV_DSD	By: Age/sex: 25+ Female	180
OVC_SERV_DSD	Sum of Age/Sex disaggregates	2,265
OVC_SERV_DSD	Age/Sex: <1	238
OVC_SERV_DSD	Age/Sex: 1-9	1,994
OVC_SERV_DSD	Program Completion: Active	4,518
OVC_SERV_DSD	Program Completion: Graduation	868
OVC_SERV_DSD	Program Completion: Transferred	301
OVC_SERV_DSD	Program Completion: Exited without graduation	298
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	80
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	85
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	50
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	26



	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	53
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	28
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	239
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	8
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	159
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	4
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	68
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	8,359
TX_CURR_DSD	Age/Sex: 15-19 Male	41
TX_CURR_DSD	Age/Sex: 15-19 Female	200
TX_CURR_DSD	Sum of age/sex disaggregates	241
TX_CURR_DSD	Age/Sex: <1	21
TX_CURR_DSD	Age/Sex: <1-9	317



TX_CURR_DSD	Age/Sex: 10-14 Male	71
TX_CURR_DSD	Age/Sex: 10-14 Female	102
TX_CURR_DSD	Age/Sex: 20-24 Male	167
TX_CURR_DSD	Age/Sex: 25-49 Male	2,280
TX_CURR_DSD	Age/Sex: 50+ Male	281
TX_CURR_DSD	Age/Sex: 20-24 Female	633
TX_CURR_DSD	Age/Sex: 25-49 Female	3,863
TX_CURR_DSD	Age/Sex: 50+ Female	383
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,905
TX_NEW_DSD	By Age/Sex: <1	21
TX_NEW_DSD	By Age/Sex: 1-9	42
TX_NEW_DSD	By Age/Sex: 10-14 Male	7
TX_NEW_DSD	By Age/Sex: 15-19 Male	8
TX_NEW_DSD	By Age/Sex: 20-24 Male	37
TX_NEW_DSD	By Age/Sex: 25-49 Male	750
TX_NEW_DSD	By Age/Sex: 50+ Male	91
TX_NEW_DSD	By Age/Sex: 10-14 Female	9
TX_NEW_DSD	By Age/Sex: 15-19 Female	55
TX_NEW_DSD	By Age/Sex: 20-24 Female	171
TX_NEW_DSD	By Age/Sex: 25-49 Female	650
TX_NEW_DSD	By Age/Sex: 50+ Female	64
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,842
TX_NEW_DSD	Pregnancy status	476
TX_NEW_DSD	Breastfeeding status	5
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	6,772
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	7,523
TX_PVLS_DSD	Numerator: Indication: Routine	6,772



TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	680
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	36
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	187
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	2,245
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	227
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	4,113
TX_PVLS_DSD	Denominator: Indication: Routine	7,523
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	754
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	40
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	208
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	2,494
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	253
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	4,568
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	768
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	850
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	26
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at	264



	12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	450
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	26
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	296
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	500
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	857
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the	1,716



	minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	39
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	33
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	846
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	798
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	1,716
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	18
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	15
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	422
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	402
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	857
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	168
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	8,359
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	5
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	4
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	103
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	56
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	280
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	231
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	5,074
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	2,774
TX_TB_DSD	Denominator: By Screen Result: Negative	7,691
TX_TB_DSD	Denominator: By Screen Result: Positive	668
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	668
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	70
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	132



TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	466
-----------	---	-----

Implementing Mechanism Details

Mechanism ID: 13717	Mechanism Name: Provision of Comprehensive CARE, Treatment and Prevention Services in Indigenous Health Facilities - AIDS Care and Treatment		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Registered Trustees for the Uganda Episcopal Conference			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		
Total All Funding Sources: 0		Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 574,741			
Total All Funding Sources and Applied Pipeline Amount: 574,741			
Funding Source	Funding Amount		
GHP-State	0		

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13717		
Mechanism Name:	Provision of Comprehensive CARE, Treatment and Prevention Services in Indigenous Health Facilities - AIDS Care and Treatment		
Prime Partner Name:	Registered Trustees for the Uganda Episcopal Conference		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	879
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	11,477
PMTCT_ART_DSD	New on ART	396
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	483
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	11,477
PMTCT_STAT_DSD	By Age (Denominator): 10-14	117
PMTCT_STAT_DSD	By Age (Denominator): <15-19	2,181
PMTCT_STAT_DSD	By Age (Denominator): 20-24	2,181
PMTCT_STAT_DSD	By Age (Denominator): 25-49	6,998
PMTCT_STAT_DSD	By Number of known positives: 10-14	9
PMTCT_STAT_DSD	By Number of known positives: 15-19	105
PMTCT_STAT_DSD	By Number of known positives: 20-24	184
PMTCT_STAT_DSD	By Number of known positives: 25-49	237
PMTCT_STAT_DSD	By Number of new positives: 10-14	4
PMTCT_STAT_DSD	By Number of new positives: 15-19	77
PMTCT_STAT_DSD	By Number of new positives: 20-24	135
PMTCT_STAT_DSD	By Number of new positives: 25-49	178
PMTCT_STAT_DSD	By Number of new negative: 10-14	109
PMTCT_STAT_DSD	By Number of new negative: 15-19	2,006
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,869
PMTCT_STAT_DSD	By Number of new negative: 25-49	6,564
PMTCT_STAT_DSD	By Age (Numerator): 10-14	117



PMTCT_STAT_DSD	By Age (Numerator): 15-19	2,181
PMTCT_STAT_DSD	By Age (Numerator): 20-24	2,181
PMTCT_STAT_DSD	By Age (Numerator): 25-49	6,998
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	8,153
VMMC_CIRC_DSD	By Age: 10-14	817
VMMC_CIRC_DSD	By Age: 15-19	1,470
VMMC_CIRC_DSD	By Age: 20-24	1,959
VMMC_CIRC_DSD	By Age: 25-29	3,099
VMMC_CIRC_DSD	By Age: 30-49	490
VMMC_CIRC_DSD	By Age: 50+	318
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	4,564
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	8,153
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	7,908
PP_PREV_DSD	Age/sex: 10-14 Male	1,029
PP_PREV_DSD	Age/sex: 15-19 Male	536
PP_PREV_DSD	Age/sex: 20-24 Male	495
PP_PREV_DSD	Age/sex: 25-49 Male	1,704
PP_PREV_DSD	Age/sex: 50+ Male	141
PP_PREV_DSD	Age/sex: 10-14 Female	1,248
PP_PREV_DSD	Age/sex: 15-19 Female	672
PP_PREV_DSD	Age/sex: 20-24 Female	478
PP_PREV_DSD	Age/sex: 25-49 Female	1,479
PP_PREV_DSD	Age/sex: 50+ Female	126
PP_PREV_DSD	Sum of Age/Sex disaggregates	7,908
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,177
KP_PREV_DSD	By key population type: Men who have sex with men	13



	who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	20
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,135
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	59,236
HTC_TST_DSD	By Test Result: Positive	3,878
HTC_TST_DSD	Sum of Test Result disaggregates	3,878
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	17



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	377
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,168
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	247
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	5,038
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	272
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	6,177
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	341
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	506
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	760
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	44



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	40
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	138
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	57
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	165
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	109
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	271
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	109
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	271
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	57
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	57



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	304
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	58
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	949
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	53
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	244
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	4,820
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	310
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	4,856
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	325
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	480



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	601
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	40
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	136
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	126
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	95



HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	87
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	2,813
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	3,283
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	2,813
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	69
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	470
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	40
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	7



HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	117
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	66
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	640
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	362
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	819
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	461
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	65
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	103
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	78
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14,	5



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	27
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	136
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	77
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	195
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	111
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	16
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	27
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1,	12



	Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	42
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	4,492
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	180
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	5,240
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	209
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	4,492
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	180
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	751
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	32
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	685
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	685
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	32
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	401
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	23
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	229
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	32
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	401



	the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	23
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	229
GEND_GBV_DSD	Number of people receiving post-GBV care	763
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	151
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	538
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	74
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	5,441
OVC_SERV_DSD	Age/Sex: 10-14 Male	493
OVC_SERV_DSD	Age/Sex: 15-17 Male	469
OVC_SERV_DSD	By: Age/sex: Male 18-24	495
OVC_SERV_DSD	By: Age/sex: Male 25+	114
OVC_SERV_DSD	Age/Sex: 10-14 Female	716
OVC_SERV_DSD	Age/Sex: 15-17 Female	381
OVC_SERV_DSD	By: Age/sex: 18-24 Female	579
OVC_SERV_DSD	By: Age/sex: 25+ Female	164
OVC_SERV_DSD	Sum of Age/Sex disaggregates	2,059
OVC_SERV_DSD	Age/Sex: <1	217
OVC_SERV_DSD	Age/Sex: 1-9	1,813
OVC_SERV_DSD	Program Completion: Active	4,108
OVC_SERV_DSD	Program Completion: Graduation	789
OVC_SERV_DSD	Program Completion: Transferred	276
OVC_SERV_DSD	Program Completion: Exited without graduation	268
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	323



TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	339
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	15
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	186
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	13
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	109
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	16
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	196
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	14
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	113



PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	712
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	22
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	472
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	11
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	207
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	35,131
TX_CURR_DSD	Age/Sex: 15-19 Male	164
TX_CURR_DSD	Age/Sex: 15-19 Female	721
TX_CURR_DSD	Sum of age/sex disaggregates	885
TX_CURR_DSD	Age/Sex: <1	79
TX_CURR_DSD	Age/Sex: <1-9	1,239
TX_CURR_DSD	Age/Sex: 10-14 Male	281
TX_CURR_DSD	Age/Sex: 10-14 Female	397
TX_CURR_DSD	Age/Sex: 20-24 Male	695
TX_CURR_DSD	Age/Sex: 25-49 Male	10,068
TX_CURR_DSD	Age/Sex: 50+ Male	1,245
TX_CURR_DSD	Age/Sex: 20-24 Female	2,282
TX_CURR_DSD	Age/Sex: 25-49 Female	16,343
TX_CURR_DSD	Age/Sex: 50+ Female	1,617
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,195
TX_NEW_DSD	By Age/Sex: <1	43
TX_NEW_DSD	By Age/Sex: 1-9	12
TX_NEW_DSD	By Age/Sex: 10-14 Male	2
TX_NEW_DSD	By Age/Sex: 15-19 Male	17
TX_NEW_DSD	By Age/Sex: 20-24 Male	68
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,166



TX_NEW_DSD	By Age/Sex: 50+ Male	150
TX_NEW_DSD	By Age/Sex: 10-14 Female	3
TX_NEW_DSD	By Age/Sex: 15-19 Female	74
TX_NEW_DSD	By Age/Sex: 20-24 Female	230
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,298
TX_NEW_DSD	By Age/Sex: 50+ Female	132
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,140
TX_NEW_DSD	Pregnancy status	802
TX_NEW_DSD	Breastfeeding status	14
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,440
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	2,874
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	31
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	26
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,542
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,275
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	2,874
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	16
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	15
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	771
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	638
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	1,440
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	702
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	35,131



TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	22
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	19
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	417
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	244
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,097
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	898
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	20,970
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	12,166
TX_TB_DSD	Denominator: By Screen Result: Negative	32,319
TX_TB_DSD	Denominator: By Screen Result: Positive	2,812
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	2,812
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	278
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	563
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,971

Implementing Mechanism Details

Mechanism ID: 13835	Mechanism Name: Strengthening National Pediatric HIV/AIDS and Scaling up Comprehensive HIV/AIDS Services in the Republic of Uganda under The President's Emergency Plan For AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Baylor College of Medicine Children's Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A



Applied Pipeline Amount: 4,596,082	
Total All Funding Sources and Applied Pipeline Amount: 4,596,082	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13835			
Mechanism Name: Strengthening National Pediatric HIV/AIDS and Scaling up Comprehensive HIV/AIDS Services in the Republic of Uganda under The			
Prime Partner Name: President's Emergency Plan For AIDS Relief			
Baylor College of Medicine Children's Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,976
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	37,501
PMTCT_ART_DSD	New on ART	880
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,096
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	925
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	15,403



	their results)	
PMTCT_ART_TA	New on ART	410
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	515
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	37,501
PMTCT_STAT_DSD	By Age (Denominator): 10-14	394
PMTCT_STAT_DSD	By Age (Denominator): <15-19	7,138
PMTCT_STAT_DSD	By Age (Denominator): 20-24	7,138
PMTCT_STAT_DSD	By Age (Denominator): 25-49	22,831
PMTCT_STAT_DSD	By Number of known positives: 10-14	15
PMTCT_STAT_DSD	By Number of known positives: 15-19	262
PMTCT_STAT_DSD	By Number of known positives: 20-24	446
PMTCT_STAT_DSD	By Number of known positives: 25-49	557
PMTCT_STAT_DSD	By Number of new positives: 10-14	6
PMTCT_STAT_DSD	By Number of new positives: 15-19	169
PMTCT_STAT_DSD	By Number of new positives: 20-24	289
PMTCT_STAT_DSD	By Number of new positives: 25-49	353
PMTCT_STAT_DSD	By Number of new negative: 10-14	381
PMTCT_STAT_DSD	By Number of new negative: 15-19	6,747
PMTCT_STAT_DSD	By Number of new negative: 20-24	6,444
PMTCT_STAT_DSD	By Number of new negative: 25-49	21,832
PMTCT_STAT_DSD	By Age (Numerator): 10-14	394
PMTCT_STAT_DSD	By Age (Numerator): 15-19	7,138
PMTCT_STAT_DSD	By Age (Numerator): 20-24	7,138
PMTCT_STAT_DSD	By Age (Numerator): 25-49	22,831
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	15,403
PMTCT_STAT_TA	By Age (Denominator): 10-14	165
PMTCT_STAT_TA	By Age (Denominator): 15-19	2,937
PMTCT_STAT_TA	By Age (Denominator): 20-24	2,937



PMTCT_STAT_TA	By Age (Denominator): 25-49	9,364
PMTCT_STAT_TA	By known positives: 10-14	7
PMTCT_STAT_TA	By known positives: 15-19	126
PMTCT_STAT_TA	By known positives: 20-24	214
PMTCT_STAT_TA	By known positives: 25-49	257
PMTCT_STAT_TA	By new positives: 15-19	84
PMTCT_STAT_TA	By new positives: 20-24	140
PMTCT_STAT_TA	By new positives: 25-49	161
PMTCT_STAT_TA	By new negatives: 10-14	160
PMTCT_STAT_TA	By new negatives: 15-19	2,754
PMTCT_STAT_TA	By new negatives: 20-24	2,612
PMTCT_STAT_TA	By new negatives: 25-49	8,888
PMTCT_STAT_TA	By Age (Numerator): 10-14	165
PMTCT_STAT_TA	By Age (Numerator): : 15-19	2,937
PMTCT_STAT_TA	By Age (Numerator): 20-24	2,937
PMTCT_STAT_TA	By Age (Numerator): 25-49	9,364
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	22,472
VMMC_CIRC_DSD	By Age: 10-14	2,248
VMMC_CIRC_DSD	By Age: 15-19	4,048
VMMC_CIRC_DSD	By Age: 20-24	5,397
VMMC_CIRC_DSD	By Age: 25-29	8,543
VMMC_CIRC_DSD	By Age: 30-49	1,350
VMMC_CIRC_DSD	By Age: 50+	886
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	12,579
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	22,472
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	600
PrEP_NEW_DSD	Male 15-19	75
PrEP_NEW_DSD	Male 20-24	75



PrEP_NEW_DSD	Male 25-49	75
PrEP_NEW_DSD	Male 50+	75
PrEP_NEW_DSD	Female 15-19	75
PrEP_NEW_DSD	Female 20-24	75
PrEP_NEW_DSD	Female 25-49	75
PrEP_NEW_DSD	Female 50+	75
PrEP_NEW_DSD	FSW	54
PrEP_NEW_DSD	MSM	2
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	494
PP_PREV_DSD	Age/sex: 10-14 Male	68
PP_PREV_DSD	Age/sex: 15-19 Male	34
PP_PREV_DSD	Age/sex: 20-24 Male	25
PP_PREV_DSD	Age/sex: 25-49 Male	44
PP_PREV_DSD	Age/sex: 50+ Male	10
PP_PREV_DSD	Age/sex: 10-14 Female	92
PP_PREV_DSD	Age/sex: 15-19 Female	61
PP_PREV_DSD	Age/sex: 20-24 Female	47
PP_PREV_DSD	Age/sex: 25-49 Female	104
PP_PREV_DSD	Age/sex: 50+ Female	9
PP_PREV_DSD	Sum of Age/Sex disaggregates	494
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	6,021
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	159
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key	240



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	64
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	67
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,491
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	205,642
HTC_TST_DSD	By Test Result: Positive	8,888
HTC_TST_DSD	Sum of Test Result disaggregates	8,888
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	546
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	503
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	2,113
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	90



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	343
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	6,939
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	251
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,353
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	20,458
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	710
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	22,127
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	727
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	1,974
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	85
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	2,737
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	107
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	686
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	3,275
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	47
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	128



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	357
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	48
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	253
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	38
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	595
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	84
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	237
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	54
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	585
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	76
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	123
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	123
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	543
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	9



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	491
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	2,187
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	100
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	355
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	7,208
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	279
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,404
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	20,448
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	783
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	22,663
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	803
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,974
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	91
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	2,802



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	114
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	680
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	3,247
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	2,729
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	92
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	77



HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	113
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	5,776
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	6,737
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	121
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	5,776
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	140
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	964
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	311
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	270
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	143
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	86
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	35



HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	410
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	244
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	62
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	1,293
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	734
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	1,197
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	687
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	144
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	87
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	164
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	99
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	389
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,774
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	176
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	151



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	107
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	50
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	132
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	86
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	29
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	384
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	250
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	334
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	206
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	53
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	62
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	23



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	195
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	748
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	10,885
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	273
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	12,685
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	317
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	10,885
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	273
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	1,834
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	61
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	60,296
HTC_TST_TA	By Test Result: Positive	2,822
HTC_TST_TA	Sum of Test Result disaggregates	2,822
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	65
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	189
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	665
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	31
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	85



HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,321
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	88
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	445
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	25
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	6,596
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	234
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	6,845
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	236
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	592
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	28
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	851
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	36
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	184
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	899
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	19
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	69
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	1



HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	190
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	747
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	42
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	88
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	2,587
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	112
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	506
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	30
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	7,202
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	294
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	7,585
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	295
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	660
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	38
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	955



HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	49
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	190
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	963
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	19
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	624
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	13
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	12
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Negative	37
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Positive	28
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Negative	25
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	124
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	145
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Negative	124
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	21
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	35
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male,	81



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	56
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	36
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	11
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	163
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	103
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	43
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	29
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Negative	481
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Positive	278
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Negative	446
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Positive	255
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	53
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	35
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	63
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	45



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	78
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	435
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	3,881
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	113
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	4,523
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	122
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Negative	3,881
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Positive	113
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	659
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Positive	26
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,327
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,327
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	66
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	757
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	51
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	453
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	66
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	757



TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	51
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	453
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	151
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	151
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	5
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	8
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	52
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	86
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	86
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	52
GEND_GBV_DSD	Number of people receiving post-GBV care	618



GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	110
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	464
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	44
GEND_GBVTAD	Number of people receiving post-GBV care	225
GEND_GBVTAD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	34
GEND_GBVTAD	By type of service: Sexual Violence (Post-Rape Care)	180
GEND_GBVTAD	By PEP service provision (related to sexual violence services provided)	11
OVC_SERVDSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	16,286
OVC_SERVDSD	Age/Sex: 10-14 Male	1,479
OVC_SERVDSD	Age/Sex: 15-17 Male	1,396
OVC_SERVDSD	By: Age/sex: Male 18-24	1,488
OVC_SERVDSD	By: Age/sex: Male 25+	340
OVC_SERVDSD	Age/Sex: 10-14 Female	2,147
OVC_SERVDSD	Age/Sex: 15-17 Female	1,137
OVC_SERVDSD	By: Age/sex: 18-24 Female	1,730
OVC_SERVDSD	By: Age/sex: 25+ Female	495
OVC_SERVDSD	Sum of Age/Sex disaggregates	6,159
OVC_SERVDSD	Age/Sex: <1	645
OVC_SERVDSD	Age/Sex: 1-9	5,429
OVC_SERVDSD	Program Completion: Active	12,298
OVC_SERVDSD	Program Completion: Graduation	2,359
OVC_SERVDSD	Program Completion: Transferred	830
OVC_SERVDSD	Program Completion: Exited without graduation	799
TB_ARTDSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	428
TB_ARTDSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB	446



	treatment during the reporting period	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	22
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	238
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	14
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	154
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	23
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	246
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	15
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	162
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART	54



	during TB treatment during the reporting period	
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	58
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	32
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	22
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	36
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	22
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,593
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	70
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	1,066
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	31
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	426
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	741
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	37
PMTCT_EID_TA	Number of infants with a negative virological test result	505



	within 2 months of birth	
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	7
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	192
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	65,185
TX_CURR_DSD	Age/Sex: 15-19 Male	892
TX_CURR_DSD	Age/Sex: 15-19 Female	2,297
TX_CURR_DSD	Sum of age/sex disaggregates	3,189
TX_CURR_DSD	Age/Sex: <1	183
TX_CURR_DSD	Age/Sex: <1-9	4,101
TX_CURR_DSD	Age/Sex: 10-14 Male	1,388
TX_CURR_DSD	Age/Sex: 10-14 Female	1,660
TX_CURR_DSD	Age/Sex: 20-24 Male	1,493
TX_CURR_DSD	Age/Sex: 25-49 Male	15,906
TX_CURR_DSD	Age/Sex: 50+ Male	1,975
TX_CURR_DSD	Age/Sex: 20-24 Female	5,338
TX_CURR_DSD	Age/Sex: 25-49 Female	27,314
TX_CURR_DSD	Age/Sex: 50+ Female	2,638
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	14,705
TX_CURR_TA	Age/Sex: 15-19 Male	73
TX_CURR_TA	Age/Sex: 15-19 Female	399
TX_CURR_TA	Sum of Age/Sex disaggregations	472
TX_CURR_TA	Age/Sex: <1	32
TX_CURR_TA	Age/Sex: 1-9	541
TX_CURR_TA	Age/Sex: 10-14 Male	122
TX_CURR_TA	Age/Sex: 10-14 Female	177
TX_CURR_TA	Age/Sex: 20-24 Male	317
TX_CURR_TA	Age/Sex: 25-49 Male	3,964
TX_CURR_TA	Age/Sex: 50+ Male	488



TX_CURR_TA	Age/Sex: 20-24 Female	1,255
TX_CURR_TA	Age/Sex: 25-49 Female	6,677
TX_CURR_TA	Age/Sex: 50+ Female	660
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	8,264
TX_NEW_DSD	By Age/Sex: <1	82
TX_NEW_DSD	By Age/Sex: 1-9	324
TX_NEW_DSD	By Age/Sex: 10-14 Male	118
TX_NEW_DSD	By Age/Sex: 15-19 Male	115
TX_NEW_DSD	By Age/Sex: 20-24 Male	212
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,516
TX_NEW_DSD	By Age/Sex: 50+ Male	350
TX_NEW_DSD	By Age/Sex: 10-14 Female	127
TX_NEW_DSD	By Age/Sex: 15-19 Female	362
TX_NEW_DSD	By Age/Sex: 20-24 Female	929
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,840
TX_NEW_DSD	By Age/Sex: 50+ Female	289
TX_NEW_DSD	Sum of Age/Sex disaggregates	7,858
TX_NEW_DSD	Pregnancy status	2,091
TX_NEW_DSD	Breastfeeding status	37
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,948
TX_NEW_TA	By Age/Sex: <1	24
TX_NEW_TA	By Age/Sex: 1-9	23
TX_NEW_TA	By Age/Sex: 10-14 Male	10
TX_NEW_TA	By Age/Sex: 15-19 Male	19
TX_NEW_TA	By Age/Sex: 20-24 Male	61
TX_NEW_TA	By Age/Sex: 25-49 Male	574
TX_NEW_TA	By Age/Sex: 50+ Male	96
TX_NEW_TA	By Age/Sex: 10-14 Female	3
TX_NEW_TA	By Age/Sex: 15-19 Female	86
TX_NEW_TA	By Age/Sex: 20-24 Female	256



TX_NEW_TA	By Age/Sex: 25-49 Female	718
TX_NEW_TA	By Age/Sex: 50+ Female	78
TX_NEW_TA	Sum of Age/Sex disaggregates	1,901
TX_NEW_TA	Pregnancy status	498
TX_NEW_TA	Breastfeeding status	10
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	3,736
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	7,443
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	311
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	271
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	3,876
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	2,985
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	7,443
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	145
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	130
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,946
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,515
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	3,736
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	883
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,758



	period).	
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	38
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	19
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	972
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	729
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	1,758
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	9
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	11
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	484
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	379
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	883
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	1,310
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	65,185
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	70
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	60
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	760
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	420
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	3,871
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,461
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	37,594
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	20,259
TX_TB_DSD	Denominator: By Screen Result: Negative	59,972
TX_TB_DSD	Denominator: By Screen Result: Positive	5,213
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	5,213
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	516
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,048
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of	3,649



	Specimen Sent]: Gene Xpert MTB / R if Assay	
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	296
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	14,705
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	3
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	186
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	107
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	482
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	390
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	8,985
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	4,848
TX_TB_TA	Denominator: By Screen Result: Negative	13,528
TX_TB_TA	Denominator: By Screen Result: Positive	1,177
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,177
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	111
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	238
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	828

Implementing Mechanism Details

Mechanism ID: 13837	Mechanism Name: Monitoring, Evaluation and Learning Program
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: QED Group, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Approved



Total All Funding Sources: 956,639	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 956,639	
Funding Source	Funding Amount
GHP-State	956,639

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13837		
Mechanism Name:	Monitoring, Evaluation and Learning Program		
Prime Partner Name:	QED Group, LLC		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	521,639	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	435,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13841	Mechanism Name: CDC-WHO collaboration
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 240,480	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 240,480	
Funding Source	Funding Amount
GHP-State	240,480

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13841		
Mechanism Name:	CDC-WHO collaboration		
Prime Partner Name:	World Health Organization		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	90,180	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	150,300	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13864	Mechanism Name: Ministry of Health, Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Ministry of Health, Uganda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 4,534,059	
Total All Funding Sources and Applied Pipeline Amount: 4,534,059	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13864			
Mechanism Name: Ministry of Health, Uganda			
Prime Partner Name: Ministry of Health, Uganda			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13874	Mechanism Name: Advocacy for Better Health
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Program for Appropriate Technology in Health	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 626,250	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 626,250	
Funding Source	Funding Amount
GHP-State	626,250

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	60,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Human Resources for Health	156,000

Budget Code Information

Mechanism ID: 13874			
Mechanism Name: Advocacy for Better Health			
Prime Partner Name: Program for Appropriate Technology in Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	83,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	338,175	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	125,250	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	79,325	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13877	Mechanism Name: New Hope Project – Provision of Comprehensive HIV/AIDS Care, Treatment and Prevention services in Track 1.0 Health Facilities in Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Children's AIDS Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,973,465	
Total All Funding Sources and Applied Pipeline Amount: 1,973,465	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)



(No data provided.)

Budget Code Information

Mechanism ID: 13877 Mechanism Name: New Hope Project – Provision of Comprehensive HIV/AIDS Care, Treatment and Prevention services in Track 1.0 Health Facilities in Prime Partner Name: Uganda Children's AIDS Fund			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	71
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	870
PMTCT_ART_DSD	New on ART	32
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	39
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	870
PMTCT_STAT_DSD	By Age (Denominator): 10-14	8
PMTCT_STAT_DSD	By Age (Denominator): <15-19	165
PMTCT_STAT_DSD	By Age (Denominator): 20-24	165
PMTCT_STAT_DSD	By Age (Denominator): 25-49	532
PMTCT_STAT_DSD	By Number of known positives: 15-19	7
PMTCT_STAT_DSD	By Number of known positives: 20-24	12
PMTCT_STAT_DSD	By Number of known positives: 25-49	17
PMTCT_STAT_DSD	By Number of new positives: 15-19	8
PMTCT_STAT_DSD	By Number of new positives: 20-24	13
PMTCT_STAT_DSD	By Number of new positives: 25-49	17
PMTCT_STAT_DSD	By Number of new negative: 10-14	8
PMTCT_STAT_DSD	By Number of new negative: 15-19	150
PMTCT_STAT_DSD	By Number of new negative: 20-24	140
PMTCT_STAT_DSD	By Number of new negative: 25-49	498
PMTCT_STAT_DSD	By Age (Numerator): 10-14	8
PMTCT_STAT_DSD	By Age (Numerator): 15-19	165
PMTCT_STAT_DSD	By Age (Numerator): 20-24	165



PMTCT_STAT_DSD	By Age (Numerator): 25-49	532
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	16,509
HTC_TST_DSD	By Test Result: Positive	1,937
HTC_TST_DSD	Sum of Test Result disaggregates	1,937
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	47
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	150
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	61
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	1,189
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	90
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	1,885
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	147
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	118
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	9



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	231
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	40
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	120
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	80
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	199
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	77
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	199
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	40
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	40



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	142
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	58
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	1,143
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	121
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	1,641
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	229
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	113
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	201
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	28



HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	24



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	308
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	175
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	684
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	385
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	84
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	46
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	3



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	86
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	48
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	220
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	123
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	26
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,529
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	72
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	1,783
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	84
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	1,529
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	72
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	254
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	12
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	55
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	55
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	34



TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	18
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	34
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	18
GEND_GBV_DSD	Number of people receiving post-GBV care	21
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	3
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	16
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	2
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	14,276
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,295
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,227
OVC_SERV_DSD	By: Age/sex: Male 18-24	1,304
OVC_SERV_DSD	By: Age/sex: Male 25+	301
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,879
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,001
OVC_SERV_DSD	By: Age/sex: 18-24 Female	1,517
OVC_SERV_DSD	By: Age/sex: 25+ Female	427



OVC_SERV_DSD	Sum of Age/Sex disaggregates	5,402
OVC_SERV_DSD	Age/Sex: <1	567
OVC_SERV_DSD	Age/Sex: 1-9	4,758
OVC_SERV_DSD	Program Completion: Active	10,777
OVC_SERV_DSD	Program Completion: Graduation	2,070
OVC_SERV_DSD	Program Completion: Transferred	715
OVC_SERV_DSD	Program Completion: Exited without graduation	714
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	26
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	28
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	15
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The	17



	number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	9
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	58
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	1
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	39
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	1
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	17
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	13,471
TX_CURR_DSD	Age/Sex: 15-19 Male	72
TX_CURR_DSD	Age/Sex: 15-19 Female	229
TX_CURR_DSD	Sum of age/sex disaggregates	301
TX_CURR_DSD	Age/Sex: <1	33
TX_CURR_DSD	Age/Sex: <1-9	505
TX_CURR_DSD	Age/Sex: 10-14 Male	113
TX_CURR_DSD	Age/Sex: 10-14 Female	164
TX_CURR_DSD	Age/Sex: 20-24 Male	308
TX_CURR_DSD	Age/Sex: 25-49 Male	3,670
TX_CURR_DSD	Age/Sex: 50+ Male	453
TX_CURR_DSD	Age/Sex: 20-24 Female	728



TX_CURR_DSD	Age/Sex: 25-49 Female	6,549
TX_CURR_DSD	Age/Sex: 50+ Female	647
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,768
TX_NEW_DSD	By Age/Sex: <1	22
TX_NEW_DSD	By Age/Sex: 15-19 Male	13
TX_NEW_DSD	By Age/Sex: 20-24 Male	60
TX_NEW_DSD	By Age/Sex: 25-49 Male	971
TX_NEW_DSD	By Age/Sex: 50+ Male	120
TX_NEW_DSD	By Age/Sex: 15-19 Female	43
TX_NEW_DSD	By Age/Sex: 20-24 Female	140
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,272
TX_NEW_DSD	By Age/Sex: 50+ Female	127
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,746
TX_NEW_DSD	Pregnancy status	693
TX_NEW_DSD	Breastfeeding status	8
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	10,912
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	12,125
TX_PVLS_DSD	Numerator: Indication: Routine	10,912
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	1,091
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	54
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	296
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,646
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	364



TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	6,606
TX_PVLS_DSD	Denominator: Indication: Routine	12,125
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	1,212
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	60
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	329
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	4,054
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	404
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	7,338
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	914
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,009
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	30
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	315
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	34
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	535
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the	30



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	351
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	34
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	594
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,246
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	2,492
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	11
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	9
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,425
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,047
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	2,492
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	5
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	4



TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	712
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	525
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	1,246
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	269
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	13,471
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	9
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	7
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	163
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	90
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	449
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	366
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	8,154
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	4,502
TX_TB_DSD	Denominator: By Screen Result: Negative	12,393
TX_TB_DSD	Denominator: By Screen Result: Positive	1,078
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,078
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	110
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	214
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	754

Implementing Mechanism Details

Mechanism ID: 13880	Mechanism Name: Provision of Comprehensive HIV/AIDS Services and Health Work Force Development for Managing Health Programs in the Republic of Uganda under the President's Plan for AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Makerere University School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,409,612	
Total All Funding Sources and Applied Pipeline Amount: 1,409,612	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13880		
Mechanism Name:	Provision of Comprehensive HIV/AIDS Services and Health Work Force Development for Managing Health Programs in the Republic of Uganda		
Prime Partner Name:	under the President's Plan for AIDS Relief Makerere University School of Public Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission	48



	(MTCT) during pregnancy	
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	514
PMTCT_ART_DSD	New on ART	21
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	27
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	825
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,780
PMTCT_ART_TA	New on ART	368
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	457
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	514
PMTCT_STAT_DSD	By Age (Denominator): 10-14	6
PMTCT_STAT_DSD	By Age (Denominator): <15-19	98
PMTCT_STAT_DSD	By Age (Denominator): 20-24	98
PMTCT_STAT_DSD	By Age (Denominator): 25-49	312
PMTCT_STAT_DSD	By Number of known positives: 15-19	7
PMTCT_STAT_DSD	By Number of known positives: 20-24	12
PMTCT_STAT_DSD	By Number of known positives: 25-49	15
PMTCT_STAT_DSD	By Number of new positives: 15-19	4
PMTCT_STAT_DSD	By Number of new positives: 20-24	6
PMTCT_STAT_DSD	By Number of new positives: 25-49	8
PMTCT_STAT_DSD	By Number of new negative: 10-14	6
PMTCT_STAT_DSD	By Number of new negative: 15-19	89
PMTCT_STAT_DSD	By Number of new negative: 20-24	82
PMTCT_STAT_DSD	By Number of new negative: 25-49	285
PMTCT_STAT_DSD	By Age (Numerator): 10-14	6
PMTCT_STAT_DSD	By Age (Numerator): 15-19	98



PMTCT_STAT_DSD	By Age (Numerator): 20-24	98
PMTCT_STAT_DSD	By Age (Numerator): 25-49	312
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,780
PMTCT_STAT_TA	By Age (Denominator): 10-14	94
PMTCT_STAT_TA	By Age (Denominator): 15-19	1,677
PMTCT_STAT_TA	By Age (Denominator): 20-24	1,677
PMTCT_STAT_TA	By Age (Denominator): 25-49	5,332
PMTCT_STAT_TA	By known positives: 10-14	4
PMTCT_STAT_TA	By known positives: 15-19	117
PMTCT_STAT_TA	By known positives: 20-24	202
PMTCT_STAT_TA	By known positives: 25-49	254
PMTCT_STAT_TA	By new positives: 10-14	1
PMTCT_STAT_TA	By new positives: 15-19	64
PMTCT_STAT_TA	By new positives: 20-24	109
PMTCT_STAT_TA	By new positives: 25-49	125
PMTCT_STAT_TA	By new negatives: 10-14	92
PMTCT_STAT_TA	By new negatives: 15-19	1,511
PMTCT_STAT_TA	By new negatives: 20-24	1,384
PMTCT_STAT_TA	By new negatives: 25-49	4,917
PMTCT_STAT_TA	By Age (Numerator): 10-14	94
PMTCT_STAT_TA	By Age (Numerator): : 15-19	1,677
PMTCT_STAT_TA	By Age (Numerator): 20-24	1,677
PMTCT_STAT_TA	By Age (Numerator): 25-49	5,332
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	2,516
VMMC_CIRC_DSD	By Age: 10-14	254
VMMC_CIRC_DSD	By Age: 15-19	454
VMMC_CIRC_DSD	By Age: 20-24	605
VMMC_CIRC_DSD	By Age: 25-29	955



VMMC_CIRC_DSD	By Age: 30-49	153
VMMC_CIRC_DSD	By Age: 50+	95
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	1,408
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	2,516
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	2,083
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	234
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	876
PrEP_NEW_DSD	Male 15-19	109
PrEP_NEW_DSD	Male 20-24	109
PrEP_NEW_DSD	Male 25-49	109
PrEP_NEW_DSD	Male 50+	109
PrEP_NEW_DSD	Female 15-19	109
PrEP_NEW_DSD	Female 20-24	109
PrEP_NEW_DSD	Female 25-49	109
PrEP_NEW_DSD	Female 50+	113
PrEP_NEW_DSD	FSW	79
PrEP_NEW_DSD	MSM	3
PrEP_NEW_DSD	TG	1
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	19,833
PP_PREV_DSD	Age/sex: 10-14 Male	402
PP_PREV_DSD	Age/sex: 15-19 Male	2,451
PP_PREV_DSD	Age/sex: 20-24 Male	4,676
PP_PREV_DSD	Age/sex: 25-49 Male	8,884
PP_PREV_DSD	Age/sex: 50+ Male	67
PP_PREV_DSD	Age/sex: 10-14 Female	492
PP_PREV_DSD	Age/sex: 15-19 Female	973
PP_PREV_DSD	Age/sex: 20-24 Female	1,258
PP_PREV_DSD	Age/sex: 25-49 Female	578



PP_PREV_DSD	Age/sex: 50+ Female	52
PP_PREV_DSD	Sum of Age/Sex disaggregates	19,833
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,357
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,357
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	9,099
HTC_TST_DSD	By Test Result: Positive	1,098
HTC_TST_DSD	Sum of Test Result disaggregates	1,098
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	95
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	53
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	183



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	1,070
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	134
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	126
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	365
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	48
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	250
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	38
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	607
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	76
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	248
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	41



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	607
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	73
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	126
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	126
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	92
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	182
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	1,052



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	64
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	132
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	146
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	170
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	146
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female,	7



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	217
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	123
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	27
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19,	5



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	41
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	25
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	75
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	345
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	197
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	49
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	297
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	345
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	297



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	50
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	3
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	40,215
HTC_TST_TA	By Test Result: Positive	3,349
HTC_TST_TA	Sum of Test Result disaggregates	3,349
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	264
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	21
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	111
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	841
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	52
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	475
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	33
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	1,607
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	97
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	9,344
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	530
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	159



HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	1,167
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	71
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	208
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	21
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	94
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	677
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	46
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	374
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	32
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	1,402
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	94
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	7,723
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	475
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	130
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	9



HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	934
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	63
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Negative	28
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Positive	15
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Negative	72
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Positive	37
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	470
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	549
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Negative	470
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	79
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	46
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	32
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male,	26



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	17
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	144
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	84
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	81
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	50
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Negative	296
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Positive	173
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Negative	1,594
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Positive	897
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	34
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	23
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	199
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	112
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	2,178
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	91
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	2,532
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	102
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Negative	2,178
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Positive	91
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	370



HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Positive	24
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	24
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	24
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	14
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	14
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	8
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	253
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	253
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during	6



	the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	12
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	89
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	146
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	146
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	89
GEND_GBV_DSD	Number of people receiving post-GBV care	373
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	23
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	117
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	4
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	3
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	29
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	42
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	12
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	31



GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	16
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	35
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	15
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	8
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	12
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	12
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The	6



	number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	4
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	122
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	128
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	72
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	41
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with	5

	documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	74
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	4
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	45
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	39
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	2
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	26
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	11
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	667
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	31
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	449
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	7
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	180
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,925



TX_CURR_DSD	Age/Sex: 15-19 Male	88
TX_CURR_DSD	Age/Sex: 15-19 Female	210
TX_CURR_DSD	Sum of age/sex disaggregates	298
TX_CURR_DSD	Age/Sex: <1	8
TX_CURR_DSD	Age/Sex: <1-9	130
TX_CURR_DSD	Age/Sex: 10-14 Male	30
TX_CURR_DSD	Age/Sex: 10-14 Female	42
TX_CURR_DSD	Age/Sex: 20-24 Male	378
TX_CURR_DSD	Age/Sex: 25-49 Male	1,387
TX_CURR_DSD	Age/Sex: 50+ Male	171
TX_CURR_DSD	Age/Sex: 20-24 Female	665
TX_CURR_DSD	Age/Sex: 25-49 Female	1,652
TX_CURR_DSD	Age/Sex: 50+ Female	164
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	21,844
TX_CURR_TA	Age/Sex: 15-19 Male	394
TX_CURR_TA	Age/Sex: 15-19 Female	930
TX_CURR_TA	Sum of Age/Sex disaggregations	1,324
TX_CURR_TA	Age/Sex: <1	35
TX_CURR_TA	Age/Sex: 1-9	581
TX_CURR_TA	Age/Sex: 10-14 Male	127
TX_CURR_TA	Age/Sex: 10-14 Female	184
TX_CURR_TA	Age/Sex: 20-24 Male	1,673
TX_CURR_TA	Age/Sex: 25-49 Male	6,150
TX_CURR_TA	Age/Sex: 50+ Male	761
TX_CURR_TA	Age/Sex: 20-24 Female	2,952
TX_CURR_TA	Age/Sex: 25-49 Female	7,330
TX_CURR_TA	Age/Sex: 50+ Female	727
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	698
TX_NEW_DSD	By Age/Sex: <1	5
TX_NEW_DSD	By Age/Sex: 15-19 Male	6



TX_NEW_DSD	By Age/Sex: 20-24 Male	25
TX_NEW_DSD	By Age/Sex: 25-49 Male	459
TX_NEW_DSD	By Age/Sex: 50+ Male	58
TX_NEW_DSD	By Age/Sex: 15-19 Female	14
TX_NEW_DSD	By Age/Sex: 20-24 Female	42
TX_NEW_DSD	By Age/Sex: 25-49 Female	81
TX_NEW_DSD	By Age/Sex: 50+ Female	8
TX_NEW_DSD	Sum of Age/Sex disaggregates	693
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,099
TX_NEW_TA	By Age/Sex: <1	24
TX_NEW_TA	By Age/Sex: 15-19 Male	31
TX_NEW_TA	By Age/Sex: 20-24 Male	107
TX_NEW_TA	By Age/Sex: 25-49 Male	2,008
TX_NEW_TA	By Age/Sex: 50+ Male	263
TX_NEW_TA	By Age/Sex: 15-19 Female	65
TX_NEW_TA	By Age/Sex: 20-24 Female	190
TX_NEW_TA	By Age/Sex: 25-49 Female	366
TX_NEW_TA	By Age/Sex: 50+ Female	45
TX_NEW_TA	Sum of Age/Sex disaggregates	3,075
TX_NEW_TA	Pregnancy status	6
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	84
HRH_PRE	By Graduates: Other	84
HRH_PRE	Sum of Graduates disaggreagtes	84
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	314
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period	628



	and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	3
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	2
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	127
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	496
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	628
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	2
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	1
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	62
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	249
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	314
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,398
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	2,791
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	20
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	8
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	560
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	2,203
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	2,791
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	3
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	3
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	279
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	1,113



TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	1,398
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	98
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	4,925
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	2
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	2
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	54
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	40
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	115
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	95
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	2,692
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	2,023
TX_TB_DSD	Denominator: By Screen Result: Negative	4,531
TX_TB_DSD	Denominator: By Screen Result: Positive	394
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	394
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	40
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	78
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	276
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	435
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	21,844
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	6
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Male	4
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	237
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	188
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	513



TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	414
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	11,939
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	8,978
TX_TB_TA	Denominator: By Screen Result: Negative	20,096
TX_TB_TA	Denominator: By Screen Result: Positive	1,748
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,748
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	182
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	346
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,220

Implementing Mechanism Details

Mechanism ID: 13892	Mechanism Name: School Health and Reading Program (SHRP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Research Triangle International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 937,601	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 937,601	
Funding Source	Funding Amount
GHP-State	937,601

Cross-Cutting Budget Attribution(s)



Gender: GBV	187,520
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	187,520
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	375,040
Education	937,601

Budget Code Information

Mechanism ID:	13892		
Mechanism Name:	School Health and Reading Program (SHRP)		
Prime Partner Name:	Research Triangle International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	168,199	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	672,794	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	1,751	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	94,857	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	24,931
PP_PREV_DSD	Age/sex: 10-14 Female	19,941
PP_PREV_DSD	Age/sex: 15-19 Female	3,741
PP_PREV_DSD	Age/sex: 20-24 Female	1,249
PP_PREV_DSD	Sum of Age/Sex disaggregates	24,931

Implementing Mechanism Details

Mechanism ID: 13901	Mechanism Name: Communication for Healthy Communities (CHC)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,795,686	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 265,295	
Total All Funding Sources and Applied Pipeline Amount: 2,060,981	
Funding Source	Funding Amount
GHP-State	1,795,686



Cross-Cutting Budget Attribution(s)

Gender: GBV	30,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Sub Area:	Implementation
Gender: Gender Equality	30,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Capacity building
Sub Area:	Implementation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Key Populations: FSW	100,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Key Populations: MSM and TG	50,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Condom programming	190,000



Budget Code Information

Mechanism ID: 13901			
Mechanism Name: Communication for Healthy Communities (CHC)			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	114,775	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	80,546	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	294,746	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	937,187	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	184,216	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	184,216	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16594	Mechanism Name: MEASURE Evaluation Phase IV
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 776,750	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 100,000	
Total All Funding Sources and Applied Pipeline Amount: 876,750	
Funding Source	Funding Amount
GHP-State	776,750

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16594		
Mechanism Name:	MEASURE Evaluation Phase IV		
Prime Partner Name:	University of North Carolina at Chapel Hill, Carolina Population Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	776,750	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16626	Mechanism Name: Uganda Private Health Support Program (PHS)
Funding Agency: USAID	Procurement Type: Contract



Prime Partner Name: Cardno Emerging Markets	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 2,043,031	
Total All Funding Sources and Applied Pipeline Amount: 2,043,031	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16626			
Mechanism Name: Uganda Private Health Support Program (PHS)			
Prime Partner Name: Cardno Emerging Markets			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	330
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,759
PMTCT_ART_DSD	New on ART	150
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	180
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	28
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	335
PMTCT_ART_TA	New on ART	13
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	15
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,759
PMTCT_STAT_DSD	By Age (Denominator): 10-14	50
PMTCT_STAT_DSD	By Age (Denominator): <15-19	907
PMTCT_STAT_DSD	By Age (Denominator): 20-24	907
PMTCT_STAT_DSD	By Age (Denominator): 25-49	2,895
PMTCT_STAT_DSD	By Number of known positives: 10-14	2
PMTCT_STAT_DSD	By Number of known positives: 15-19	44
PMTCT_STAT_DSD	By Number of known positives: 20-24	77
PMTCT_STAT_DSD	By Number of known positives: 25-49	102
PMTCT_STAT_DSD	By Number of new positives: 10-14	2
PMTCT_STAT_DSD	By Number of new positives: 15-19	25
PMTCT_STAT_DSD	By Number of new positives: 20-24	44



PMTCT_STAT_DSD	By Number of new positives: 25-49	54
PMTCT_STAT_DSD	By Number of new negative: 10-14	48
PMTCT_STAT_DSD	By Number of new negative: 15-19	841
PMTCT_STAT_DSD	By Number of new negative: 20-24	789
PMTCT_STAT_DSD	By Number of new negative: 25-49	2,731
PMTCT_STAT_DSD	By Age (Numerator): 10-14	50
PMTCT_STAT_DSD	By Age (Numerator): 15-19	907
PMTCT_STAT_DSD	By Age (Numerator): 20-24	907
PMTCT_STAT_DSD	By Age (Numerator): 25-49	2,895
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	335
PMTCT_STAT_TA	By Age (Denominator): 10-14	4
PMTCT_STAT_TA	By Age (Denominator): 15-19	64
PMTCT_STAT_TA	By Age (Denominator): 20-24	64
PMTCT_STAT_TA	By Age (Denominator): 25-49	203
PMTCT_STAT_TA	By known positives: 15-19	3
PMTCT_STAT_TA	By known positives: 20-24	6
PMTCT_STAT_TA	By known positives: 25-49	7
PMTCT_STAT_TA	By new positives: 15-19	3
PMTCT_STAT_TA	By new positives: 20-24	4
PMTCT_STAT_TA	By new positives: 25-49	6
PMTCT_STAT_TA	By new negatives: 10-14	4
PMTCT_STAT_TA	By new negatives: 15-19	58
PMTCT_STAT_TA	By new negatives: 20-24	55
PMTCT_STAT_TA	By new negatives: 25-49	189
PMTCT_STAT_TA	By Age (Numerator): 10-14	4
PMTCT_STAT_TA	By Age (Numerator): : 15-19	64
PMTCT_STAT_TA	By Age (Numerator): 20-24	64
PMTCT_STAT_TA	By Age (Numerator): 25-49	203
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention	2,847



	program within the reporting period	
VMMC_CIRC_DSD	By Age: 10-14	286
VMMC_CIRC_DSD	By Age: 15-19	514
VMMC_CIRC_DSD	By Age: 20-24	684
VMMC_CIRC_DSD	By Age: 25-29	1,081
VMMC_CIRC_DSD	By Age: 30-49	172
VMMC_CIRC_DSD	By Age: 50+	110
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	1,594
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	2,847
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	31,080
HTC_TST_DSD	By Test Result: Positive	1,801
HTC_TST_DSD	Sum of Test Result disaggregates	1,801
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	326
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,021
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	125
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49,	3,938



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	202
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	3,902
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	199
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	390
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	487
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	15
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	23
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	17
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	39
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	6



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	14
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	39
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	295
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	909
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	170
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	11



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	3,372
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	182
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	3,391
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	180
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	336
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	420
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	20



HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	881
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	1,028
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	881
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	148
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	66
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	288
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	163



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	272
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	154
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	15
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	62
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	57
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+,	8



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,797
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	53
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	2,096
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	1,797
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	53
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	301
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	11
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,212
HTC_TST_TA	By Test Result: Positive	114
HTC_TST_TA	Sum of Test Result disaggregates	114
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	43
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male,	2



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	179
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	156
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	18
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	15
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	11
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	50
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	206
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	11



	Female, Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	191
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	20
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	20
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	189
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	220
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Negative	189
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	32
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	5



HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Negative	18
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	141
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	165
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Negative	141
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	25
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Positive	2
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	330
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	330



TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	16
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	191
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	111
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	16
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	191
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	12
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	111
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	26
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	26
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total	9



	number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	15
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	15
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	37,260
OVC_SERV_DSD	Age/Sex: 10-14 Male	3,380
OVC_SERV_DSD	Age/Sex: 15-17 Male	3,203
OVC_SERV_DSD	By: Age/sex: Male 18-24	3,403
OVC_SERV_DSD	By: Age/sex: Male 25+	780
OVC_SERV_DSD	Age/Sex: 10-14 Female	4,908
OVC_SERV_DSD	Age/Sex: 15-17 Female	2,615
OVC_SERV_DSD	By: Age/sex: 18-24 Female	3,955
OVC_SERV_DSD	By: Age/sex: 25+ Female	1,123
OVC_SERV_DSD	Sum of Age/Sex disaggregates	14,106
OVC_SERV_DSD	Age/Sex: <1	1,481
OVC_SERV_DSD	Age/Sex: 1-9	12,412
OVC_SERV_DSD	Program Completion: Active	28,132
OVC_SERV_DSD	Program Completion: Graduation	5,401
OVC_SERV_DSD	Program Completion: Transferred	1,883



OVC_SERV_DSD	Program Completion: Exited without graduation	1,844
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	141
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	149
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	80
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	50
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	7
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	84
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	6



TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	52
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	14
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	15
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	8
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The	1



	number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	5
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	263
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	12
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	178
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	4
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	69
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	22
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	1
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	15
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	1
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	5
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	11,222
TX_CURR_DSD	Age/Sex: 15-19 Male	63
TX_CURR_DSD	Age/Sex: 15-19 Female	287
TX_CURR_DSD	Sum of age/sex disaggregates	350
TX_CURR_DSD	Age/Sex: <1	27
TX_CURR_DSD	Age/Sex: <1-9	398



TX_CURR_DSD	Age/Sex: 10-14 Male	89
TX_CURR_DSD	Age/Sex: 10-14 Female	129
TX_CURR_DSD	Age/Sex: 20-24 Male	268
TX_CURR_DSD	Age/Sex: 25-49 Male	3,023
TX_CURR_DSD	Age/Sex: 50+ Male	372
TX_CURR_DSD	Age/Sex: 20-24 Female	904
TX_CURR_DSD	Age/Sex: 25-49 Female	5,153
TX_CURR_DSD	Age/Sex: 50+ Female	509
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	333
TX_CURR_TA	Age/Sex: 15-19 Male	2
TX_CURR_TA	Age/Sex: 15-19 Female	9
TX_CURR_TA	Sum of Age/Sex disaggregations	11
TX_CURR_TA	Age/Sex: 1-9	11
TX_CURR_TA	Age/Sex: 10-14 Male	2
TX_CURR_TA	Age/Sex: 10-14 Female	4
TX_CURR_TA	Age/Sex: 20-24 Male	8
TX_CURR_TA	Age/Sex: 25-49 Male	87
TX_CURR_TA	Age/Sex: 50+ Male	11
TX_CURR_TA	Age/Sex: 20-24 Female	27
TX_CURR_TA	Age/Sex: 25-49 Female	156
TX_CURR_TA	Age/Sex: 50+ Female	16
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,481
TX_NEW_DSD	By Age/Sex: <1	16
TX_NEW_DSD	By Age/Sex: 1-9	2
TX_NEW_DSD	By Age/Sex: 15-19 Male	8
TX_NEW_DSD	By Age/Sex: 20-24 Male	28
TX_NEW_DSD	By Age/Sex: 25-49 Male	549
TX_NEW_DSD	By Age/Sex: 50+ Male	71
TX_NEW_DSD	By Age/Sex: 10-14 Female	1
TX_NEW_DSD	By Age/Sex: 15-19 Female	45



TX_NEW_DSD	By Age/Sex: 20-24 Female	139
TX_NEW_DSD	By Age/Sex: 25-49 Female	565
TX_NEW_DSD	By Age/Sex: 50+ Female	57
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,463
TX_NEW_DSD	Pregnancy status	372
TX_NEW_DSD	Breastfeeding status	6
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	26
TX_NEW_TA	By Age/Sex: 20-24 Male	2
TX_NEW_TA	By Age/Sex: 25-49 Male	4
TX_NEW_TA	By Age/Sex: 50+ Male	1
TX_NEW_TA	By Age/Sex: 15-19 Female	1
TX_NEW_TA	By Age/Sex: 20-24 Female	3
TX_NEW_TA	By Age/Sex: 25-49 Female	13
TX_NEW_TA	By Age/Sex: 50+ Female	2
TX_NEW_TA	Sum of Age/Sex disaggregates	26
TX_NEW_TA	Pregnancy status	7
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	667
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,335
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	11
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	8
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	719
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	597
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	1,335
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	5



TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	3
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	357
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	302
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	667
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	12
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	23
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	14
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	9
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	23
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	7
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	5
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	12
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	226
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	11,222
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	7
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	7
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	139
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	73
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	356
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	287
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	6,849
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	3,730
TX_TB_DSD	Denominator: By Screen Result: Negative	10,324



TX_TB_DSD	Denominator: By Screen Result: Positive	898
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	898
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	90
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	179
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	629
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	7
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	333
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	5
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	2
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	10
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	7
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	207
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	109
TX_TB_TA	Denominator: By Screen Result: Negative	306
TX_TB_TA	Denominator: By Screen Result: Positive	27
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	27
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	3
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	5
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	19

Implementing Mechanism Details

Mechanism ID: 17063	Mechanism Name: Social Marketing Program
----------------------------	---

Approved



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Uganda Health Marketing Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,260,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,260,000	
Funding Source	Funding Amount
GHP-State	1,260,000

Cross-Cutting Budget Attribution(s)

Condom procurement	1,260,000
--------------------	-----------

Budget Code Information

Mechanism ID:	17063		
Mechanism Name:	Social Marketing Program		
Prime Partner Name:	Uganda Health Marketing Group		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,260,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 17065	Mechanism Name: Sustainable Outcomes for Children and Youth Central and Western Uganda (SOCY)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 7,428,800	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 7,428,800	
Funding Source	Funding Amount
GHP-State	7,428,800

Cross-Cutting Budget Attribution(s)

Gender: GBV	250,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Gender: Gender Equality	550,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Capacity building
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation



Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Economic Strengthening	1,500,000
Education	1,015,000
Water	92,500
Food and Nutrition: Policy, Tools, and Service Delivery	1,756,817

Budget Code Information

Mechanism ID:	17065		
Mechanism Name:	Sustainable Outcomes for Children and Youth Central and Western Uganda (SOCY)		
Prime Partner Name:	Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	7,352,763	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	76,037	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	132,672
OVC_SERV_DSD	Age/Sex: 10-14 Male	12,040
OVC_SERV_DSD	Age/Sex: 15-17 Male	11,408



OVC_SERV_DSD	By: Age/sex: Male 18-24	12,114
OVC_SERV_DSD	By: Age/sex: Male 25+	2,788
OVC_SERV_DSD	Age/Sex: 10-14 Female	17,473
OVC_SERV_DSD	Age/Sex: 15-17 Female	9,301
OVC_SERV_DSD	By: Age/sex: 18-24 Female	14,078
OVC_SERV_DSD	By: Age/sex: 25+ Female	3,987
OVC_SERV_DSD	Sum of Age/Sex disaggregates	50,222
OVC_SERV_DSD	Age/Sex: <1	5,274
OVC_SERV_DSD	Age/Sex: 1-9	44,209
OVC_SERV_DSD	Program Completion: Active	100,173
OVC_SERV_DSD	Program Completion: Graduation	19,235
OVC_SERV_DSD	Program Completion: Transferred	6,662
OVC_SERV_DSD	Program Completion: Exited without graduation	6,602

Implementing Mechanism Details

Mechanism ID: 17066	Mechanism Name: HIV/Health Initiatives in Workplaces Activity (HIWA)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Vision	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,061,113	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,061,113	
Funding Source	Funding Amount
GHP-State	1,061,113

Cross-Cutting Budget Attribution(s)

Gender: GBV	180,000
-------------	---------



Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	150,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Water	30,000
Condom programming	30,000

Budget Code Information

Mechanism ID: 17066



Mechanism Name: HIV/Health Initiatives in Workplaces Activity (HIWA)			
Prime Partner Name: World Vision			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	38,208	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	9,172	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	1,564	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	136,826	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	104,278	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	680,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	12,767	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	77,119	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,179	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
------------------	-------	------



PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	213
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,881
PMTCT_ART_DSD	New on ART	96
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	117
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	20
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	229
PMTCT_ART_TA	New on ART	9
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	11
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,881
PMTCT_STAT_DSD	By Age (Denominator): 10-14	28
PMTCT_STAT_DSD	By Age (Denominator): <15-19	548
PMTCT_STAT_DSD	By Age (Denominator): 20-24	548
PMTCT_STAT_DSD	By Age (Denominator): 25-49	1,757
PMTCT_STAT_DSD	By Number of known positives: 10-14	1
PMTCT_STAT_DSD	By Number of known positives: 15-19	25
PMTCT_STAT_DSD	By Number of known positives: 20-24	45
PMTCT_STAT_DSD	By Number of known positives: 25-49	62
PMTCT_STAT_DSD	By Number of new positives: 10-14	1
PMTCT_STAT_DSD	By Number of new positives: 15-19	17
PMTCT_STAT_DSD	By Number of new positives: 20-24	31
PMTCT_STAT_DSD	By Number of new positives: 25-49	43
PMTCT_STAT_DSD	By Number of new negative: 10-14	26
PMTCT_STAT_DSD	By Number of new negative: 15-19	506



PMTCT_STAT_DSD	By Number of new negative: 20-24	472
PMTCT_STAT_DSD	By Number of new negative: 25-49	1,652
PMTCT_STAT_DSD	By Age (Numerator): 10-14	28
PMTCT_STAT_DSD	By Age (Numerator): 15-19	548
PMTCT_STAT_DSD	By Age (Numerator): 20-24	548
PMTCT_STAT_DSD	By Age (Numerator): 25-49	1,757
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	229
PMTCT_STAT_TA	By Age (Denominator): 10-14	3
PMTCT_STAT_TA	By Age (Denominator): 15-19	43
PMTCT_STAT_TA	By Age (Denominator): 20-24	43
PMTCT_STAT_TA	By Age (Denominator): 25-49	140
PMTCT_STAT_TA	By known positives: 15-19	3
PMTCT_STAT_TA	By known positives: 20-24	5
PMTCT_STAT_TA	By known positives: 25-49	5
PMTCT_STAT_TA	By new positives: 15-19	1
PMTCT_STAT_TA	By new positives: 20-24	3
PMTCT_STAT_TA	By new positives: 25-49	3
PMTCT_STAT_TA	By new negatives: 10-14	3
PMTCT_STAT_TA	By new negatives: 15-19	39
PMTCT_STAT_TA	By new negatives: 20-24	35
PMTCT_STAT_TA	By new negatives: 25-49	132
PMTCT_STAT_TA	By Age (Numerator): 10-14	3
PMTCT_STAT_TA	By Age (Numerator): : 15-19	43
PMTCT_STAT_TA	By Age (Numerator): 20-24	43
PMTCT_STAT_TA	By Age (Numerator): 25-49	140
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	13,994
VMMC_CIRC_DSD	By Age: 10-14	1,399
VMMC_CIRC_DSD	By Age: 15-19	2,520



VMMC_CIRC_DSD	By Age: 20-24	3,358
VMMC_CIRC_DSD	By Age: 25-29	5,316
VMMC_CIRC_DSD	By Age: 30-49	840
VMMC_CIRC_DSD	By Age: 50+	561
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	7,838
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	13,994
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	450
PrEP_NEW_DSD	Male 15-19	56
PrEP_NEW_DSD	Male 20-24	56
PrEP_NEW_DSD	Male 25-49	56
PrEP_NEW_DSD	Male 50+	56
PrEP_NEW_DSD	Female 15-19	56
PrEP_NEW_DSD	Female 20-24	56
PrEP_NEW_DSD	Female 25-49	56
PrEP_NEW_DSD	Female 50+	58
PrEP_NEW_DSD	FSW	41
PrEP_NEW_DSD	MSM	2
PrEP_NEW_DSD	TG	1
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	40,004
PP_PREV_DSD	Age/sex: 10-14 Male	5,199
PP_PREV_DSD	Age/sex: 15-19 Male	2,698
PP_PREV_DSD	Age/sex: 20-24 Male	2,489
PP_PREV_DSD	Age/sex: 25-49 Male	8,661
PP_PREV_DSD	Age/sex: 50+ Male	765
PP_PREV_DSD	Age/sex: 10-14 Female	6,310
PP_PREV_DSD	Age/sex: 15-19 Female	3,387
PP_PREV_DSD	Age/sex: 20-24 Female	2,411
PP_PREV_DSD	Age/sex: 25-49 Female	7,467



PP_PREV_DSD	Age/sex: 50+ Female	617
PP_PREV_DSD	Sum of Age/Sex disaggregates	40,004
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	29,910
HTC_TST_DSD	By Test Result: Positive	1,813
HTC_TST_DSD	Sum of Test Result disaggregates	1,813
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	99
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	57
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	721
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	98
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	1,410
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	61
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female,	1



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	105
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	50
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	149
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	100
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	248
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	87
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	248
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	50
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+,	3



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	50
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	73
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	353
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	313
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,197
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	129
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	1,047
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	51
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	4,706
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	263
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	96
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male,	109



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	106
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	66
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	1



HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	1,888
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	2,202
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	1,888
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	316
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	247
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	139
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	107
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	61
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	508
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	284



HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	45
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	26
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	95
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	52



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	2,376
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	88
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	2,771
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	104
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	2,376
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	88
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	396
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	15
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	39
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	39
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	24
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	13
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during	1



	the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	24
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	13
GEND_GBV_DSD	Number of people receiving post-GBV care	157
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	31
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	111
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	15
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	19
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	21
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	14
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The	15



	number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	5
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	174
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	5
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	115
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	1
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	53
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	17
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	11
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	6
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,540
TX_CURR_DSD	Age/Sex: 15-19 Male	26
TX_CURR_DSD	Age/Sex: 15-19 Female	97
TX_CURR_DSD	Sum of age/sex disaggregates	123
TX_CURR_DSD	Age/Sex: <1	14
TX_CURR_DSD	Age/Sex: <1-9	14
TX_CURR_DSD	Age/Sex: 10-14 Male	39
TX_CURR_DSD	Age/Sex: 10-14 Female	39
TX_CURR_DSD	Age/Sex: 20-24 Male	160
TX_CURR_DSD	Age/Sex: 25-49 Male	270



TX_CURR_DSD	Age/Sex: 50+ Male	3
TX_CURR_DSD	Age/Sex: 20-24 Female	291
TX_CURR_DSD	Age/Sex: 25-49 Female	490
TX_CURR_DSD	Age/Sex: 50+ Female	97
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	309
TX_NEW_DSD	By Age/Sex: 15-19 Male	15
TX_NEW_DSD	By Age/Sex: 20-24 Male	93
TX_NEW_DSD	By Age/Sex: 25-49 Male	172
TX_NEW_DSD	By Age/Sex: 50+ Male	2
TX_NEW_DSD	By Age/Sex: 15-19 Female	2
TX_NEW_DSD	By Age/Sex: 20-24 Female	8
TX_NEW_DSD	By Age/Sex: 25-49 Female	15
TX_NEW_DSD	By Age/Sex: 50+ Female	2
TX_NEW_DSD	Sum of Age/Sex disaggregates	309
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,249
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,388
TX_PVLS_DSD	Numerator: Indication: Routine	1,249
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	125
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	6
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	45
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	366
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	45
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+	793



	Female Routine	
TX_PVLS_DSD	Denominator: Indication: Routine	1,388
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	138
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	6
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	52
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	408
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	52
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	876
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	224
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	250
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	73
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	133
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	9



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	85
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	147
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	139
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	280
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	25
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	255
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	280
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	11
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	128
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	139
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	31



TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	1,540
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	21
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	10
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	55
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	55
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	978
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	452
TX_TB_DSD	Denominator: By Screen Result: Negative	1,416
TX_TB_DSD	Denominator: By Screen Result: Positive	124
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	124
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	11
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	26
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	87

Implementing Mechanism Details

Mechanism ID: 17078	Mechanism Name: Applying Science to Strengthen and Improve Systems (ASSIST) Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,003,500	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,003,500	



Funding Source	Funding Amount
GHP-State	1,003,500

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17078			
Mechanism Name: Applying Science to Strengthen and Improve Systems (ASSIST) Project			
Prime Partner Name: University Research Council			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	83,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	420,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17094	Mechanism Name: Uganda Health Supply Chain
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,276,535	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,545,765	
Total All Funding Sources and Applied Pipeline Amount: 2,822,300	
Funding Source	Funding Amount
GHP-State	1,276,535

Cross-Cutting Budget Attribution(s)

Human Resources for Health	382,961
----------------------------	---------

Budget Code Information

Mechanism ID:	17094		
Mechanism Name:	Uganda Health Supply Chain		
Prime Partner Name:	Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	1,087,698	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	188,837	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17649	Mechanism Name: Regional Health Integration to Enhance Services in East Central Region (RHITES EC)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 10,025,345	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 2,225,391	
Total All Funding Sources and Applied Pipeline Amount: 12,250,736	
Funding Source	Funding Amount
GHP-State	10,025,345

Cross-Cutting Budget Attribution(s)

Gender: GBV	371,104
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation



Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	212,509
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Key Populations: FSW	177,249
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	118,166
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Condom programming	472,665
Water	397,611
Food and Nutrition: Policy, Tools, and Service Delivery	354,499



Budget Code Information

Mechanism ID:	17649		
Mechanism Name:	Regional Health Integration to Enhance Services in East Central Region (RHITES EC)		
Prime Partner Name:	University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,922,841	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	457,885	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	164,195	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	93,170	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	236,969	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,734,021	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	606,866	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	574,014	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,126,092	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	109,292	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,237
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	65,242
PMTCT_ART_DSD	New on ART	1,010
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,227
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,750
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	114,286
PMTCT_ART_TA	New on ART	1,688
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	2,062
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	65,242
PMTCT_STAT_DSD	By Age (Denominator): 10-14	650
PMTCT_STAT_DSD	By Age (Denominator): <15-19	12,396
PMTCT_STAT_DSD	By Age (Denominator): 20-24	12,396
PMTCT_STAT_DSD	By Age (Denominator): 25-49	39,800
PMTCT_STAT_DSD	By Number of known positives: 10-14	5
PMTCT_STAT_DSD	By Number of known positives: 15-19	234



PMTCT_STAT_DSD	By Number of known positives: 20-24	421
PMTCT_STAT_DSD	By Number of known positives: 25-49	571
PMTCT_STAT_DSD	By Number of new positives: 10-14	4
PMTCT_STAT_DSD	By Number of new positives: 15-19	213
PMTCT_STAT_DSD	By Number of new positives: 20-24	380
PMTCT_STAT_DSD	By Number of new positives: 25-49	529
PMTCT_STAT_DSD	By Number of new negative: 10-14	641
PMTCT_STAT_DSD	By Number of new negative: 15-19	11,948
PMTCT_STAT_DSD	By Number of new negative: 20-24	11,593
PMTCT_STAT_DSD	By Number of new negative: 25-49	38,703
PMTCT_STAT_DSD	By Age (Numerator): 10-14	650
PMTCT_STAT_DSD	By Age (Numerator): 15-19	12,396
PMTCT_STAT_DSD	By Age (Numerator): 20-24	12,396
PMTCT_STAT_DSD	By Age (Numerator): 25-49	39,800
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	114,286
PMTCT_STAT_TA	By Age (Denominator): 10-14	1,138
PMTCT_STAT_TA	By Age (Denominator): 15-19	21,720
PMTCT_STAT_TA	By Age (Denominator): 20-24	21,720
PMTCT_STAT_TA	By Age (Denominator): 25-49	69,708
PMTCT_STAT_TA	By known positives: 10-14	6
PMTCT_STAT_TA	By known positives: 15-19	394
PMTCT_STAT_TA	By known positives: 20-24	713
PMTCT_STAT_TA	By known positives: 25-49	992
PMTCT_STAT_TA	By new positives: 10-14	5
PMTCT_STAT_TA	By new positives: 15-19	348
PMTCT_STAT_TA	By new positives: 20-24	622
PMTCT_STAT_TA	By new positives: 25-49	866
PMTCT_STAT_TA	By new negatives: 10-14	1,127
PMTCT_STAT_TA	By new negatives: 15-19	20,978
PMTCT_STAT_TA	By new negatives: 20-24	20,384



PMTCT_STAT_TA	By new negatives: 25-49	67,851
PMTCT_STAT_TA	By Age (Numerator): 10-14	1,138
PMTCT_STAT_TA	By Age (Numerator): : 15-19	21,720
PMTCT_STAT_TA	By Age (Numerator): 20-24	21,720
PMTCT_STAT_TA	By Age (Numerator): 25-49	69,708
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	28,415
VMMC_CIRC_DSD	By Age: 10-14	2,842
VMMC_CIRC_DSD	By Age: 15-19	5,112
VMMC_CIRC_DSD	By Age: 20-24	6,820
VMMC_CIRC_DSD	By Age: 25-29	10,795
VMMC_CIRC_DSD	By Age: 30-49	1,705
VMMC_CIRC_DSD	By Age: 50+	1,141
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	15,915
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	28,415
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	39,591
PP_PREV_DSD	Age/sex: 10-14 Male	5,134
PP_PREV_DSD	Age/sex: 15-19 Male	2,670
PP_PREV_DSD	Age/sex: 20-24 Male	2,460
PP_PREV_DSD	Age/sex: 25-49 Male	8,567
PP_PREV_DSD	Age/sex: 50+ Male	762
PP_PREV_DSD	Age/sex: 10-14 Female	6,252
PP_PREV_DSD	Age/sex: 15-19 Female	3,350
PP_PREV_DSD	Age/sex: 20-24 Female	2,390
PP_PREV_DSD	Age/sex: 25-49 Female	7,392
PP_PREV_DSD	Age/sex: 50+ Female	614
PP_PREV_DSD	Sum of Age/Sex disaggregates	39,591
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum	13,924



	standards required	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	13,924
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	339,936
HTC_TST_DSD	By Test Result: Positive	13,937
HTC_TST_DSD	Sum of Test Result disaggregates	13,937
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	654
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	522
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	3,082
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	102
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	307
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	9,882
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	325
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,460
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	53



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	31,048
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	1,131
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	28,592
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	991
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	3,110
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	113
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	3,540
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	123
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	1,271
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	3,253
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	49
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	464
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	45
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	1,385
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	154
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	925
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	106
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	2,321



	20-24, Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	267
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	891
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	109
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	2,321
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	260
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	463
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	463
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	672
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	544
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	4,041
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	142
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	527
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	20



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	12,932
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	450
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,636
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	105
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	45,550
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	1,736
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	47,374
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	1,832
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	4,582
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	176
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	5,857
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	226
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	1,302
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	3,364
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	3,217
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female,	26



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	162
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	75
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	127
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	123
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	4,732
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	5,517



HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	95
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	4,732
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	113
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	789
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	363
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	304
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	145
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	79
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	464
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	261
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	91
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	1,611
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	922
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male,	1,633



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	920
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	159
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	87
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	201
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	109
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	737
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,813
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	195
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	537
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	443
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	56
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	207
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	106
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	19
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	7



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	761
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	475
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	718
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	405
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	57
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	82
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	851
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	2,791
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	20,065
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	368
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	23,398
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	429
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	20,065
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	368
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	3,346
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	62



HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	531,217
HTC_TST_TA	By Test Result: Positive	16,490
HTC_TST_TA	Sum of Test Result disaggregates	16,490
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	2,089
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	23
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,685
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	4,149
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	119
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	399
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	13,923
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	409
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	2,320
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	74
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	47,212
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	1,477
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male,	44,763



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	1,348
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	4,653
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	142
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	5,352
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	160
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	3,008
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	32
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	10,584
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	96
HTC_TST_TA	Service Delivery Point (Facility) Malnutrition: Negative	576
HTC_TST_TA	Service Delivery Point (Facility) Malnutrition: Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,994
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	21
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,710
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	20
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	6,819
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	204
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	771
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	24
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24,	22,782



	Female, Negative	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	688
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	4,389
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	146
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	81,093
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	2,565
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	82,425
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	2,618
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	7,916
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	255
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	9,877
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	318
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	2,897
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Positive	37
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	10,583
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	102
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	9,110
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	94
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	62



HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	68
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	40
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Negative	222
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Positive	106
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Negative	157
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Positive	64
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	109
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	337
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	2,972
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	23
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	3,466
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	62
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Negative	2,972
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Positive	71
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	495



HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1,072
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	895
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	194
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	110
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	656
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	368
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	121
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	67
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Negative	2,200
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Positive	1,252
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Negative	2,261
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Positive	1,266
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female,	211



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	117
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	272
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	146
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	1,540
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	5,603
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	73
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	31,715
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	520
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	36,972
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	589
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Negative	31,715
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Positive	520
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	5,289
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Positive	91
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,281
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,281
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	93
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,363
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	68
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number	757



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	93
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,363
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	68
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	757
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,720
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	1,720
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	44
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	67
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	571
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,038
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	67
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented	1,038



	HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	44
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	571
GEND_GBV_DSD	Number of people receiving post-GBV care	1,150
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	232
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	804
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	114
GEND_GBV_TA	Number of people receiving post-GBV care	1,833
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	363
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	1,282
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	188
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	901
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	947
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	34
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	543
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The	27



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	297
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	35
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	571
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	28
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	313
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	582
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	613
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with	369



	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	193
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	13
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	387
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	10
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	203
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,753
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	87
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	1,156
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	42
PMTCT_EID_DSD	Number of infants with a negative virological test result	468



	between 2 and 12 months of birth	
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,949
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	138
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	1,951
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	72
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	788
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	60,720
TX_CURR_DSD	Age/Sex: 15-19 Male	352
TX_CURR_DSD	Age/Sex: 15-19 Female	1,346
TX_CURR_DSD	Sum of age/sex disaggregates	1,698
TX_CURR_DSD	Age/Sex: <1	133
TX_CURR_DSD	Age/Sex: <1-9	2,047
TX_CURR_DSD	Age/Sex: 10-14 Male	460
TX_CURR_DSD	Age/Sex: 10-14 Female	661
TX_CURR_DSD	Age/Sex: 20-24 Male	1,514
TX_CURR_DSD	Age/Sex: 25-49 Male	16,199
TX_CURR_DSD	Age/Sex: 50+ Male	2,000
TX_CURR_DSD	Age/Sex: 20-24 Female	4,258
TX_CURR_DSD	Age/Sex: 25-49 Female	28,894
TX_CURR_DSD	Age/Sex: 50+ Female	2,856
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	45,993
TX_CURR_TA	Age/Sex: 15-19 Male	268
TX_CURR_TA	Age/Sex: 15-19 Female	1,076
TX_CURR_TA	Sum of Age/Sex disaggregations	1,344
TX_CURR_TA	Age/Sex: <1	110
TX_CURR_TA	Age/Sex: 1-9	1,772



TX_CURR_TA	Age/Sex: 10-14 Male	403
TX_CURR_TA	Age/Sex: 10-14 Female	571
TX_CURR_TA	Age/Sex: 20-24 Male	1,136
TX_CURR_TA	Age/Sex: 25-49 Male	12,270
TX_CURR_TA	Age/Sex: 50+ Male	1,519
TX_CURR_TA	Age/Sex: 20-24 Female	3,414
TX_CURR_TA	Age/Sex: 25-49 Female	21,343
TX_CURR_TA	Age/Sex: 50+ Female	2,111
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	14,967
TX_NEW_DSD	By Age/Sex: <1	188
TX_NEW_DSD	By Age/Sex: 1-9	179
TX_NEW_DSD	By Age/Sex: 10-14 Male	28
TX_NEW_DSD	By Age/Sex: 15-19 Male	68
TX_NEW_DSD	By Age/Sex: 20-24 Male	297
TX_NEW_DSD	By Age/Sex: 25-49 Male	5,316
TX_NEW_DSD	By Age/Sex: 50+ Male	658
TX_NEW_DSD	By Age/Sex: 10-14 Female	36
TX_NEW_DSD	By Age/Sex: 15-19 Female	477
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,514
TX_NEW_DSD	By Age/Sex: 25-49 Female	5,646
TX_NEW_DSD	By Age/Sex: 50+ Female	560
TX_NEW_DSD	Sum of Age/Sex disaggregates	14,600
TX_NEW_DSD	Pregnancy status	3,744
TX_NEW_DSD	Breastfeeding status	45
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	13,328
TX_NEW_TA	By Age/Sex: <1	150
TX_NEW_TA	By Age/Sex: 1-9	358
TX_NEW_TA	By Age/Sex: 10-14 Male	59
TX_NEW_TA	By Age/Sex: 15-19 Male	55
TX_NEW_TA	By Age/Sex: 20-24 Male	263



TX_NEW_TA	By Age/Sex: 25-49 Male	4,866
TX_NEW_TA	By Age/Sex: 50+ Male	600
TX_NEW_TA	By Age/Sex: 10-14 Female	70
TX_NEW_TA	By Age/Sex: 15-19 Female	403
TX_NEW_TA	By Age/Sex: 20-24 Female	1,291
TX_NEW_TA	By Age/Sex: 25-49 Female	4,745
TX_NEW_TA	By Age/Sex: 50+ Female	468
TX_NEW_TA	Sum of Age/Sex disaggregates	12,820
TX_NEW_TA	Pregnancy status	3,343
TX_NEW_TA	Breastfeeding status	33
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	49,183
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	54,648
TX_PVLS_DSD	Numerator: Indication: Routine	49,183
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	4,917
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	250
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,201
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	16,257
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	1,471
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	30,254
TX_PVLS_DSD	Denominator: Indication: Routine	54,648
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	5,464
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	273



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,336
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	18,066
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,640
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	33,606
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	37,254
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	41,396
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	1,271
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,043
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	22,641
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	12,299
TX_PVLS_TA	Numerator: Indication: Routine	37,254
TX_PVLS_TA	Numerator: Preg/BF by Indication: Breastfeeding Routine	196
TX_PVLS_TA	Numerator: Preg/BF by Indication: Pregnant Routine	3,723
TX_PVLS_TA	Denominator: Indication: Routine	41,396
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,419
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,163
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	25,145



TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	13,669
TX_PVLS_TA	Denominator: Preg/BF by Indication: Breastfeeding Routine	208
TX_PVLS_TA	Denominator: Preg/BF by Indication: Pregnant Routine	4,135
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,463
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,038
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	183
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,877
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	204
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,199
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	183
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,102
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the	204



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,549
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,838
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,464
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	197
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,994
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	219
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,428
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	197
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped	2,243



	ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	220
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,804
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	6,736
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	13,470
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	216
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	182
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	7,378
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	5,694
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	13,470
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	102
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	88
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	3,689
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	2,857
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	6,736
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	6,001



TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	11,999
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	322
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	269
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	6,219
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	5,189
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	11,999
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	144
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	121
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	3,110
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	2,626
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	6,001
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	1,213
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	60,720
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	31
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	26
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	745
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	411
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,821
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,480
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	37,350
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	20,069
TX_TB_DSD	Denominator: By Screen Result: Negative	55,860
TX_TB_DSD	Denominator: By Screen Result: Positive	4,860
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB	4,860



	disease	
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	487
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	971
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	3,402
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	927
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	45,993
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	23
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Male	17
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	563
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	324
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	1,573
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	1,283
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	27,947
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	15,190
TX_TB_TA	Denominator: By Screen Result: Negative	42,315
TX_TB_TA	Denominator: By Screen Result: Positive	3,678
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	3,678
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	361
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	736
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2,581

Implementing Mechanism Details

Mechanism ID: 17651	TBD: Yes
---------------------	----------



REDACTED

Implementing Mechanism Details

Mechanism ID: 17654	Mechanism Name: Regional Health Integration to Enhance Services in South West Region (RHITES-SW)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 11,521,435	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 3,500,000	
Total All Funding Sources and Applied Pipeline Amount: 15,021,435	
Funding Source	Funding Amount
GHP-State	11,521,435

Cross-Cutting Budget Attribution(s)

Gender: GBV	472,824
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



Gender: Gender Equality	270,185
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	225,834
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Key Populations: MSM and TG	150,556
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Collection and use of strategic information
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Training of health workers and community outreach workers
Condom programming	602,223
Renovation	401,515
Water	506,597
Food and Nutrition: Policy, Tools, and Service Delivery	451,668



Budget Code Information

Mechanism ID:	17654		
Mechanism Name:	Regional Health Integration to Enhance Services in South West Region (RHITES-SW)		
Prime Partner Name:	Elizabeth Glaser Pediatric AIDS Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,475,445	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	588,424	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	225,248	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	33,245	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	815,511	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,180,477	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	109,956	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	619,232	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	5,320,022	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	153,875	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	5,382
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	83,876
PMTCT_ART_DSD	New on ART	2,442
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,940
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,994
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	71,476
PMTCT_ART_TA	New on ART	2,271
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	2,723
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	83,876
PMTCT_STAT_DSD	By Age (Denominator): 10-14	840
PMTCT_STAT_DSD	By Age (Denominator): <15-19	15,939
PMTCT_STAT_DSD	By Age (Denominator): 20-24	15,939
PMTCT_STAT_DSD	By Age (Denominator): 25-49	51,158
PMTCT_STAT_DSD	By Number of known positives: 10-14	26
PMTCT_STAT_DSD	By Number of known positives: 15-19	670



PMTCT_STAT_DSD	By Number of known positives: 20-24	1,192
PMTCT_STAT_DSD	By Number of known positives: 25-49	1,619
PMTCT_STAT_DSD	By Number of new positives: 10-14	9
PMTCT_STAT_DSD	By Number of new positives: 15-19	406
PMTCT_STAT_DSD	By Number of new positives: 20-24	731
PMTCT_STAT_DSD	By Number of new positives: 25-49	1,001
PMTCT_STAT_DSD	By Number of new negative: 10-14	803
PMTCT_STAT_DSD	By Number of new negative: 15-19	14,862
PMTCT_STAT_DSD	By Number of new negative: 20-24	14,015
PMTCT_STAT_DSD	By Number of new negative: 25-49	48,542
PMTCT_STAT_DSD	By Age (Numerator): 10-14	840
PMTCT_STAT_DSD	By Age (Numerator): 15-19	15,939
PMTCT_STAT_DSD	By Age (Numerator): 20-24	15,939
PMTCT_STAT_DSD	By Age (Numerator): 25-49	51,158
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	71,476
PMTCT_STAT_TA	By Age (Denominator): 10-14	717
PMTCT_STAT_TA	By Age (Denominator): 15-19	13,585
PMTCT_STAT_TA	By Age (Denominator): 20-24	13,585
PMTCT_STAT_TA	By Age (Denominator): 25-49	43,589
PMTCT_STAT_TA	By known positives: 10-14	11
PMTCT_STAT_TA	By known positives: 15-19	600
PMTCT_STAT_TA	By known positives: 20-24	1,057
PMTCT_STAT_TA	By known positives: 25-49	1,457
PMTCT_STAT_TA	By new positives: 10-14	6
PMTCT_STAT_TA	By new positives: 15-19	408
PMTCT_STAT_TA	By new positives: 20-24	724
PMTCT_STAT_TA	By new positives: 25-49	1,006
PMTCT_STAT_TA	By new negatives: 10-14	700
PMTCT_STAT_TA	By new negatives: 15-19	12,577
PMTCT_STAT_TA	By new negatives: 20-24	11,804



PMTCT_STAT_TA	By new negatives: 25-49	41,126
PMTCT_STAT_TA	By Age (Numerator): 10-14	717
PMTCT_STAT_TA	By Age (Numerator): : 15-19	13,585
PMTCT_STAT_TA	By Age (Numerator): 20-24	13,585
PMTCT_STAT_TA	By Age (Numerator): 25-49	43,589
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	99,867
VMMC_CIRC_DSD	By Age: 10-14	9,996
VMMC_CIRC_DSD	By Age: 15-19	17,978
VMMC_CIRC_DSD	By Age: 20-24	23,967
VMMC_CIRC_DSD	By Age: 25-29	37,937
VMMC_CIRC_DSD	By Age: 30-49	5,994
VMMC_CIRC_DSD	By Age: 50+	3,995
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	55,936
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	99,867
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	2,504
PrEP_NEW_DSD	Male 15-19	314
PrEP_NEW_DSD	Male 20-24	314
PrEP_NEW_DSD	Male 25-49	314
PrEP_NEW_DSD	Male 50+	314
PrEP_NEW_DSD	Female 15-19	314
PrEP_NEW_DSD	Female 20-24	314
PrEP_NEW_DSD	Female 25-49	314
PrEP_NEW_DSD	Female 50+	306
PrEP_NEW_DSD	FSW	227
PrEP_NEW_DSD	MSM	9
PrEP_NEW_DSD	TG	3
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,201



PP_PREV_DSD	Age/sex: 10-14 Male	168
PP_PREV_DSD	Age/sex: 15-19 Male	68
PP_PREV_DSD	Age/sex: 20-24 Male	62
PP_PREV_DSD	Age/sex: 25-49 Male	261
PP_PREV_DSD	Age/sex: 50+ Male	14
PP_PREV_DSD	Age/sex: 10-14 Female	232
PP_PREV_DSD	Age/sex: 15-19 Female	98
PP_PREV_DSD	Age/sex: 20-24 Female	61
PP_PREV_DSD	Age/sex: 25-49 Female	226
PP_PREV_DSD	Age/sex: 50+ Female	11
PP_PREV_DSD	Sum of Age/Sex disaggregates	1,201
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	5,621
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	36
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	54
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	14
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence	15



	and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,502
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	466,305
HTC_TST_DSD	By Test Result: Positive	22,037
HTC_TST_DSD	Sum of Test Result disaggregates	22,037
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,729
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,493
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	3,022
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	147
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	610
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	9,763
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	467
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	2,791
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	120



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	59,785
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	2,607
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	45,117
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	2,045
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	5,909
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	252
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	5,554
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	249
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	953
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	9,754
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	122
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	134
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	400
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	268
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	26
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	668



	20-24, Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	80
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	250
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	54
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	668
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	76
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	129
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	129
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,721
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,493
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	2,065
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	100
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	443
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	7



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	6,763
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	326
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,055
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	96
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	44,335
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	2,064
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	30,972
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	1,516
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	4,375
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	195
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	3,830
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	183
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	933
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	9,700
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	116
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	7,591
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	81
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female,	96



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	65
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	286
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	130
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	179
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	64
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	455
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	19,971
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	154
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	23,287
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	410
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	19,971
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	481
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	3,330
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	35



HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	947
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	817
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	225
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	128
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	50
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	724
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	401
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	219
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	118
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	4,316
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	2,455
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	3,323
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	1,865
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	425



HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	236
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	413
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	227
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	516
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	5,311
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	68
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	670
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	443
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	486
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	50
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	221
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	109
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	46
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	15



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	1,323
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	824
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	994
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	554
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	110
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	45
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	105
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	44
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	269
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	2,834
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	25,888
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	752
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	30,181
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	862
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	25,888
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	752
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	4,317
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	127
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	223,233
HTC_TST_TA	By Test Result: Positive	10,727



HTC_TST_TA	Sum of Test Result disaggregates	10,727
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	120
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	792
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	857
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	42
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	79
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	4,762
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	244
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,423
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	65
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	29,216
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	1,326
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	22,604
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	1,019
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female,	2,430



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	125
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	2,417
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	121
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	150
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	5,170
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	50
HTC_TST_TA	Service Delivery Point (Facility) Malnutrition: Negative	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	122
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	790
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	627
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	29
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	52
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	3,515
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	182
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	985
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	49



HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	22,121
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	1,091
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	16,521
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	807
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,587
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	84
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,539
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	82
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	194
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	5,191
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	60
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	3,160
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	40
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Negative	166
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female,	87



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Negative	82
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Positive	18
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	5,972
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	44
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	6,959
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	128
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Negative	5,972
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Positive	141
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	995
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	50
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	424
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	72
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	39
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	2



HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	444
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	250
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	124
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	68
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Negative	2,492
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Positive	1,407
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Negative	1,915
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Positive	1,078
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	203
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	113
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	200
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	114
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	69
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	2,617
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	34
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	17,193
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	534
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	20,048
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	602
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Negative	17,193
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Positive	534



HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	2,868
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Positive	78
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,526
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	4,526
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	173
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,730
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	128
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,495
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	173
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,730
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	128
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,495
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,466
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	1,466



TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	30
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	48
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	487
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	901
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	48
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	901
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	30
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	487
GEND_GBV_DSD	Number of people receiving post-GBV care	1,109
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	220
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	770
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	119
GEND_GBV_TA	Number of people receiving post-GBV care	1,549
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	308
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	1,081

GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	160
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,764
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,860
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	62
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,072
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	47
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	583
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	67
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1,125
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	49



	during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	619
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	671
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	703
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	17
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	432
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	211
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	18
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	450



TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	12
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	223
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,389
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	103
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	2,899
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	38
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	1,349
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,043
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	121
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	2,674
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	45
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	1,203
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	120,111
TX_CURR_DSD	Age/Sex: 15-19 Male	632
TX_CURR_DSD	Age/Sex: 15-19 Female	3,040
TX_CURR_DSD	Sum of age/sex disaggregates	3,672
TX_CURR_DSD	Age/Sex: <1	314



TX_CURR_DSD	Age/Sex: <1-9	4,903
TX_CURR_DSD	Age/Sex: 10-14 Male	1,114
TX_CURR_DSD	Age/Sex: 10-14 Female	1,581
TX_CURR_DSD	Age/Sex: 20-24 Male	2,698
TX_CURR_DSD	Age/Sex: 25-49 Male	31,724
TX_CURR_DSD	Age/Sex: 50+ Male	3,923
TX_CURR_DSD	Age/Sex: 20-24 Female	9,616
TX_CURR_DSD	Age/Sex: 25-49 Female	55,114
TX_CURR_DSD	Age/Sex: 50+ Female	5,452
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	15,891
TX_CURR_TA	Age/Sex: 15-19 Male	81
TX_CURR_TA	Age/Sex: 15-19 Female	407
TX_CURR_TA	Sum of Age/Sex disaggregations	488
TX_CURR_TA	Age/Sex: <1	34
TX_CURR_TA	Age/Sex: 1-9	711
TX_CURR_TA	Age/Sex: 10-14 Male	174
TX_CURR_TA	Age/Sex: 10-14 Female	228
TX_CURR_TA	Age/Sex: 20-24 Male	385
TX_CURR_TA	Age/Sex: 25-49 Male	4,117
TX_CURR_TA	Age/Sex: 50+ Male	503
TX_CURR_TA	Age/Sex: 20-24 Female	1,325
TX_CURR_TA	Age/Sex: 25-49 Female	7,210
TX_CURR_TA	Age/Sex: 50+ Female	716
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	27,117
TX_NEW_DSD	By Age/Sex: <1	274
TX_NEW_DSD	By Age/Sex: 1-9	457
TX_NEW_DSD	By Age/Sex: 10-14 Male	69
TX_NEW_DSD	By Age/Sex: 15-19 Male	134
TX_NEW_DSD	By Age/Sex: 20-24 Male	605
TX_NEW_DSD	By Age/Sex: 25-49 Male	8,797



TX_NEW_DSD	By Age/Sex: 50+ Male	1,085
TX_NEW_DSD	By Age/Sex: 10-14 Female	89
TX_NEW_DSD	By Age/Sex: 15-19 Female	616
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,954
TX_NEW_DSD	By Age/Sex: 25-49 Female	11,865
TX_NEW_DSD	By Age/Sex: 50+ Female	1,172
TX_NEW_DSD	Sum of Age/Sex disaggregates	26,386
TX_NEW_DSD	Pregnancy status	6,794
TX_NEW_DSD	Breastfeeding status	78
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,301
TX_NEW_TA	By Age/Sex: <1	32
TX_NEW_TA	By Age/Sex: 1-9	43
TX_NEW_TA	By Age/Sex: 10-14 Male	9
TX_NEW_TA	By Age/Sex: 15-19 Male	10
TX_NEW_TA	By Age/Sex: 20-24 Male	76
TX_NEW_TA	By Age/Sex: 25-49 Male	1,073
TX_NEW_TA	By Age/Sex: 50+ Male	127
TX_NEW_TA	By Age/Sex: 10-14 Female	5
TX_NEW_TA	By Age/Sex: 15-19 Female	69
TX_NEW_TA	By Age/Sex: 20-24 Female	288
TX_NEW_TA	By Age/Sex: 25-49 Female	1,436
TX_NEW_TA	By Age/Sex: 50+ Female	133
TX_NEW_TA	Sum of Age/Sex disaggregates	3,226
TX_NEW_TA	Pregnancy status	840
TX_NEW_TA	Breastfeeding status	2
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	97,296
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	108,104



TX_PVLS_DSD	Numerator: Indication: Routine	97,296
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	9,736
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	502
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	2,885
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	31,581
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	3,525
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	59,305
TX_PVLS_DSD	Denominator: Indication: Routine	108,104
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	10,810
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	547
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	3,212
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	35,092
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	3,921
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	65,879
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	12,875
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	14,303
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	524
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male	414



	Routine	
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	7,820
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	4,117
TX_PVLS_TA	Numerator: Indication: Routine	12,875
TX_PVLS_TA	Numerator: Preg/BF by Indication: Breastfeeding Routine	59
TX_PVLS_TA	Numerator: Preg/BF by Indication: Pregnant Routine	1,299
TX_PVLS_TA	Denominator: Indication: Routine	14,303
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	596
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	470
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	8,656
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	4,581
TX_PVLS_TA	Denominator: Preg/BF by Indication: Breastfeeding Routine	59
TX_PVLS_TA	Denominator: Preg/BF by Indication: Pregnant Routine	1,427
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	12,858
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	14,205
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	424
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,443
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number	473



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,518
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	424
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,954
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	475
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,352
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,193
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,638
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	136
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of	1,442



	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	153
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,462
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	136
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,625
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	153
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,724
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	12,204
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period	24,414



	but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	444
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	365
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	14,055
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	9,550
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	24,414
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	200
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	176
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	7,024
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	4,804
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	12,204
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,484
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	2,980
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	61
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	32
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	1,744
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	1,143
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	2,980
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	11
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	10
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	875
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	588
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	1,484



TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	2,404
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	120,111
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	75
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	59
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	1,468
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	802
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	4,349
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,563
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	73,209
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	38,990
TX_TB_DSD	Denominator: By Screen Result: Negative	110,504
TX_TB_DSD	Denominator: By Screen Result: Positive	9,607
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	9,607
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	953
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,923
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	6,731
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	314
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	15,891
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	3
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Male	2
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	209
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	100
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	641
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	506



TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	9,668
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	5,076
TX_TB_TA	Denominator: By Screen Result: Negative	14,622
TX_TB_TA	Denominator: By Screen Result: Positive	1,269
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,269
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	127
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	245
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	897

Implementing Mechanism Details

Mechanism ID: 17688	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17690	Mechanism Name: Strengthening HRH
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 594,907	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 763,972	
Total All Funding Sources and Applied Pipeline Amount: 1,358,879	
Funding Source	Funding Amount
GHP-State	594,907



Cross-Cutting Budget Attribution(s)

Human Resources for Health	137,696
----------------------------	---------

Budget Code Information

Mechanism ID:	17690		
Mechanism Name:	Strengthening HRH		
Prime Partner Name:	IntraHealth International, Inc		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	594,907	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	253
HRH_PRE	By Graduates: Nurses	25
HRH_PRE	By Graduates: Midwives	53
HRH_PRE	By Graduates: Other	175
HRH_PRE	Sum of Graduates disaggreagtes	253

Implementing Mechanism Details

Mechanism ID: 17696	Mechanism Name: Better Outcomes for Children and Youth Eastern and Northern Regions
----------------------------	--



	(BOCY)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Education	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 8,304,049	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 8,304,049	
Funding Source	Funding Amount
GHP-State	8,304,049

Cross-Cutting Budget Attribution(s)

Gender: GBV	250,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Gender: Gender Equality	200,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Focus Area:	Equity in HIV prevention, care, treatment and support
Education	1,600,000
Food and Nutrition: Commodities	200,000
Food and Nutrition: Policy, Tools, and Service Delivery	30,000
Economic Strengthening	2,260,000



Water	70,000
-------	--------

Budget Code Information

Mechanism ID:	17696		
Mechanism Name:	Better Outcomes for Children and Youth Eastern and Northern Regions (BOCY)		
Prime Partner Name:	World Education		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	8,037,381	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	266,668	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	146,044
OVC_SERV_DSD	Age/Sex: 10-14 Male	13,250
OVC_SERV_DSD	Age/Sex: 15-17 Male	12,548
OVC_SERV_DSD	By: Age/sex: Male 18-24	13,335
OVC_SERV_DSD	By: Age/sex: Male 25+	3,076
OVC_SERV_DSD	Age/Sex: 10-14 Female	19,235
OVC_SERV_DSD	Age/Sex: 15-17 Female	10,237
OVC_SERV_DSD	By: Age/sex: 18-24 Female	15,508
OVC_SERV_DSD	By: Age/sex: 25+ Female	4,380
OVC_SERV_DSD	Sum of Age/Sex disaggregates	55,270
OVC_SERV_DSD	Age/Sex: <1	5,803



OVC_SERV_DSD	Age/Sex: 1-9	48,672
OVC_SERV_DSD	Program Completion: Active	110,269
OVC_SERV_DSD	Program Completion: Graduation	21,172
OVC_SERV_DSD	Program Completion: Transferred	7,317
OVC_SERV_DSD	Program Completion: Exited without graduation	7,286

Implementing Mechanism Details

Mechanism ID: 17698	Mechanism Name: Provision of comprehensive HIV/AIDS and TB services including prevention, care, support and treatment to prisoners and staff of the prisons service in the Republic of Uganda under PEPFAR	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Uganda Prisons Services		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	

Total All Funding Sources: 2,111,208	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 600,242	
Total All Funding Sources and Applied Pipeline Amount: 2,711,450	
Funding Source	Funding Amount
GHP-State	2,111,208

Cross-Cutting Budget Attribution(s)

Gender: GBV	200,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Food and Nutrition: Policy, Tools, and Service Delivery	21,112
Food and Nutrition: Commodities	10,556
Water	21,112

Budget Code Information

Mechanism ID:	17698		
Mechanism Name:	Provision of comprehensive HIV/AIDS and TB services including prevention, care, support and treatment to prisoners and staff of the		
Prime Partner Name:	prisons service in the Republic of Uganda under PEPFAR		
	Uganda Prisons Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	80,681	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	18,953	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	414	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	32,508	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	33,370	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,767,756	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	10,925	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	166,341	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	260	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	233
PMTCT_ART_TA	Number of pregnant women with known HIV status	2,995



	(includes women who were tested for HIV and received their results)	
PMTCT_ART_TA	New on ART	105
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	128
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,995
PMTCT_STAT_TA	By Age (Denominator): 10-14	31
PMTCT_STAT_TA	By Age (Denominator): 15-19	569
PMTCT_STAT_TA	By Age (Denominator): 20-24	569
PMTCT_STAT_TA	By Age (Denominator): 25-49	1,826
PMTCT_STAT_TA	By known positives: 10-14	1
PMTCT_STAT_TA	By known positives: 15-19	27
PMTCT_STAT_TA	By known positives: 20-24	50
PMTCT_STAT_TA	By known positives: 25-49	69
PMTCT_STAT_TA	By new positives: 10-14	1
PMTCT_STAT_TA	By new positives: 15-19	18
PMTCT_STAT_TA	By new positives: 20-24	33
PMTCT_STAT_TA	By new positives: 25-49	46
PMTCT_STAT_TA	By new negatives: 10-14	29
PMTCT_STAT_TA	By new negatives: 15-19	524
PMTCT_STAT_TA	By new negatives: 20-24	486
PMTCT_STAT_TA	By new negatives: 25-49	1,711
PMTCT_STAT_TA	By Age (Numerator): 10-14	31
PMTCT_STAT_TA	By Age (Numerator): : 15-19	569
PMTCT_STAT_TA	By Age (Numerator): 20-24	569
PMTCT_STAT_TA	By Age (Numerator): 25-49	1,826
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	31,188
PP_PREV_DSD	Age/sex: 10-14 Male	4,047
PP_PREV_DSD	Age/sex: 15-19 Male	2,107



PP_PREV_DSD	Age/sex: 20-24 Male	1,941
PP_PREV_DSD	Age/sex: 25-49 Male	6,751
PP_PREV_DSD	Age/sex: 50+ Male	601
PP_PREV_DSD	Age/sex: 10-14 Female	4,912
PP_PREV_DSD	Age/sex: 15-19 Female	2,641
PP_PREV_DSD	Age/sex: 20-24 Female	1,884
PP_PREV_DSD	Age/sex: 25-49 Female	5,820
PP_PREV_DSD	Age/sex: 50+ Female	484
PP_PREV_DSD	Sum of Age/Sex disaggregates	31,188
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	90,054
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	90,054
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	679
HTC_TST_DSD	By Test Result: Positive	107
HTC_TST_DSD	Sum of Test Result disaggregates	107
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	23
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	71
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	47
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	5



	20-24, Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	120
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	50
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	120
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	23
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	23
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	28
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49,	9



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	51
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	28
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	17,861
HTC_TST_TA	By Test Result: Positive	1,167
HTC_TST_TA	Sum of Test Result disaggregates	1,167
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	42
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	274
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	165
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,694
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	94
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	272
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	20
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	3,096



HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	175
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	42
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	42
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	49
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	288
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	17
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	181
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,758
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	110
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	294
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	21
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	3,194
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	197



HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	49
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	49
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	24
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Negative	44
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Positive	18
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	2



HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	26
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	155
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	86
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Negative	22
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Positive	18
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Negative	279
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Positive	156
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	1,384
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	51
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	1,610
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	57
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Negative	1,384
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Positive	51



HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	232
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Positive	8
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	307
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	307
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	9
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	13
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	101
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	184
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	13
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	184
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	101
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	147
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB	153

	treatment during the reporting period	
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	92
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	48
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	4
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	95
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	3
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	51
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	191



PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	5
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	125
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	1
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	60
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	4,649
TX_CURR_TA	Age/Sex: 15-19 Male	186
TX_CURR_TA	Age/Sex: 15-19 Female	126
TX_CURR_TA	Sum of Age/Sex disaggregations	312
TX_CURR_TA	Age/Sex: 10-14 Male	24
TX_CURR_TA	Age/Sex: 10-14 Female	24
TX_CURR_TA	Age/Sex: 20-24 Male	1,123
TX_CURR_TA	Age/Sex: 25-49 Male	1,992
TX_CURR_TA	Age/Sex: 50+ Male	36
TX_CURR_TA	Age/Sex: 20-24 Female	379
TX_CURR_TA	Age/Sex: 25-49 Female	633
TX_CURR_TA	Age/Sex: 50+ Female	126
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	915
TX_NEW_TA	By Age/Sex: <1	1
TX_NEW_TA	By Age/Sex: 1-9	2
TX_NEW_TA	By Age/Sex: 10-14 Male	1
TX_NEW_TA	By Age/Sex: 15-19 Male	45
TX_NEW_TA	By Age/Sex: 20-24 Male	275
TX_NEW_TA	By Age/Sex: 25-49 Male	494
TX_NEW_TA	By Age/Sex: 50+ Male	8
TX_NEW_TA	By Age/Sex: 10-14 Female	1
TX_NEW_TA	By Age/Sex: 15-19 Female	8
TX_NEW_TA	By Age/Sex: 20-24 Female	27



TX_NEW_TA	By Age/Sex: 25-49 Female	45
TX_NEW_TA	By Age/Sex: 50+ Female	8
TX_NEW_TA	Sum of Age/Sex disaggregates	912
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	3,764
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	4,185
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	21
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	21
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,017
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	2,705
TX_PVLS_TA	Numerator: Indication: Routine	3,764
TX_PVLS_TA	Numerator: Preg/BF by Indication: Breastfeeding Routine	20
TX_PVLS_TA	Numerator: Preg/BF by Indication: Pregnant Routine	376
TX_PVLS_TA	Denominator: Indication: Routine	4,185
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	23
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	23
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,132
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,007
TX_PVLS_TA	Denominator: Preg/BF by Indication: Breastfeeding Routine	21
TX_PVLS_TA	Denominator: Preg/BF by Indication: Pregnant Routine	418



TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,000
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,105
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	34
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	344
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	37
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	585
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	34
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	384
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	37
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	650



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	412
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	824
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	3
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	3
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	80
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	738
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	824
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	1
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	1
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	39
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	371
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	412
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	93
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	4,649
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	26
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	67
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	24
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	24
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	1,262
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	3,339



TX_TB_TA	Denominator: By Screen Result: Negative	4,276
TX_TB_TA	Denominator: By Screen Result: Positive	373
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	373
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	36
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	75
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	262

Implementing Mechanism Details

Mechanism ID: 17703	Mechanism Name: Monitoring and Evaluation Technical Support (METS)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Makerere University School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 2,539,387	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 3,241,183	
Total All Funding Sources and Applied Pipeline Amount: 5,780,570	
Funding Source	Funding Amount
GHP-State	2,539,387

Cross-Cutting Budget Attribution(s)

Gender: GBV	300,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation



Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Food and Nutrition: Policy, Tools, and Service Delivery	32,483
Water	32,483
Economic Strengthening	97,448
Education	32,483
Food and Nutrition: Commodities	16,241

Budget Code Information

Mechanism ID: 17703			
Mechanism Name: Monitoring and Evaluation Technical Support (METS)			
Prime Partner Name: Makerere University School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	41,688	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	225,230	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	31,369	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	49,579	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,059,654	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	566,029	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	16,513	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	61,912	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	207,610	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	108,739	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	119,058	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	52,006	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	124
HRH_PRE	By Graduates: Other	124
HRH_PRE	Sum of Graduates disaggregates	124

Implementing Mechanism Details

Mechanism ID: 17704	Mechanism Name: African Society for Laboratory Medicine - LIMS Support for hubs
----------------------------	--

Approved



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 548,485	
Total All Funding Sources and Applied Pipeline Amount: 548,485	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17704		
Mechanism Name:	African Society for Laboratory Medicine - LIMS Support for hubs		
Prime Partner Name:	African Society for Laboratory Medicine		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17705	Mechanism Name: Implementation science-Birth
----------------------------	---



	Defects surveillance study
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Makerere University John Hopkins University Collaboration	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 417,500	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 417,500	
Funding Source	Funding Amount
GHP-State	417,500

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	4,175
Water	4,175
Food and Nutrition: Commodities	2,088

Budget Code Information

Mechanism ID:	17705		
Mechanism Name:	Implementation science-Birth Defects surveillance study		
Prime Partner Name:	Makerere University John Hopkins University Collaboration		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	417,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	0	0
-----------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17706	Mechanism Name: Scaling up HIV services in Western and West Nile Regions of Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Infectious Disease Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 10,932,012	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 4,391,049	
Total All Funding Sources and Applied Pipeline Amount: 15,323,061	
Funding Source	Funding Amount
GHP-State	10,932,012

Cross-Cutting Budget Attribution(s)

Gender: GBV	200,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	200,000



Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Motor Vehicles: Purchased	210,000
Food and Nutrition: Policy, Tools, and Service	50,233



Delivery	
Water	50,233
Renovation	125,000
Food and Nutrition: Commodities	25,116
Human Resources for Health	5,444,132

Budget Code Information

Mechanism ID: 17706			
Mechanism Name: Scaling up HIV services in Western and West Nile Regions of Uganda			
Prime Partner Name: Infectious Disease Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,202,436	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	244,575	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	446,998	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	210,118	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	61,987	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	754,316	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	2,024,713	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	50,615	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	594,275	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,202,565	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	139,414	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,086
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	28,047
PMTCT_ART_DSD	New on ART	493
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	593
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	5,787
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	158,762



PMTCT_ART_TA	New on ART	2,621
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	3,166
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	28,047
PMTCT_STAT_DSD	By Age (Denominator): 10-14	280
PMTCT_STAT_DSD	By Age (Denominator): <15-19	5,329
PMTCT_STAT_DSD	By Age (Denominator): 20-24	5,329
PMTCT_STAT_DSD	By Age (Denominator): 25-49	17,109
PMTCT_STAT_DSD	By Number of known positives: 10-14	4
PMTCT_STAT_DSD	By Number of known positives: 15-19	115
PMTCT_STAT_DSD	By Number of known positives: 20-24	208
PMTCT_STAT_DSD	By Number of known positives: 25-49	282
PMTCT_STAT_DSD	By Number of new positives: 10-14	4
PMTCT_STAT_DSD	By Number of new positives: 15-19	100
PMTCT_STAT_DSD	By Number of new positives: 20-24	181
PMTCT_STAT_DSD	By Number of new positives: 25-49	247
PMTCT_STAT_DSD	By Number of new negative: 10-14	272
PMTCT_STAT_DSD	By Number of new negative: 15-19	5,114
PMTCT_STAT_DSD	By Number of new negative: 20-24	4,938
PMTCT_STAT_DSD	By Number of new negative: 25-49	16,582
PMTCT_STAT_DSD	By Age (Numerator): 10-14	280
PMTCT_STAT_DSD	By Age (Numerator): 15-19	5,329
PMTCT_STAT_DSD	By Age (Numerator): 20-24	5,329
PMTCT_STAT_DSD	By Age (Numerator): 25-49	17,109
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	158,762
PMTCT_STAT_TA	By Age (Denominator): 10-14	1,585
PMTCT_STAT_TA	By Age (Denominator): 15-19	30,153
PMTCT_STAT_TA	By Age (Denominator): 20-24	30,153
PMTCT_STAT_TA	By Age (Denominator): 25-49	96,871



PMTCT_STAT_TA	By known positives: 10-14	11
PMTCT_STAT_TA	By known positives: 15-19	635
PMTCT_STAT_TA	By known positives: 20-24	1,118
PMTCT_STAT_TA	By known positives: 25-49	1,529
PMTCT_STAT_TA	By new positives: 10-14	8
PMTCT_STAT_TA	By new positives: 15-19	535
PMTCT_STAT_TA	By new positives: 20-24	950
PMTCT_STAT_TA	By new positives: 25-49	1,308
PMTCT_STAT_TA	By new negatives: 10-14	1,565
PMTCT_STAT_TA	By new negatives: 15-19	28,982
PMTCT_STAT_TA	By new negatives: 20-24	28,084
PMTCT_STAT_TA	By new negatives: 25-49	94,037
PMTCT_STAT_TA	By Age (Numerator): 10-14	1,585
PMTCT_STAT_TA	By Age (Numerator): : 15-19	30,153
PMTCT_STAT_TA	By Age (Numerator): 20-24	30,153
PMTCT_STAT_TA	By Age (Numerator): 25-49	96,871
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	90,172
VMMC_CIRC_DSD	By Age: 10-14	9,019
VMMC_CIRC_DSD	By Age: 15-19	16,230
VMMC_CIRC_DSD	By Age: 20-24	21,644
VMMC_CIRC_DSD	By Age: 25-29	34,257
VMMC_CIRC_DSD	By Age: 30-49	5,411
VMMC_CIRC_DSD	By Age: 50+	3,611
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	50,504
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	90,172
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,357
PP_PREV_DSD	Age/sex: 10-14 Male	176
PP_PREV_DSD	Age/sex: 15-19 Male	93



PP_PREV_DSD	Age/sex: 20-24 Male	84
PP_PREV_DSD	Age/sex: 25-49 Male	291
PP_PREV_DSD	Age/sex: 50+ Male	20
PP_PREV_DSD	Age/sex: 10-14 Female	225
PP_PREV_DSD	Age/sex: 15-19 Female	113
PP_PREV_DSD	Age/sex: 20-24 Female	81
PP_PREV_DSD	Age/sex: 25-49 Female	255
PP_PREV_DSD	Age/sex: 50+ Female	19
PP_PREV_DSD	Sum of Age/Sex disaggregates	1,357
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	4,202
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,202
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	192,573
HTC_TST_DSD	By Test Result: Positive	9,076
HTC_TST_DSD	Sum of Test Result disaggregates	9,076
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	300
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	237
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,073
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	35



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	162
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	3,344
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	111
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	720
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	22,063
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	728
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	12,612
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	439
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	2,182
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	71
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	1,581
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	55
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	313
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,542
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	28
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	201



	15-19, Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	595
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	58
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	395
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	37
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	999
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	122
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	377
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	999
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	111
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	196
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	196
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	299
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14,	2



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	236
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	862
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	132
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	2,703
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	111
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	545
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	18,661
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	916
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	10,460
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	543
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,838
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	91
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male,	1,305



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	306
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,545
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	1,300
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	85
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	45
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female,	6



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	125
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	13,787
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	104
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	16,082
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	285
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	13,787
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	328
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	2,297
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	164
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	129
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	70
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female,	218



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	121
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	1,711
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	965
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	1,072
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	603
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	171
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	95
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	134
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	76
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	162
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	845
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	193
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	634
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14,	652



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	55
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	208
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	106
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	41
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	1,616
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	961
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	1,004
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	565
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	143
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	70
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	107
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	54
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1,	419



	Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	3,732
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	53
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	10,011
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	210
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	11,675
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	242
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	10,011
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	210
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	1,669
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	34
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	785,706
HTC_TST_TA	By Test Result: Positive	25,558
HTC_TST_TA	Sum of Test Result disaggregates	25,558
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	2,483
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	27
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	3,330
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	30
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	7,510
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	194
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	838
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	18



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	26,381
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	696
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	6,151
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	155
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	121,395
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	3,498
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	79,139
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	2,220
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	12,129
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	356
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	10,140
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	285
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	1,496
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	17,368
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	178
HTC_TST_TA	Service Delivery Point (Facility) Malnutrition: Negative	709
HTC_TST_TA	Service Delivery Point (Facility) Malnutrition: Positive	10
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	2,545
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14,	33



	Female, Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	3,285
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	38
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	5,476
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	159
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	547
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	19,865
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	585
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	4,915
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	150
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	102,235
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	3,453
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	75,823
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	2,326
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	10,254
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	347
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male,	9,817



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	298
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	1,469
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Positive	16
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	17,387
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	184
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	13,138
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	146
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	61
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	117
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	47
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Negative	358
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Positive	179
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Negative	188
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Positive	64
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	11
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	46



HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	484
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	10,194
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	75
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	11,885
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	211
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Negative	10,194
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Positive	242
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	1,700
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Positive	23
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1,401
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1,691
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	21
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	242
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	140
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	26
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	872
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	492
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	212
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	117



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Negative	5,649
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Positive	3,183
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Negative	3,707
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Positive	2,080
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	570
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	317
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	460
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	261
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	793
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	9,253
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	108
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	43,254
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	780
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	50,433
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	894
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Negative	43,254
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Positive	780
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	7,217
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Positive	123
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,442
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,442



TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	58
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	867
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	41
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	476
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	58
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	867
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	41
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	476
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,504
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	3,504
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	93
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	126
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total	1,160



	number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,125
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	126
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,125
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	93
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,160
GEND_GBV_DSD	Number of people receiving post-GBV care	510
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	102
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	355
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	53
GEND_GBV_TA	Number of people receiving post-GBV care	2,559
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	511
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	1,785
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	263
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	4,348
OVC_SERV_DSD	Age/Sex: 10-14 Male	394
OVC_SERV_DSD	Age/Sex: 15-17 Male	374
OVC_SERV_DSD	By: Age/sex: Male 18-24	399



OVC_SERV_DSD	By: Age/sex: Male 25+	92
OVC_SERV_DSD	Age/Sex: 10-14 Female	574
OVC_SERV_DSD	Age/Sex: 15-17 Female	306
OVC_SERV_DSD	By: Age/sex: 18-24 Female	460
OVC_SERV_DSD	By: Age/sex: 25+ Female	129
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,648
OVC_SERV_DSD	Age/Sex: <1	171
OVC_SERV_DSD	Age/Sex: 1-9	1,449
OVC_SERV_DSD	Program Completion: Active	3,285
OVC_SERV_DSD	Program Completion: Graduation	631
OVC_SERV_DSD	Program Completion: Transferred	222
OVC_SERV_DSD	Program Completion: Exited without graduation	210
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	491
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	516
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	17
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	297
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	15
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	162



TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	18
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	313
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	15
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	170
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	958
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,008
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	26
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	600
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	16
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The	316



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	28
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	638
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	17
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	325
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	870
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	29
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	577
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	13
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	251
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,648
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	162
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	3,079



PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	65
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	1,342
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	46,451
TX_CURR_DSD	Age/Sex: 15-19 Male	201
TX_CURR_DSD	Age/Sex: 15-19 Female	1,122
TX_CURR_DSD	Sum of age/sex disaggregates	1,323
TX_CURR_DSD	Age/Sex: <1	100
TX_CURR_DSD	Age/Sex: <1-9	1,561
TX_CURR_DSD	Age/Sex: 10-14 Male	352
TX_CURR_DSD	Age/Sex: 10-14 Female	503
TX_CURR_DSD	Age/Sex: 20-24 Male	852
TX_CURR_DSD	Age/Sex: 25-49 Male	12,445
TX_CURR_DSD	Age/Sex: 50+ Male	1,538
TX_CURR_DSD	Age/Sex: 20-24 Female	3,557
TX_CURR_DSD	Age/Sex: 25-49 Female	22,041
TX_CURR_DSD	Age/Sex: 50+ Female	2,179
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	65,016
TX_CURR_TA	Age/Sex: 15-19 Male	250
TX_CURR_TA	Age/Sex: 15-19 Female	1,665
TX_CURR_TA	Sum of Age/Sex disaggregations	1,915
TX_CURR_TA	Age/Sex: <1	188
TX_CURR_TA	Age/Sex: 1-9	3,095
TX_CURR_TA	Age/Sex: 10-14 Male	716
TX_CURR_TA	Age/Sex: 10-14 Female	1,001
TX_CURR_TA	Age/Sex: 20-24 Male	1,102
TX_CURR_TA	Age/Sex: 25-49 Male	17,242
TX_CURR_TA	Age/Sex: 50+ Male	2,126
TX_CURR_TA	Age/Sex: 20-24 Female	5,305



TX_CURR_TA	Age/Sex: 25-49 Female	29,414
TX_CURR_TA	Age/Sex: 50+ Female	2,912
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	12,700
TX_NEW_DSD	By Age/Sex: <1	103
TX_NEW_DSD	By Age/Sex: 1-9	163
TX_NEW_DSD	By Age/Sex: 10-14 Male	25
TX_NEW_DSD	By Age/Sex: 15-19 Male	45
TX_NEW_DSD	By Age/Sex: 20-24 Male	201
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,712
TX_NEW_DSD	By Age/Sex: 50+ Male	461
TX_NEW_DSD	By Age/Sex: 10-14 Female	33
TX_NEW_DSD	By Age/Sex: 15-19 Female	271
TX_NEW_DSD	By Age/Sex: 20-24 Female	848
TX_NEW_DSD	By Age/Sex: 25-49 Female	6,221
TX_NEW_DSD	By Age/Sex: 50+ Female	617
TX_NEW_DSD	Sum of Age/Sex disaggregates	12,434
TX_NEW_DSD	Pregnancy status	3,177
TX_NEW_DSD	Breastfeeding status	39
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	19,218
TX_NEW_TA	By Age/Sex: <1	157
TX_NEW_TA	By Age/Sex: 1-9	489
TX_NEW_TA	By Age/Sex: 10-14 Male	84
TX_NEW_TA	By Age/Sex: 15-19 Male	72
TX_NEW_TA	By Age/Sex: 20-24 Male	374
TX_NEW_TA	By Age/Sex: 25-49 Male	5,784
TX_NEW_TA	By Age/Sex: 50+ Male	723
TX_NEW_TA	By Age/Sex: 10-14 Female	90
TX_NEW_TA	By Age/Sex: 15-19 Female	461
TX_NEW_TA	By Age/Sex: 20-24 Female	1,513
TX_NEW_TA	By Age/Sex: 25-49 Female	8,618



TX_NEW_TA	By Age/Sex: 50+ Female	853
TX_NEW_TA	Sum of Age/Sex disaggregates	18,572
TX_NEW_TA	Pregnancy status	4,826
TX_NEW_TA	Breastfeeding status	45
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	37,627
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	41,807
TX_PVLS_DSD	Numerator: Indication: Routine	37,627
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	3,762
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	187
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	918
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	12,185
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	1,120
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	23,404
TX_PVLS_DSD	Denominator: Indication: Routine	41,807
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	4,179
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	208
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,020
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	13,541
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,245
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+	26,001



	Female Routine	
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	52,667
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	58,524
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	2,226
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,823
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	31,845
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	16,773
TX_PVLS_TA	Numerator: Indication: Routine	52,667
TX_PVLS_TA	Numerator: Preg/BF by Indication: Breastfeeding Routine	278
TX_PVLS_TA	Numerator: Preg/BF by Indication: Pregnant Routine	5,283
TX_PVLS_TA	Denominator: Indication: Routine	58,524
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,501
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,043
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	35,325
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	18,655
TX_PVLS_TA	Denominator: Preg/BF by Indication: Breastfeeding Routine	293
TX_PVLS_TA	Denominator: Preg/BF by Indication: Pregnant Routine	5,856
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,454



TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,813
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	115
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,191
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	131
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,017
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	115
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,326
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	131
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped	2,241



	ART, and those lost to follow-up)	
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	9,557
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	10,570
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	316
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,284
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	357
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,600
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	316
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,684
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	357
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total	6,213



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	5,714
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	11,430
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	155
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	136
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	7,163
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	3,976
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	11,430
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	76
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	67
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	3,581
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,990
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	5,714
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	8,659
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	17,305



TB_PREV_TA	By Age/Sex (Denominator): <15, Female	430
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	336
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	10,310
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	6,229
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	17,305
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	169
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	148
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	5,154
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	3,188
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	8,659
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	930
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	46,451
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	29
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	23
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	578
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	300
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,383
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,133
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	28,892
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	15,043
TX_TB_DSD	Denominator: By Screen Result: Negative	42,734
TX_TB_DSD	Denominator: By Screen Result: Positive	3,717
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	3,717
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	372
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	743
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2,602



TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	1,301
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	65,016
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	36
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Male	30
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	790
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	445
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	2,753
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	2,247
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	39,303
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	20,713
TX_TB_TA	Denominator: By Screen Result: Negative	59,815
TX_TB_TA	Denominator: By Screen Result: Positive	5,201
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	5,201
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	508
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,041
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	3,652

Implementing Mechanism Details

Mechanism ID: 17855	Mechanism Name: Comprehensive HIV/AIDS Prevention, Care, Treatment and Support Project with the Uganda People Defense Forces
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Research Triangle International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
Total All Funding Sources: 1,951,131	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 824,697	
Total All Funding Sources and Applied Pipeline Amount: 2,775,828	
Funding Source	Funding Amount
GHP-State	1,951,131

Cross-Cutting Budget Attribution(s)

Gender: GBV	10,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Food and Nutrition: Policy, Tools, and Service Delivery	5,000
Economic Strengthening	10,000
Motor Vehicles: Purchased	52,000
Condom programming	10,000

Budget Code Information

Mechanism ID:	17855
Mechanism Name:	Comprehensive HIV/AIDS Prevention, Care, Treatment and Support Project with the Uganda People Defense Forces
Prime Partner Name:	Research Triangle International



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	336,758	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	299,194	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	82,354	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	25,700	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	32,049	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	58,739	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	124,889	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	239,343	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	31,732	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	698,090	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	22,283	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	777
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,460
PMTCT_ART_TA	New on ART	350
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	427
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,460
PMTCT_STAT_TA	By Age (Denominator): 10-14	85
PMTCT_STAT_TA	By Age (Denominator): 15-19	1,607
PMTCT_STAT_TA	By Age (Denominator): 20-24	1,607
PMTCT_STAT_TA	By Age (Denominator): 25-49	5,161
PMTCT_STAT_TA	By known positives: 10-14	4
PMTCT_STAT_TA	By known positives: 15-19	78
PMTCT_STAT_TA	By known positives: 20-24	139
PMTCT_STAT_TA	By known positives: 25-49	188
PMTCT_STAT_TA	By new positives: 10-14	4
PMTCT_STAT_TA	By new positives: 15-19	78
PMTCT_STAT_TA	By new positives: 20-24	139
PMTCT_STAT_TA	By new positives: 25-49	188
PMTCT_STAT_TA	By new negatives: 10-14	77
PMTCT_STAT_TA	By new negatives: 15-19	1,451
PMTCT_STAT_TA	By new negatives: 20-24	1,329
PMTCT_STAT_TA	By new negatives: 25-49	4,785
PMTCT_STAT_TA	By Age (Numerator): 10-14	85
PMTCT_STAT_TA	By Age (Numerator): : 15-19	1,607



PMTCT_STAT_TA	By Age (Numerator): 20-24	1,607
PMTCT_STAT_TA	By Age (Numerator): 25-49	5,161
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	17,723
VMMC_CIRC_DSD	By Age: 15-19	3,190
VMMC_CIRC_DSD	By Age: 20-24	4,254
VMMC_CIRC_DSD	By Age: 25-29	8,507
VMMC_CIRC_DSD	By Age: 30-49	1,063
VMMC_CIRC_DSD	By Age: 50+	709
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	8,153
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	17,723
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	50,203
HTC_TST_DSD	By Test Result: Positive	3,740
HTC_TST_DSD	Sum of Test Result disaggregates	3,740
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	2,196
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	116
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	6,589
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	347
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	4,393
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	231
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	10,981
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	578



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	4,393
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	230
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	10,981
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	578
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	2,196
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	116
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	2,196
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	116
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	101
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	51
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	152
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	86
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	76
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	483



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	271
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	1,625
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	914
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	25
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	25
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	14
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	76,856
HTC_TST_TA	By Test Result: Positive	3,489
HTC_TST_TA	Sum of Test Result disaggregates	3,489
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	326
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	164
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	490
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	20
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	245
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	10



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	1,550
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	65
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	5,222
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	218
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	81
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	81
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	652
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,460
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	62
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	733
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	31
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	2,192
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	93
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,096
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	46



	Male, Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	6,939
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	296
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	23,381
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	991
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	364
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	15
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	364
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	15
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	385
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	337
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	20
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	8



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	10
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Negative	65
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Positive	27
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Negative	217
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Positive	87
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	5,211
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	50
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	6,079
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	134
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Negative	5,211
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Positive	156
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	868
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	48
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	27
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	24



HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	73
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	41
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	36
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	20
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Negative	230
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Positive	129
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Negative	774
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Positive	435
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	12
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	12
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	337
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	2,415
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	123
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	2,818
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	143
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Negative	2,415
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Positive	123



HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	403
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Positive	20
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,046
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	1,046
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	31
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	42
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	345
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	628
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	42
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	628
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	31
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	345
GEND_GBV_TA	Number of people receiving post-GBV care	139
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	28
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	97



GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	14
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	3,960
OVC_SERV_DSD	Age/Sex: 10-14 Male	359
OVC_SERV_DSD	Age/Sex: 15-17 Male	340
OVC_SERV_DSD	By: Age/sex: Male 18-24	361
OVC_SERV_DSD	By: Age/sex: Male 25+	83
OVC_SERV_DSD	Age/Sex: 10-14 Female	522
OVC_SERV_DSD	Age/Sex: 15-17 Female	278
OVC_SERV_DSD	By: Age/sex: 18-24 Female	421
OVC_SERV_DSD	By: Age/sex: 25+ Female	119
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,499
OVC_SERV_DSD	Age/Sex: <1	157
OVC_SERV_DSD	Age/Sex: 1-9	1,320
OVC_SERV_DSD	Program Completion: Active	2,990
OVC_SERV_DSD	Program Completion: Graduation	574
OVC_SERV_DSD	Program Completion: Transferred	198
OVC_SERV_DSD	Program Completion: Exited without graduation	198
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	523
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	551
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	21
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	313



TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	16
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	173
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	22
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	330
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	17
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	182
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	654
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	432
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	222
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	23,609
TX_CURR_TA	Age/Sex: 15-19 Male	389
TX_CURR_TA	Age/Sex: 15-19 Female	1,244
TX_CURR_TA	Sum of Age/Sex disaggregations	1,633



TX_CURR_TA	Age/Sex: <1	118
TX_CURR_TA	Age/Sex: 1-9	118
TX_CURR_TA	Age/Sex: 10-14 Male	236
TX_CURR_TA	Age/Sex: 10-14 Female	236
TX_CURR_TA	Age/Sex: 20-24 Male	531
TX_CURR_TA	Age/Sex: 25-49 Male	12,453
TX_CURR_TA	Age/Sex: 50+ Male	195
TX_CURR_TA	Age/Sex: 20-24 Female	1,867
TX_CURR_TA	Age/Sex: 25-49 Female	5,911
TX_CURR_TA	Age/Sex: 50+ Female	311
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,732
TX_NEW_TA	By Age/Sex: 15-19 Male	135
TX_NEW_TA	By Age/Sex: 20-24 Male	202
TX_NEW_TA	By Age/Sex: 25-49 Male	4,309
TX_NEW_TA	By Age/Sex: 50+ Male	67
TX_NEW_TA	By Age/Sex: 15-19 Female	269
TX_NEW_TA	By Age/Sex: 20-24 Female	404
TX_NEW_TA	By Age/Sex: 25-49 Female	1,279
TX_NEW_TA	By Age/Sex: 50+ Female	67
TX_NEW_TA	Sum of Age/Sex disaggregates	6,732
TX_NEW_TA	Pregnancy status	1,683
TX_NEW_TA	Breastfeeding status	21
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	19,123
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	21,248
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	287
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male	287



	Routine	
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	7,559
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	10,990
TX_PVLS_TA	Numerator: Indication: Routine	19,123
TX_PVLS_TA	Numerator: Preg/BF by Indication: Breastfeeding Routine	95
TX_PVLS_TA	Numerator: Preg/BF by Indication: Pregnant Routine	1,913
TX_PVLS_TA	Denominator: Indication: Routine	21,248
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	319
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	319
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	8,399
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	12,211
TX_PVLS_TA	Denominator: Preg/BF by Indication: Breastfeeding Routine	106
TX_PVLS_TA	Denominator: Preg/BF by Indication: Pregnant Routine	2,125
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,790
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,977
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	58
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	620
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number	66



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,046
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	59
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	689
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	67
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,162
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	3,029
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	6,059



TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	1,817
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	4,242
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	6,059
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	908
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	2,121
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	3,029
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	472
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	23,609
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	7
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Male	7
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	187
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	271
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	354
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	354
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	9,333
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	13,568
TX_TB_TA	Denominator: By Screen Result: Negative	21,720
TX_TB_TA	Denominator: By Screen Result: Positive	1,889
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,889
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	189
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	378
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,322

Implementing Mechanism Details

Mechanism ID: 17874	Mechanism Name: NAMERU
Funding Agency: DOD	Procurement Type: Grant

Approved



Prime Partner Name: National Medical Research Unit	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 125,250	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 125,250	
Funding Source	Funding Amount
GHP-State	125,250

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	32,000
---------------------------	--------

Budget Code Information

Mechanism ID: 17874			
Mechanism Name: NAMERU			
Prime Partner Name: National Medical Research Unit			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	125,250	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17976	Mechanism Name: Supporting Laboratory
----------------------------	--



Strengthening Activities in Resource-Limited Countries Under the President's Emergency Plan for AIDS Relief	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 141,579	
Total All Funding Sources and Applied Pipeline Amount: 141,579	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17976		
Mechanism Name:	Supporting Laboratory Strengthening Activities in Resource-Limited Countries Under the President's Emergency Plan for AIDS Relief		
Prime Partner Name:	Association of Public Health Laboratories		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

Approved



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17977	Mechanism Name: Biomedical Engineering Support for Equipment Maintenance and Training in Clinical Laboratory Sites Providing HIV/AIDS Care and Treatment		
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement		
Prime Partner Name: American International Health Alliance Twinning Center			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		
Total All Funding Sources: 338,175		Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 338,175			
Funding Source	Funding Amount		
GHP-State	338,175		

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17977		
Mechanism Name:	Biomedical Engineering Support for Equipment Maintenance and Training in Clinical Laboratory Sites Providing HIV/AIDS Care and Treatment		
Prime Partner Name:	American International Health Alliance Twinning Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	338,175	0
------------------------	------	---------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17978	Mechanism Name: Acceleration of Regional Comprehensive HIV & AIDS Service Delivery through HSS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Infectious Disease Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 19,666,670	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 4,499,700	
Total All Funding Sources and Applied Pipeline Amount: 24,166,370	
Funding Source	Funding Amount
GHP-State	19,666,670

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	74,225
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs



Key Populations: FSW	320,448
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Collection and use of strategic information on SWs and clients
Gender: GBV	150,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	100,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Sub Area:	Collection and Use of Gender-related Strategic Information
Human Resources for Health	8,630,140
Economic Strengthening	567,972
Renovation	79,020
Motor Vehicles: Purchased	450,000
Food and Nutrition: Policy, Tools, and Service Delivery	189,324
Education	189,324
Water	326,182
Food and Nutrition: Commodities	94,662

Budget Code Information

Mechanism ID:	17978		
Mechanism Name:	Acceleration of Regional Comprehensive HIV & AIDS Service Delivery through HSS		
Prime Partner Name:	Infectious Disease Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	4,014,109	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,846,135	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	924,976	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	502,464	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	372,428	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	734,279	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	708,771	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	898,225	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	775,340	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	8,627,427	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	262,516	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
------------------	-------	------



PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	7,020
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	87,197
PMTCT_ART_DSD	New on ART	3,169
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,851
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	5,790
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	71,593
PMTCT_ART_TA	New on ART	2,619
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	3,171
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	87,197
PMTCT_STAT_DSD	By Age (Denominator): 10-14	871
PMTCT_STAT_DSD	By Age (Denominator): <15-19	16,568
PMTCT_STAT_DSD	By Age (Denominator): 20-24	16,568
PMTCT_STAT_DSD	By Age (Denominator): 25-49	53,190
PMTCT_STAT_DSD	By Number of known positives: 10-14	37
PMTCT_STAT_DSD	By Number of known positives: 15-19	772
PMTCT_STAT_DSD	By Number of known positives: 20-24	1,384
PMTCT_STAT_DSD	By Number of known positives: 25-49	1,879
PMTCT_STAT_DSD	By Number of new positives: 10-14	30
PMTCT_STAT_DSD	By Number of new positives: 15-19	630
PMTCT_STAT_DSD	By Number of new positives: 20-24	1,128
PMTCT_STAT_DSD	By Number of new positives: 25-49	1,532
PMTCT_STAT_DSD	By Number of new negative: 10-14	802
PMTCT_STAT_DSD	By Number of new negative: 15-19	15,161



PMTCT_STAT_DSD	By Number of new negative: 20-24	14,054
PMTCT_STAT_DSD	By Number of new negative: 25-49	49,788
PMTCT_STAT_DSD	By Age (Numerator): 10-14	871
PMTCT_STAT_DSD	By Age (Numerator): 15-19	16,568
PMTCT_STAT_DSD	By Age (Numerator): 20-24	16,568
PMTCT_STAT_DSD	By Age (Numerator): 25-49	53,190
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	71,593
PMTCT_STAT_TA	By Age (Denominator): 10-14	717
PMTCT_STAT_TA	By Age (Denominator): 15-19	13,602
PMTCT_STAT_TA	By Age (Denominator): 20-24	13,602
PMTCT_STAT_TA	By Age (Denominator): 25-49	43,672
PMTCT_STAT_TA	By known positives: 10-14	25
PMTCT_STAT_TA	By known positives: 15-19	586
PMTCT_STAT_TA	By known positives: 20-24	1,045
PMTCT_STAT_TA	By known positives: 25-49	1,433
PMTCT_STAT_TA	By new positives: 10-14	25
PMTCT_STAT_TA	By new positives: 15-19	568
PMTCT_STAT_TA	By new positives: 20-24	1,019
PMTCT_STAT_TA	By new positives: 25-49	1,393
PMTCT_STAT_TA	By new negatives: 10-14	667
PMTCT_STAT_TA	By new negatives: 15-19	12,448
PMTCT_STAT_TA	By new negatives: 20-24	11,538
PMTCT_STAT_TA	By new negatives: 25-49	40,846
PMTCT_STAT_TA	By Age (Numerator): 10-14	717
PMTCT_STAT_TA	By Age (Numerator): : 15-19	13,602
PMTCT_STAT_TA	By Age (Numerator): 20-24	13,602
PMTCT_STAT_TA	By Age (Numerator): 25-49	43,672
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	68,660



VMMC_CIRC_DSD	By Age: 10-14	6,866
VMMC_CIRC_DSD	By Age: 15-19	12,359
VMMC_CIRC_DSD	By Age: 20-24	16,477
VMMC_CIRC_DSD	By Age: 25-29	26,089
VMMC_CIRC_DSD	By Age: 30-49	4,120
VMMC_CIRC_DSD	By Age: 50+	2,749
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	38,451
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	68,660
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	2,000
PrEP_NEW_DSD	Male 15-19	250
PrEP_NEW_DSD	Male 20-24	250
PrEP_NEW_DSD	Male 25-49	250
PrEP_NEW_DSD	Male 50+	250
PrEP_NEW_DSD	Female 15-19	250
PrEP_NEW_DSD	Female 20-24	250
PrEP_NEW_DSD	Female 25-49	250
PrEP_NEW_DSD	Female 50+	250
PrEP_NEW_DSD	FSW	181
PrEP_NEW_DSD	MSM	8
PrEP_NEW_DSD	TG	3
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	34,746
PP_PREV_DSD	Age/sex: 10-14 Male	4,509
PP_PREV_DSD	Age/sex: 15-19 Male	2,347
PP_PREV_DSD	Age/sex: 20-24 Male	2,163
PP_PREV_DSD	Age/sex: 25-49 Male	7,508
PP_PREV_DSD	Age/sex: 50+ Male	673
PP_PREV_DSD	Age/sex: 10-14 Female	5,476
PP_PREV_DSD	Age/sex: 15-19 Female	2,945



PP_PREV_DSD	Age/sex: 20-24 Female	2,099
PP_PREV_DSD	Age/sex: 25-49 Female	6,486
PP_PREV_DSD	Age/sex: 50+ Female	540
PP_PREV_DSD	Sum of Age/Sex disaggregates	34,746
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	14,335
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,185
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,785
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	475
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	510
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10,380
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12	311,647



	months	
HTC_TST_DSD	By Test Result: Positive	27,638
HTC_TST_DSD	Sum of Test Result disaggregates	27,638
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	912
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	64
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	312
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,868
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	210
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,210
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	86
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	25,990
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	1,892
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	20,996
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	1,576
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	2,577
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	185
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	2,595
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	193



	Positive	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	727
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	79
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	2,174
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	236
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	1,447
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	161
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	3,630
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	409
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	1,406
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	151
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	3,630
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	402
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	726
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	77
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	726
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	77
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19,	989



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	80
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	337
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	3,081
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	274
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,308
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	111
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	28,304
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	2,433
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	21,129
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	2,263
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	2,802
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	238
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	2,615
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	279
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female,	8



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	86
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	802
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	334
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	576
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	231
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	75
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	71
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	13,990
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	104
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	16,323
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	288
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	13,990
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	334



HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	2,332
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	188
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	106
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	609
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	345
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	249
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	138
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	5,213
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	2,936
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	5,839
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	3,280
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	516
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	292
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	719
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	401



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	72
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	279
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	154
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	101
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	50
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	1,935
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	1,101
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	3,538
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	1,992
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	190
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	105
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	421
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	235
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	24,983
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	1,048



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	29,134
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	1,215
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	24,983
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	1,048
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	4,162
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	170
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	180,558
HTC_TST_TA	By Test Result: Positive	16,409
HTC_TST_TA	Sum of Test Result disaggregates	16,409
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	432
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	32
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	71
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,914
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	142
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	567
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	40
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	9,814
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	742
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	17,114
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	1,322



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	960
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	74
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	1,989
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	154
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	465
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	49
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	69
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	2,109
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	216
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	668
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	68
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	11,778
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	1,217
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	17,313
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	2,246
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+,	1,125



	Female, Negative	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	117
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,999
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	262
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	56
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	17
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Negative	339
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Positive	147
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Negative	458
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Positive	187
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	28
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	50



HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	16
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	9,208
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	69
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	10,742
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	194
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Negative	9,208
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Positive	216
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	1,536
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Positive	19
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	125
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	69
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	18
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	534
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	299
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	179
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	96
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Negative	3,050
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Positive	1,720
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Negative	6,442
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Positive	3,625



HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	299
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	169
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	759
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	428
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	15,816
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	729
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	18,434
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	843
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Negative	15,816
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Positive	729
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	2,642
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Positive	123
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,175
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,175
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	43
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	714
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	31
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	387
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during	43



	the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	714
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	31
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	387
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	633
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	633
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	13
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	21
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	209
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	390
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	21
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	390
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	13



TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	209
GEND_GBV_DSD	Number of people receiving post-GBV care	1,789
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	358
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,252
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	179
GEND_GBV_TA	Number of people receiving post-GBV care	516
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	103
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	361
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	52
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	20,524
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,862
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,766
OVC_SERV_DSD	By: Age/sex: Male 18-24	1,873
OVC_SERV_DSD	By: Age/sex: Male 25+	433
OVC_SERV_DSD	Age/Sex: 10-14 Female	2,702
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,438
OVC_SERV_DSD	By: Age/sex: 18-24 Female	2,181
OVC_SERV_DSD	By: Age/sex: 25+ Female	614
OVC_SERV_DSD	Sum of Age/Sex disaggregates	7,768
OVC_SERV_DSD	Age/Sex: <1	816
OVC_SERV_DSD	Age/Sex: 1-9	6,839
OVC_SERV_DSD	Program Completion: Active	15,495
OVC_SERV_DSD	Program Completion: Graduation	2,977
OVC_SERV_DSD	Program Completion: Transferred	1,028
OVC_SERV_DSD	Program Completion: Exited without graduation	1,024
TB_ART_DSD	The number of registered new and relapse TB cases	574



	with documented HIV-positive status who are on ART during TB treatment during the reporting period	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	604
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	20
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	349
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	15
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	190
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	20
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	369
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	15
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with	200



	documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	309
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	327
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	191
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	102
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	9
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	206
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment	7



	during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	105
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	5,739
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	115
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	3,785
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	59
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	1,780
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,714
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	114
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	3,114
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	48
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	1,438
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	169,832
TX_CURR_DSD	Age/Sex: 15-19 Male	1,476
TX_CURR_DSD	Age/Sex: 15-19 Female	3,597
TX_CURR_DSD	Sum of age/sex disaggregates	5,073
TX_CURR_DSD	Age/Sex: <1	359
TX_CURR_DSD	Age/Sex: <1-9	6,987
TX_CURR_DSD	Age/Sex: 10-14 Male	2,088
TX_CURR_DSD	Age/Sex: 10-14 Female	2,614



TX_CURR_DSD	Age/Sex: 20-24 Male	3,672
TX_CURR_DSD	Age/Sex: 25-49 Male	46,233
TX_CURR_DSD	Age/Sex: 50+ Male	6,479
TX_CURR_DSD	Age/Sex: 20-24 Female	9,456
TX_CURR_DSD	Age/Sex: 25-49 Female	79,048
TX_CURR_DSD	Age/Sex: 50+ Female	7,823
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	20,423
TX_CURR_TA	Age/Sex: 15-19 Male	122
TX_CURR_TA	Age/Sex: 15-19 Female	420
TX_CURR_TA	Sum of Age/Sex disaggregations	542
TX_CURR_TA	Age/Sex: <1	39
TX_CURR_TA	Age/Sex: 1-9	671
TX_CURR_TA	Age/Sex: 10-14 Male	150
TX_CURR_TA	Age/Sex: 10-14 Female	212
TX_CURR_TA	Age/Sex: 20-24 Male	495
TX_CURR_TA	Age/Sex: 25-49 Male	6,296
TX_CURR_TA	Age/Sex: 50+ Male	784
TX_CURR_TA	Age/Sex: 20-24 Female	1,323
TX_CURR_TA	Age/Sex: 25-49 Female	9,018
TX_CURR_TA	Age/Sex: 50+ Female	893
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	34,162
TX_NEW_DSD	By Age/Sex: <1	219
TX_NEW_DSD	By Age/Sex: 1-9	213
TX_NEW_DSD	By Age/Sex: 10-14 Male	100
TX_NEW_DSD	By Age/Sex: 15-19 Male	188
TX_NEW_DSD	By Age/Sex: 20-24 Male	532
TX_NEW_DSD	By Age/Sex: 25-49 Male	15,157
TX_NEW_DSD	By Age/Sex: 50+ Male	2,016
TX_NEW_DSD	By Age/Sex: 10-14 Female	104
TX_NEW_DSD	By Age/Sex: 15-19 Female	490



TX_NEW_DSD	By Age/Sex: 20-24 Female	1,384
TX_NEW_DSD	By Age/Sex: 25-49 Female	12,514
TX_NEW_DSD	By Age/Sex: 50+ Female	1,245
TX_NEW_DSD	Sum of Age/Sex disaggregates	33,730
TX_NEW_DSD	Pregnancy status	8,543
TX_NEW_DSD	Breastfeeding status	104
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,437
TX_NEW_TA	By Age/Sex: <1	33
TX_NEW_TA	By Age/Sex: 15-19 Male	12
TX_NEW_TA	By Age/Sex: 20-24 Male	79
TX_NEW_TA	By Age/Sex: 25-49 Male	3,140
TX_NEW_TA	By Age/Sex: 50+ Male	384
TX_NEW_TA	By Age/Sex: 15-19 Female	54
TX_NEW_TA	By Age/Sex: 20-24 Female	203
TX_NEW_TA	By Age/Sex: 25-49 Female	1,391
TX_NEW_TA	By Age/Sex: 50+ Female	141
TX_NEW_TA	Sum of Age/Sex disaggregates	5,404
TX_NEW_TA	Pregnancy status	1,330
TX_NEW_TA	Breastfeeding status	11
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	137,564
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	152,850
TX_PVLS_DSD	Numerator: Indication: Routine	137,564
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	13,759
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	691
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	4,539



TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	46,861
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	5,218
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	80,946
TX_PVLS_DSD	Denominator: Indication: Routine	152,850
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	15,286
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	765
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	5,047
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	52,074
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	5,802
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	89,927
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	16,541
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	18,381
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	471
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	384
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	9,455
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	6,231
TX_PVLS_TA	Numerator: Indication: Routine	16,541



TX_PVLS_TA	Numerator: Preg/BF by Indication: Breastfeeding Routine	92
TX_PVLS_TA	Numerator: Preg/BF by Indication: Pregnant Routine	1,657
TX_PVLS_TA	Denominator: Indication: Routine	18,381
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	539
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	443
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	10,474
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	6,925
TX_PVLS_TA	Denominator: Preg/BF by Indication: Breastfeeding Routine	96
TX_PVLS_TA	Denominator: Preg/BF by Indication: Pregnant Routine	1,837
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	15,071
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	16,641
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	496
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,209
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	558
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,808
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total	501



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,793
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	564
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,783
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,289
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,748
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	142
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,470
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	161
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number	2,516



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	142
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,653
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	161
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,792
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	15,375
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	30,749
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	301
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	277
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	14,087



TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	16,084
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	30,749
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	143
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	133
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	7,042
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	8,057
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	15,375
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,450
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	4,898
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	24
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	9
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	1,608
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	3,257
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	4,898
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	2
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	1
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	811
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	1,636
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	2,450
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	3,396
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	169,832
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	128
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	112



TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	1,997
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	1,159
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	6,444
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	5,605
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	99,925
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	57,858
TX_TB_DSD	Denominator: By Screen Result: Negative	156,245
TX_TB_DSD	Denominator: By Screen Result: Positive	13,587
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	13,587
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	1,357
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	2,717
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	9,513
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	407
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	20,423
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	6
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Male	4
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	235
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	162
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	591
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	481
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	11,653
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	7,698
TX_TB_TA	Denominator: By Screen Result: Negative	18,792
TX_TB_TA	Denominator: By Screen Result: Positive	1,631
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic	1,631



	diagnosis of active TB disease	
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	158
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	330
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,143

Implementing Mechanism Details

Mechanism ID: 17979	Mechanism Name: To support the centralized procurement; warehousing and distribution of HIV/AIDS related commodities for CDC funded programs in Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Medical Access Uganda Limited (MAUL)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 39,581,963	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 23,695,892	
Total All Funding Sources and Applied Pipeline Amount: 63,277,855	
Funding Source	Funding Amount
GHP-State	39,581,963

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	372,728
Water	372,728
Food and Nutrition: Commodities	186,364
Motor Vehicles: Purchased	110,000



Budget Code Information

Mechanism ID:	17979		
Mechanism Name:	To support the centralized procurement; warehousing and distribution of		
Prime Partner Name:	HIV/AIDS related commodities for CDC funded programs in Uganda		
Prime Partner Name:	Medical Access Uganda Limited (MAUL)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	3,043,122	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	472,206	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	1,285,853	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	2,309,129	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	940,682	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	92,928	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	24,557,887	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	6,880,156	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Treatment	PDTX	0	0
-----------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18003	Mechanism Name: Technical assistance for strengthening national laboratory systems in Uganda under the President's Emergency Plan for AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Global Healthcare Public Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 157,112	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 494,388	
Total All Funding Sources and Applied Pipeline Amount: 651,500	
Funding Source	Funding Amount
GHP-State	157,112

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	136,000
---------------------------	---------

Budget Code Information

Mechanism ID: 18003



Mechanism Name: Technical assistance for strengthening national laboratory systems in			
Prime Partner Name: Uganda under the President's Emergency Plan for AIDS Relief			
		Global Healthcare Public Foundation	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	157,112	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18017	Mechanism Name: EGPAF: HQ Technical Assistance CoAg
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 300,001	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 275,187	
Total All Funding Sources and Applied Pipeline Amount: 575,188	
Funding Source	Funding Amount
GHP-State	300,001

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	3,000
Water	3,000
Food and Nutrition: Commodities	1,500



Budget Code Information

Mechanism ID: 18017			
Mechanism Name: EGPAF: HQ Technical Assistance CoAg			
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	169,347	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	65,327	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	65,327	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18032	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18033	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18034	Mechanism Name: Acceleration of Regional
----------------------------	---



	Comprehensive HIV & AIDS Service Delivery through HSS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: The AIDS Support Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,287,306	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,297,200	
Total All Funding Sources and Applied Pipeline Amount: 6,584,506	
Funding Source	Funding Amount
GHP-State	5,287,306

Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



Sub Area:	Operation Research
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Key Populations: FSW	19,797
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs



Renovation	478,321
Human Resources for Health	2,862,691
Motor Vehicles: Purchased	708,330

Budget Code Information

Mechanism ID:	18034		
Mechanism Name:	Acceleration of Regional Comprehensive HIV & AIDS Service Delivery through HSS		
Prime Partner Name:	The AIDS Support Organization		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,238,241	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	263,614	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	183,042	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	154,481	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	CIRC	264,021	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,100,636	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	22,873	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	267,681	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,679,214	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	113,503	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,642
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	86,242
PMTCT_ART_DSD	New on ART	1,194
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,448
PMTCT_STAT_DSD	Number of pregnant women with known HIV status	86,242



	(includes women who were tested for HIV and received their results)	
PMTCT_STAT_DSD	By Age (Denominator): 10-14	868
PMTCT_STAT_DSD	By Age (Denominator): <15-19	16,389
PMTCT_STAT_DSD	By Age (Denominator): 20-24	16,389
PMTCT_STAT_DSD	By Age (Denominator): 25-49	52,596
PMTCT_STAT_DSD	By Number of known positives: 10-14	4
PMTCT_STAT_DSD	By Number of known positives: 15-19	397
PMTCT_STAT_DSD	By Number of known positives: 20-24	710
PMTCT_STAT_DSD	By Number of known positives: 25-49	986
PMTCT_STAT_DSD	By Number of new positives: 15-19	128
PMTCT_STAT_DSD	By Number of new positives: 20-24	227
PMTCT_STAT_DSD	By Number of new positives: 25-49	328
PMTCT_STAT_DSD	By Number of new negative: 10-14	864
PMTCT_STAT_DSD	By Number of new negative: 15-19	15,863
PMTCT_STAT_DSD	By Number of new negative: 20-24	15,451
PMTCT_STAT_DSD	By Number of new negative: 25-49	51,284
PMTCT_STAT_DSD	By Age (Numerator): 10-14	868
PMTCT_STAT_DSD	By Age (Numerator): 15-19	16,389
PMTCT_STAT_DSD	By Age (Numerator): 20-24	16,389
PMTCT_STAT_DSD	By Age (Numerator): 25-49	52,596
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	26,271
VMMC_CIRC_DSD	By Age: 10-14	2,627
VMMC_CIRC_DSD	By Age: 15-19	4,729
VMMC_CIRC_DSD	By Age: 20-24	6,304
VMMC_CIRC_DSD	By Age: 25-29	9,983
VMMC_CIRC_DSD	By Age: 30-49	1,577
VMMC_CIRC_DSD	By Age: 50+	1,051
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	14,711
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	26,271



PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	481
PP_PREV_DSD	Age/sex: 10-14 Male	64
PP_PREV_DSD	Age/sex: 15-19 Male	26
PP_PREV_DSD	Age/sex: 20-24 Male	22
PP_PREV_DSD	Age/sex: 25-49 Male	102
PP_PREV_DSD	Age/sex: 50+ Male	3
PP_PREV_DSD	Age/sex: 10-14 Female	110
PP_PREV_DSD	Age/sex: 15-19 Female	42
PP_PREV_DSD	Age/sex: 20-24 Female	23
PP_PREV_DSD	Age/sex: 25-49 Female	86
PP_PREV_DSD	Age/sex: 50+ Female	3
PP_PREV_DSD	Sum of Age/Sex disaggregates	481
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	669
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	669
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	593,061
HTC_TST_DSD	By Test Result: Positive	9,727
HTC_TST_DSD	Sum of Test Result disaggregates	9,727
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,598
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,677



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	4,124
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	66
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	588
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	13,376
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	223
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	3,744
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	54,921
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	917
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	43,298
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	736
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	5,456
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	97
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	5,353
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	90



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	1,452
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	9,760
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	108
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	13
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	39
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	26
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	74
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	27
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	64
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,566
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	14



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,743
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	9,000
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	138
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,274
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	29,826
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	463
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	8,098
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	131
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	122,609
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	1,941
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	95,360
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	1,555
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	12,254
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	192
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	11,634



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	194
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	1,507
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	9,664
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	102
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	7,725
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	78
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	58
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	53
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	84
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	39
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	308
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	8,534
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	65



HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	9,953
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	176
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	8,534
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	203
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	1,423
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	852
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	932
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	45
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	171
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	99
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	50
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	735
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	442
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	615



HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	352
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	74
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	75
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	834
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	5,107
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	483
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	350
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	299
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	23
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	189
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	125
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	111
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	54



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	338
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	1,909
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	24,966
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	212
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	29,110
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	235
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	24,966
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	212
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	4,165
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	20
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,087
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,087
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	76
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,262
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	57
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number	692



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	76
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,262
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	57
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	692
GEND_GBV_DSD	Number of people receiving post-GBV care	1,419
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	282
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	991
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	146
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	4,773
OVC_SERV_DSD	Age/Sex: 10-14 Male	432
OVC_SERV_DSD	Age/Sex: 15-17 Male	410
OVC_SERV_DSD	By: Age/sex: Male 18-24	435
OVC_SERV_DSD	By: Age/sex: Male 25+	101
OVC_SERV_DSD	Age/Sex: 10-14 Female	630
OVC_SERV_DSD	Age/Sex: 15-17 Female	337
OVC_SERV_DSD	By: Age/sex: 18-24 Female	506
OVC_SERV_DSD	By: Age/sex: 25+ Female	143
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,809
OVC_SERV_DSD	Age/Sex: <1	190
OVC_SERV_DSD	Age/Sex: 1-9	1,589



OVC_SERV_DSD	Program Completion: Active	3,605
OVC_SERV_DSD	Program Completion: Graduation	692
OVC_SERV_DSD	Program Completion: Transferred	241
OVC_SERV_DSD	Program Completion: Exited without graduation	235
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	816
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	860
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	23
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	507
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	17
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	269
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	26
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	532
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The	18



	number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	284
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,104
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	84
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	1,397
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	35
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	588
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	41,173
TX_CURR_DSD	Age/Sex: 15-19 Male	135
TX_CURR_DSD	Age/Sex: 15-19 Female	682
TX_CURR_DSD	Sum of age/sex disaggregates	817
TX_CURR_DSD	Age/Sex: <1	192
TX_CURR_DSD	Age/Sex: <1-9	3,063
TX_CURR_DSD	Age/Sex: 10-14 Male	700
TX_CURR_DSD	Age/Sex: 10-14 Female	986
TX_CURR_DSD	Age/Sex: 20-24 Male	594
TX_CURR_DSD	Age/Sex: 25-49 Male	10,563
TX_CURR_DSD	Age/Sex: 50+ Male	1,308
TX_CURR_DSD	Age/Sex: 20-24 Female	2,154
TX_CURR_DSD	Age/Sex: 25-49 Female	18,922
TX_CURR_DSD	Age/Sex: 50+ Female	1,874
TX_NEW_DSD	Number of adults and children newly enrolled on	8,616



	antiretroviral therapy (ART)	
TX_NEW_DSD	By Age/Sex: <1	108
TX_NEW_DSD	By Age/Sex: 1-9	320
TX_NEW_DSD	By Age/Sex: 10-14 Male	53
TX_NEW_DSD	By Age/Sex: 15-19 Male	46
TX_NEW_DSD	By Age/Sex: 20-24 Male	220
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,763
TX_NEW_DSD	By Age/Sex: 50+ Male	339
TX_NEW_DSD	By Age/Sex: 10-14 Female	61
TX_NEW_DSD	By Age/Sex: 15-19 Female	241
TX_NEW_DSD	By Age/Sex: 20-24 Female	779
TX_NEW_DSD	By Age/Sex: 25-49 Female	3,353
TX_NEW_DSD	By Age/Sex: 50+ Female	333
TX_NEW_DSD	Sum of Age/Sex disaggregates	8,188
TX_NEW_DSD	Pregnancy status	2,166
TX_NEW_DSD	Breastfeeding status	18
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	33,351
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	37,061
TX_PVLS_DSD	Numerator: Indication: Routine	33,351
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	3,343
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	171
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,796
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	10,207
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	2,198



TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	19,150
TX_PVLS_DSD	Denominator: Indication: Routine	37,061
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	3,707
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	182
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,010
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	11,345
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,449
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	21,257
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,666
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,065
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	119
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,264
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	138
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,145
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the	119



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,423
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	138
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,385
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	3,880
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	7,762
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	278
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	228
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	4,243
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	3,013
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	7,762
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	118
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	104



TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	2,122
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,536
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	3,880
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	824
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	41,173
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	39
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	33
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	477
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	275
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,716
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,225
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	23,631
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	12,601
TX_TB_DSD	Denominator: By Screen Result: Negative	37,882
TX_TB_DSD	Denominator: By Screen Result: Positive	3,291
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	3,291
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	329
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	656
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2,306

Implementing Mechanism Details

Mechanism ID: 18041	TBD: Yes
REDACTED	

Implementing Mechanism Details



Mechanism ID: 18042	Mechanism Name: Technical Assistance for Public Health Workforce Development
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Makerere University School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 850,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,995,750	
Total All Funding Sources and Applied Pipeline Amount: 2,845,750	
Funding Source	Funding Amount
GHP-State	850,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18042		
Mechanism Name:	Technical Assistance for Public Health Workforce Development		
Prime Partner Name:	Makerere University School of Public Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	850,000	0

Implementing Mechanism Indicator Information

Approved



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18273	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18274	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18276	Mechanism Name: PPL-LER Monitoring and Evaluation IDIQ
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: DevTech Systems Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 500,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 500,000	
Funding Source	Funding Amount
GHP-State	500,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	18276		
Mechanism Name:	PPL-LER Monitoring and Evaluation IDIQ		
Prime Partner Name:	DevTech Systems Inc		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	500,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18361	Mechanism Name: 4Children - Coordinating Comprehensive Care for Children
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 59,035	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 59,035	
Funding Source	Funding Amount
GHP-State	59,035

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 18361			
Mechanism Name: 4Children - Coordinating Comprehensive Care for Children			
Prime Partner Name: Catholic Relief Services			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	59,035	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18369	Mechanism Name: Global Health Supply Chain – Procurement and Supply Management (GHSC-PSM) - HIV/AIDS Task Order
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 16,222,162	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 20,000,000	
Total All Funding Sources and Applied Pipeline Amount: 36,222,162	
Funding Source	Funding Amount
GHP-State	16,222,162



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18369		
Mechanism Name:	Global Health Supply Chain – Procurement and Supply Management		
Prime Partner Name:	(GHSC-PSM) - HIV/AIDS Task Order		
	Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	428,853	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	204,916	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	947,298	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	74,081	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,319,701	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	374,458	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	7,733,466	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	5,139,389	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18502	Mechanism Name: DREAMS Initiative and HIV/AIDS Prevention Support to the Ugandan Peoples Defense
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 850,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 850,000	
Funding Source	Funding Amount
GHP-State	850,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	10,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	10,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Food and Nutrition: Policy, Tools, and Service Delivery	5,000
Condom programming	20,000
Motor Vehicles: Purchased	42,000
Economic Strengthening	5,000

Budget Code Information

Mechanism ID:	18502		
Mechanism Name:	DREAMS Initiative and HIV/AIDS Prevention Support to the Ugandan Peoples Defense		
Prime Partner Name:	Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Prevention	HVOP	850,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	50,000
PP_PREV_DSD	Age/sex: 10-14 Male	3,234
PP_PREV_DSD	Age/sex: 15-19 Male	3,560
PP_PREV_DSD	Age/sex: 20-24 Male	7,567
PP_PREV_DSD	Age/sex: 25-49 Male	15,836
PP_PREV_DSD	Age/sex: 50+ Male	912
PP_PREV_DSD	Age/sex: 10-14 Female	2,315
PP_PREV_DSD	Age/sex: 15-19 Female	2,787
PP_PREV_DSD	Age/sex: 20-24 Female	3,281
PP_PREV_DSD	Age/sex: 25-49 Female	9,560
PP_PREV_DSD	Age/sex: 50+ Female	948
PP_PREV_DSD	Sum of Age/Sex disaggregates	50,000

Implementing Mechanism Details

Mechanism ID: 18553	Mechanism Name: Strengthening High Impact Interventions for an AIDS-free Generation (AIDSFree) Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes

Approved



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 182,545	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 182,545	
Funding Source	Funding Amount
GHP-State	182,545

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18553		
Mechanism Name:	Strengthening High Impact Interventions for an AIDS-free Generation		
Prime Partner Name:	(AIDSFree) Project John Snow Inc (JSI)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	182,545	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18554	Mechanism Name: EQUIP
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Right to Care	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 208,750	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 208,750	
Funding Source	Funding Amount
GHP-State	208,750

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18554			
Mechanism Name: EQUIP			
Prime Partner Name: Right to Care			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	41,750	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	41,750	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	41,750	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	41,750	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	41,750	0
-----------	------	--------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18557	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18559	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18560	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18561	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18562	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 18563	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18565	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18566	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18567	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18568	Mechanism Name: Project SOAR (Supporting Operational AIDS Research)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 54,764	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 54,764	
Funding Source	Funding Amount
GHP-State	54,764

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18568		
Mechanism Name:	Project SOAR (Supporting Operational AIDS Research)		
Prime Partner Name:	Population Council		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	54,764	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18569	Mechanism Name: UNICEF MCH Umbrella Grant
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: UNICEF	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 101,818	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 101,818	
Funding Source	Funding Amount
GHP-State	101,818

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18569		
Mechanism Name:	UNICEF MCH Umbrella Grant		
Prime Partner Name:	UNICEF		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	101,818	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18583	Mechanism Name: STOP TB Partnership
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: STOP TB Partnership Trust Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 987,367	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 987,367	
Funding Source	Funding Amount
GHP-State	987,367

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18583			
Mechanism Name: STOP TB Partnership			
Prime Partner Name: STOP TB Partnership Trust Fund			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	987,367	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18668	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18671	Mechanism Name: REFUGEE - Over five years this follow-on mechanism will utilize comprehensive facility and community approaches to build on existing interventions and scale up HIV prevention, care and treatment
----------------------------	---



	services in the mid-Western and West-Nile regions of Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Infectious Disease Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18671		
Mechanism Name:	REFUGEE - Over five years this follow-on mechanism will utilize comprehensive facility and community approaches to build on existing interventions and scale up HIV prevention, care and treatment services in the mid-Western and West-Nile regions of Uganda		
Prime Partner Name:	Infectious Disease Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,491
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	46,186
PMTCT_ART_DSD	New on ART	675
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	816
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	46,186
PMTCT_STAT_DSD	By Age (Denominator): 10-14	460
PMTCT_STAT_DSD	By Age (Denominator): <15-19	8,776
PMTCT_STAT_DSD	By Age (Denominator): 20-24	8,776
PMTCT_STAT_DSD	By Age (Denominator): 25-49	28,174
PMTCT_STAT_DSD	By Number of known positives: 10-14	4
PMTCT_STAT_DSD	By Number of known positives: 15-19	150
PMTCT_STAT_DSD	By Number of known positives: 20-24	269
PMTCT_STAT_DSD	By Number of known positives: 25-49	361
PMTCT_STAT_DSD	By Number of new positives: 10-14	4
PMTCT_STAT_DSD	By Number of new positives: 15-19	151
PMTCT_STAT_DSD	By Number of new positives: 20-24	270
PMTCT_STAT_DSD	By Number of new positives: 25-49	364
PMTCT_STAT_DSD	By Number of new negative: 10-14	442
PMTCT_STAT_DSD	By Number of new negative: 15-19	8,301
PMTCT_STAT_DSD	By Number of new negative: 20-24	8,243
PMTCT_STAT_DSD	By Number of new negative: 25-49	27,033
PMTCT_STAT_DSD	By Number of new negative: 50+	594
PMTCT_STAT_DSD	By Age (Numerator): 10-14	460
PMTCT_STAT_DSD	By Age (Numerator): 15-19	8,776



PMTCT_STAT_DSD	By Age (Numerator): 20-24	8,776
PMTCT_STAT_DSD	By Age (Numerator): 25-49	28,174
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	508,621
HTC_TST_DSD	By Test Result: Positive	5,571
HTC_TST_DSD	Sum of Test Result disaggregates	5,571
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	1,635
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	55
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	1,687
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	51
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	30,615
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	205
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	25,259
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	232
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	6,606
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	122
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	6,803
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	111
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	124,233
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC:	935



	15+, Female, Positive	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	102,473
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	937
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	1,295
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	233
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	31
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	9
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	32
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	541
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	9
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	432
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	2,198
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	87
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	2,060
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	85
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	37,486
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	537
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	30,933



	Male, Negative	
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	540
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	49,711
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	777
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	69,950
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	1,571
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,349
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,349
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	52
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	807
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	43
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	447
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	54
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	807
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	45



TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	447
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	135
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	140
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	90
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	43
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	92
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with	1



	documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	46
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,253
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	40
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	787
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	19
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	407
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,440
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	671
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,061
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	819
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,244
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,490
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	5,305
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	6,795
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,757
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	521
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,583
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	594
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,059
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,757
TX_NEW_DSD	Pregnancy status	784



TX_NEW_DSD	Breastfeeding status	1
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	5,502
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	6,116
TX_PVLS_DSD	Numerator: Indication: Routine	5,502
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	593
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	35
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	539
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	860
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	664
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	3,439
TX_PVLS_DSD	Denominator: Indication: Routine	6,116
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	610
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	30
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	606
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	956
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	739
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	3,822
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	235



TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	252
TX_RET_DSD	Numerator by Status: Pregnant	31
TX_RET_DSD	Denominator by Status: Pregnant	43
TX_RET_DSD	Denominator by Status: Breastfeeding	2
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	90
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	142
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	100
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	152
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,051
TB_PREV_DSD	The number of ART patients who were newly started on	4,094



	<p>TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).</p>	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	492
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	397
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,672
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,574
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	4,094
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	244
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	196
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	838
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	773
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	2,051
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	134
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	6,795
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	15
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	12
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	85
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	22
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	819
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	671
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	4,244
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	1,051
TX_TB_DSD	Denominator: By Screen Result: Negative	6,250
TX_TB_DSD	Denominator: By Screen Result: Positive	545
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	545

Approved



TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	52
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	110
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	383

Implementing Mechanism Details

Mechanism ID: 18672	TBD: Yes
REDACTED	



Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		391,500		391,500	0	391,500
ICASS		2,340,000		2,340,000	0	2,340,000
Institutional Contractors		1,325,086		1,325,086	1,781,516	3,106,602
Management Meetings/Professional Development		130,500		130,500	0	130,500
Non-ICASS Administrative Costs		965,340		965,340	0	965,340
Staff Program Travel		1,153,800		1,153,800	0	1,153,800
USG Staff Salaries and Benefits - Internationally Recruited		499,974		499,974	1,113,447	1,613,421
USG Staff Salaries and Benefits - Locally Recruited		189,035		189,035	1,558,826	1,747,861
Total	0	6,995,235	0	6,995,235	4,453,789	11,449,024



U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
ICASS		53,207		53,207	61,792	114,999
Management Meetings/Professional Development		10,517		10,517	42,000	52,517
Non-ICASS Administrative Costs		157,484		157,484	13,280	170,764
Staff Program Travel		28,045		28,045	47,760	75,805
USG Staff Salaries and Benefits - Internationally Recruited		180,800		180,800	0	180,800
USG Staff Salaries and Benefits - Locally Recruited				0	112,700	112,700
Total	0	430,053	0	430,053	277,532	707,585

U.S. Department of Health and Human Services/Centers for Disease Control and



Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		2,383,584		2,383,584	0	2,383,584
Computers/IT Services		762,953		762,953	0	762,953
ICASS		2,382,400		2,382,400	0	2,382,400
Management Meetings/Professional Development	285,877	639,048		924,925	0	924,925
Non-ICASS Administrative Costs		1,004,496		1,004,496	0	1,004,496
Non-ICASS Motor Vehicles		368,250		368,250	0	368,250
Staff Program Travel	900,000	509,546		1,409,546	0	1,409,546
USG Staff Salaries and Benefits - Internationally Recruited	2,026,623	97,125		2,123,748	0	2,123,748
USG Staff Salaries and Benefits - Locally Recruited	0	2,640,744		2,640,744	1,347,191	3,987,935
Total	3,212,500	10,788,146	0	14,000,646	1,347,191	15,347,837



U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		5,000		5,000	0	5,000
ICASS		90,000		90,000	55,000	145,000
Indirect Costs		55,000		55,000	0	55,000
Institutional Contractors				0	0	0
Management Meetings/Professional Development		60,000		60,000	0	60,000
Non-ICASS Administrative Costs		37,608		37,608	0	37,608
Staff Program Travel		185,000		185,000	0	185,000
USG Staff Salaries and Benefits - Internationally Recruited		144,664		144,664	0	144,664
USG Staff Salaries and Benefits - Locally Recruited		140,000		140,000	0	140,000
Total	0	717,272	0	717,272	55,000	772,272



U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Non-ICASS Administrative Costs		38,491		38,491	37,390	75,881
Peace Corps Volunteer Costs		708,286		708,286	688,011	1,396,297
Staff Program Travel		19,682		19,682	19,119	38,801
USG Staff Salaries and Benefits - Locally Recruited		243,068		243,068	236,110	479,178
Total	0	1,009,527	0	1,009,527	980,630	1,990,157